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ABSTRACT
A major hope for treatment of haemophilia is via a gene based approach. But with this 
hope as for any new novel treatment for haemophilia, is the occurrence of an immune 
response. This thesis attempts to examine the role of the immune response to Gene 
transfer by a muscle directed approach. It characterises the humoral and cellular 
immune response to the secretable human transgene product human factor IX in both 
small and large animal models of haemophilia.
The humoral responses were studied by means of Elisa, Western Blot and Clotting 
based assays in both normal and haemophilic animal models. The aim of these 
experiments was to look for the presence of an antibody to human factor EX, 
determine whether it was inhibitory or not, and look for factors which may influence 
it’s occurrence. Cellular immune responses were analysed histologically, and also by 
devising an invitro, and later an in vivo based cytotoxic T cell assay (CTL) assay to 
look for the presence of specific cellular based responses to the secretable transgene 
product human factor EX.
The results demonstrated that humoral responses were observed to the transgene 
product human factor EX, and that the antibody subtype IgGl was induced, in keeping 
with a TH2 cellular driven immune response to adeno-associated viral gene transfer. 
In the case of plasmid and Adenoviral vectors, a more dominant THl cellular driven 
response was observed. In the large animal studies a humoral response was observed, 
but in this scenario the response was less inhibitory than observed in the mice. The 
development of a humoral response could be overcome by setting immunomodulatory 
strategies designed to suppress inhibitor formation. The cellular based responses 
showed that for Adenoviral based gene transfer, strong Cytotoxic T cell responses 
were observed, but not for AAV based muscle transduction.
The conclusions from these studies showed that likely immune responses induced 
were influenced by vector and transgene selection. Other factors such as route of gene 
transfer administration and underlying mutation status in recipient animals also 
affected outcome.
Finally it was shown that some of these immune responses could be overcome by the 
design of immunomodulatory strategies. These findings have significant implications 
for the design of human clinical studies of gene transfer treatments for haemophilia.
DEDICATION
I wish to dedicate the work in this thesis to Gaynor, Carole and the late Joseph 
Mitzman.
ACKNOWLEDGEMENTS
The work in this thesis was begun in the UK at the Royal Free Hospital, Department 
of Haematology. I wish to acknowledge the help and support of all the staff at the 
Katharine Dormandy Haemophilia centre at the Royal Free Hospital, London. I wish 
to especially thank my Supervisors, Professors John Pasi and Geoff Goldspink for 
their constant encouragement and help in formulating and critically reviewing the 
final revisions. Special thanks to Professor Christine Lee for her support and 
encouragement. Thanks to “Pip” for proof reading the final revision.
A major proportion of the work was carried out at the Children’s Hospital of 
Philadelphia in the USA in the laboratory of Professor Katherine High. I wish to 
thank Professor High for permitting me to do this work, and also for her constant 
encouragement, enthusiasm and instruction. I especially wish to thank Drs Roland 
Herzog and Valder Arruda for their support and helpful suggestions .
Finally, I wish to thank the Medical Research Council (M.R.C UK, Clinical training 
fellowship) and the Katharine Dormandy Trust for their financial support whilst 
performing this work.
Ill
CONTENTS
Abstract.................................................................................................................................. i
Dedication.............................................................................................................................ii
Acknowledgements.............................................................................................................iii
Contents................................................................................................................................ iv
Figures................................................................................................................................viii
Tables ................................................................................................................................... x
Abbreviations...................................................................................................................... xi
Publications....................................................................................................................... xiii
Chapter 1: Introduction
1.1 Historical perspectives................................................................................................... 2
1.2 Clinical features.............................................................................................................. 9
1.3 Coagulation cascades................................................................................................... 11
1.3.1 Classical coagulation.................................................................................... 11
1.3.2 Revised hypothesis of coagulation.............................................................. 13
1.3.3 Role of FIX....................................................................................................14
1.4 Molecular Genetics.......................................................................................................14
1.4.1 FIX gene........................................................................................................ 14
1.4.2 FIX mutations................................................................................................15
1.4.3 FVIII gene..................................................................................................... 18
1.4.4 FVIII intron................................................................................................... 19
1.4.5 FVIII mutations............................................................................................ 21
1.5 Treatment of Haemophilia...........................................................................................20
1.5.1 Replacement Therapy...................................................................................22
1.6 Complications of Treatment........................................................................................ 25
1.6.1 Inhibitor formation....................................................................................... 25
1.6.2 Management of Inhibitors............................................................................28
1.6.3 Transfusion transmitted infection................................................................32
1.7 Gene Therapy................................................................................................................34
1.7.1 Introduction...................................................................................................34
1.7.2 Experimental Considerations.......................................................................36
1.8 Haemophilia and Gene Therapy..................................................................................37
1.8.1 Introduction...................................................................................................37
1.8.2 Advantages of a gene based approach...................................................... 38
1.8.3 Approaches to Gene therapy for haemophilia............................................40
1.8.4 E r vivo approaches....................................................................................... 41
1.8.5 In vivo approaches........................................................................................ 41
1.9 Choice of gene delivery vehicle..................................................................................41
1.9.1 Potential complications of gene base approach........................................53
Chapter 2: Initial Aims And Objectives
2.1 The immune response to a gene transfer approach....................................................58
2.2 Immunological components of a Gene based approach, which may limit success 60
2.2.1 External factors.............................................................................................60
2.2.2 Internal factors............................................................................................. 62
IV
2.3 Primary objectives and experimental approaches adopted.................................... 62
Chapter 3: Materials And Methods
3.1 Clotting Based Assays: Murine................................................................................... 65
3.1.1 Modified APTT.............................................................................................65
3.1.2 Bethesda Assay............................................................................................. 65
3.2 Clotting Based Assays: Canine................................................................................... 65
3.2.1 WBCT............................................................................................................ 65
3.2.2 Modified Appt............................................................................................... 66
3.3 Immunological Assays: Murine.................................................................................. 66
3.3.1 FIX Antigen Elisa......................................................................................... 66
3.3.2 Antibody Subclass Elisa (hPIX ).................................................................67
3.3.3 Antibody Subclass Elisa (mFIX)................................................................67
3.3.4 Cytokine Elisas..............................................................................................68
3.3.5 Western Blot: Antibody................................................................................70
3.4 Murine Proliferation assay........................................................................................... 70
3.5 Immunological Assays: Canine...................................................................................73
3.5.1 Canine FIX Elisa...........................................................................................73
3.5.2 Canine Antibody Elisa..................................................................................73
3.5.3 Western Blot..................................................................................................74
3.6 Canine proliferation assay............................................................................................74
3.7 Histological analysis.....................................................................................................75
3.7.1 Murine............................................................................................................ 75
3.7.2 Canine.............................................................................................................76
3.8 Generic Molecular techniques..................................................................................... 76
3.8.1 Restriction digests.........................................................................................76
3.8.2 Ligation reaction........................................................................................... 76
3.8.3 Dephosphorylation........................................................................................77
3.8.4 Agarose gel electrophoresis......................................................................... 77
3.8.5 Transformations............................................................................................ 78
3.8.6 Minipreps: Required for Colony..................................................................78
3.8.7 Maxipreps...................................................................................................... 79
3.8.8 Transfection................................................................................................... 80
3.9 Specific Molecular assays............................................................................................ 80
3.9.1 Murine PCR for FIX cDNA in Muscle.......................................................81
3.9.2 Canine RT-PCR for isolation of canine cytokines.....................................81
Chapter 4: Vector Construction And Production
4.1 Plasmid vectors
4.1.1 FVII/PCDNA-3............................................................................................. 85
4.1.2 AAVmFIX..................................................................................................... 86
4.1.3 AAVhFIX...................................................................................................... 87
4.2 In vitro studies..............................................................................................................90
4.3 In vitro results...............................................................................................................90
4.3.1 FVIT. C2CI2..................................................................................................91
4.3.2 FIX: C2C12................................................................................................... 91
4.4 Viral vector production: AAV.....................................................................................93
4.4.1 Adeno-Associated Virus Research preparation: Methods....................... 96
4.4.2 Adeno-Associated Virus: Research preparation: Results..................... 105
4.5 Viral vector production: Adenovirus...................................................................... 107
4.5.1 Research preparation: Methods and results............................................ 109
Chapter 5: Gene Based Transfer To Mice: Humoral Responses And Parameters 
Affecting The Immune Response
5.1 Introduction................................................................................................................. 114
5.2 Vector selection......................................................................................................... 115
5.3 Effect of transgene...................................................................................................... 126
5.3.1 Species Specific Transgenes...................................................................... 127
5.4 Other factors that may affect the immune response...............................................130
5.4.1 Route of vector administration/ Host Strain.............................................130
5.4.2 Experimental strategies to address effect of route of 
administration/host strain........................................................................... 133
5.5 Role of Haplotype...................................................................................................... 139
5.6 Role of Interleukin-10................................................................................................141
Chapter 6: Cellular Based Immune Responses In Normal And Haemophilia B 
Mice
6.1 Introduction................................................................................................................. 149
6.2 Development of a Cytotoxic T cell assays (CTL)....................................................151
6.2.1 CTL responses to B galactosidase protein.................................................151
6.3 A study of the CTL responses to the Transgene product human factor IX
in the context of Adeno-associated or Adenoviral mediated gene transfer........... 154
6.3.1 Cytokine analysis immunised animals......................................................159
6.4 In vivo CTL..................................................................................................................160
6.5 Discussion....................................................................................................................163
Chapter 7: Inhibitor Formation In Haemophilia And Characterisation In A
Gene Based Approach And Ways To Overcome It
7.1 Background..................................................................................................................169
7.2 Aetiology of Inhibitor formation............................................................................... 170
7.2.1 Non Genetic causes.....................................................................................170
7.2.2 Genetic causes.............................................................................................170
7.3 Other inherited characteristics................................................................................... 174
7.3.1 HLA Association..........................................................................................174
7.4 Pathways in the immune response.............................................................................175
7.4.1 Antigen processing pathways.................................................................... 176
7.4.2 CD4 Th cell activation................................................................................178
7.4.3 Role of Antibody subtype..........................................................................179
7.4.4 Role of co stimulatory pathway................................................................ 180
7.4.5 Mechanism of tolerance and inhibitor developments............................. 184
7.5 Characterisation of inhibitory responses in a Gene Based approach..................... 188
7.5.1 Haemophilia B mice studies.......................................................................188
7.5.2 Cellular immune responses........................................................................ 194
VI
7.6 Haemophilia B treated with immunomodulation.....................................................196
7.6.2 Experimental approaches.......................................................................... 201
7.6.3 Results......................................................................................................... 202
7.7 Discussion................................................................................................................... 205
Chapter 8: Gene Transfer In A Large Model
8.1 Introduction.................................................................................................................213
8.2 Canine models of Haemophilia.................................................................................214
8.3 Gene Therapy in canine haemophilia B ................................................................... 215
8.3.1 Canine subclasses....................................................................................... 216
8.4 Canine experimental protocol................................................................................... 217
8.4.1 Cellular Immune responses........................................................................225
8.4.2 RT-PCR Studies for intracellular cytokine expression...........................228
8.5 Immunomodulation strategies to overcome inhibitory responses..........................230
8.6 Discussion................................................................................................................... 233
Chapter 9: Summary of Results...................................................................................236
Chapter 10: Discussion.................................................................................................. 239
References........................................................................................................................ 250
Vll
FIGURES
Figure 1 Royal Family T ree ............................................................................................ 8
Figure 2 Classical Coagulation Pathway...................................................................... 11
Figure 3 Revised Hypothesis of Blood coagulation....................................................13
Figure 4 FIX Gene and Protein structure...................................................................... 15
Figure 5 % Mutations in 1998 Haemophilia B database.............................................16
Figure 6 FIX Promoter Mutations.................................................................................18
Figure 7 Ex vivo and In vivo approaches.....................................................................40
Figure 8 Viral Infection target cells..............................................................................43
Figure 9 Generation of Recombinant AAV vectors....................................................52
Figure 10 Immune response and Gene Expression.......................................................58
Figure 11 Immunological components in a Gene Based Approach.............................59
Figure 12 Gene versus Protein based............................................................................. 61
Figure 13 FVII/PCDNA plasmid....................................................................................86
Figure 14 AAVmFIX plasm id........................................................................................ 87
Figure 15 AAVhFIX3 plasmid........................................................................................ 88
Figure 16 PCEPIV/FIX plasmid.....................................................................................89
Figure 17 PCEPIVIntron/FIX plasmid........................................................................... 89
Figure 18 FVII levels post transfection C2C12............................................................. 91
Figure 19 FIX Ag post transfection C2C12....................................................................92
Figure 20 AAV genome.................................................................................................. 94
Figure 21 Triple Transfection AAV............................................................................... 95
Figure 22 rAAV................................................................................................................ 97
Figure 23 Densities post 3rd centrifugation ................................................................106
Figure 24 PCR AAV fractions.......................................................................................106
Figure 25 Dot Blot.......................................................................................................... 107
Figure 26 Adenovirus production..................................................................................108
Figure 27 Collection procedure for Virus..................................................................... 110
Figure 28 Isotype profiles.............................................................................................. 117
Figure 29 Normal Muscle.............................................................................................. 121
Figure 30 AAV Injected animals...................................................................................121
Figure 31 Plasmid Injected animals.............................................................................. 122
Figure 32 Adenoviral based transduction.....................................................................123
Figure 33 Western blot AAVmFIX injection into normal mice.................................129
Figure 34 FIX Ag expression in WT C57BL6 and Balb/C m ice...............................134
Figure 35 Antibody titres Balb/C .................................................................................135
Figure 36 Adenovirus intravenous followed by AAV intramuscular injection 137
Figure 37 Role of H-2 Alleles in antigen presentation................................................140
Figure 38 Antigen and Antibody levels in FVB following AdhFIX injection 142
Figure 39 Roles of IE-10............................................................................................... 143
Figure 40 FIX Ag IL-10 KO mice.................................................................................145
Figure 41 Anti FIX Ab Balb/C......................................................................................145
Figure 42 % Lysis Beta Galactosidase......................................................................... 153
Figure 43 In vitro CTL....................................................................................................156
Vlll
Figure 44 In vitro CTL result........................................................................................ 157
Figure 45 In vivo CTL ................................................................................................... 162
Figure 46 In vivo CTL result..........................................................................................163
Figure 47 Adenoviral transduced muscle..................................................................... 164
Figure 48 Adeno-associated based transduced muscle................................................ 165
Figure 49 Mutation incidence Haemophilia A and Haemophilia B ........................... 171
Figure 50 CD4 T cell H elp.............................................................................................175
Figure 51 Humoral profiles in m ice..............................................................................180
Figure 52 Costimulatory pathways...............................................................................181
Figure 53 Costimulatory pathway blocking................................................................. 187
Figure 54 Western Blot, Temporal pattern antibody form ation................................ 190
Figure 55 Subclass Antibody induction following AAVmFIX injection...................191
Figure 56 aPTT values of Haemophilia B injected animals........................................193
Figure 57 Bethesda titres of Haemophilia B mice post injection.............................. 193
Figure 58 FIXcDNA expression in injected m uscle................................................... 195
Figure 59 Immunomodulatory agents in T- B cognate cell interactions ...................198
Figure 60 Cyclophosphamide treated m ice..................................................................202
Figure 61 anti CD40L Ab treated m ice........................................................................ 203
Figure 62 FK506 treated m ice.......................................................................................204
Figure 63 anti CTLA-Ig treated mice........................................................................... 205
Figure 64 Scale up: Murine -  Canine -H um an........................................................... 213
Figure 65 Canine mutation............................................................................................ 214
Figure 66 Canine FIX Antigen levels Dogs 1 & 2........................................................ 220
Figure 67 Canine FIX Antigen Dog 3 .......................................................................... 221
Figure 68 Antibody titre .................................................................................................223
Figure 69 Canine antigen dog 5.....................................................................................222
Figure 70 Antibody data Dog 5 .....................................................................................223
Figure 71 Dog 7: WBCT tim e.......................................................................................224
Figure 72 Antibody titre Dog 7 .....................................................................................224
Figure 73 Histology canine muscle...............................................................................226
Figure 74 Stimulation indices........................................................................................ 227
Figure 75 RT-PCR for intracellular cytokine expression in canine T cells............... 229
Figure 76 Canine FIX Antigen Dogs 6 & 8..................................................................231
Figure 77 Elisa Antibody titre Dogs 6 & 8...................................................................231
Figure 78 Western b lo t...................................................................................................232
Figure 79 Evolution of therapy for Haemophilia........................................................ 240
Figure 80 Relationship mutation status and inhibitor development...........................245
IX
TABLES
Table 1 Clinical features haemophilia............................................................................9
Table 2 Candidate genetic diseases amenable to a Gene Based approach................. 36
Table 3 Comparison of vectors.....................................................................................53
Table 4 AAV densities................................................................................................ 105
Table 5 Mouse stimulation indices............................................................................. 138
Table 6 Mouse Haplotypes.......................................................................................... 141
Table 7 Cytokine release assay...................................................................................159
Table 8 Point mutations in the human FIX gene associated with inhibitors 173
Table 9 Immunomodulatory agents used in gene based protocols.......................... 208
Table 10 Dosage schedule AAVcFIX injections........................................................219
Table 11 Results AAVcFIX injections.........................................................................219
Table 12 Dosage schedule immunomodulated dogs...................................................230
Table 13 Results summary............................................................................................237
ABBREVIATIONS
AAV adeno-associated virus
Ad adenovirus
Ag antigen
Ab antibody
APC antigen presenting cell
APTT activated partial thromboplastin time
bp base pairs
BU Bethesda Unit
CD cluster of differentiation
CD40L CD40 ligand
CMI cell mediated immunity
CMV cytomegalovirus
CsCl caesium chloride
CTL cytotoxic T lymphocyte
CTLA-4 cytotoxic T lymphocyte antigen-4
cFDC canine factor nine
cDNA complementary DNA
DNA deoxyribonucleic acid
ELISA enzyme linked immunoabsorbent assay
E:T effector: target
FBS foetal bovine serum
FIX factor IX
FITC fluorescence isothiocyanate conjugate
FVIII factor VIII
HLA human leukocyte antigen
IgG immunoglobulin
IL-2 interleukin 2
IL-4 interleukin 4
IL-10 interleukin 10
IM intramuscular
i.p. intraperitoneal
XI
ITR inverted terminal repeat
i.v. intravenous
kb kilobase
L litre
M molar
mAb monoclonal antibody
MgCli magnesium chloride
Mg2S0 4 magnesium sulphate
MHC major histocompatiblity complex
ml millilitre
mRNA messenger Ribose nucleic acid
mFIX murine factor nine
OD optical density
PBMC peripheral blood mononuclear cells
PBS phosphate buffered saline
PCR polymerase chain reaction
RNA ribonucleic acid
RT reverse transcription / room temperature
s.c. Subcutaneous
SI stimulation index
TBE Tris-Borate-EDTA
TCR T cell receptor
TE Tris EDTA
Th T helper cell
pi micro litre
|liM micromolar
Pg micro gram
WBCT whole blood clotting time
Xll
PUBLICATIONS
Roland W. Herzog, Paul A. Fields, Valder R. Arruda, Jeff O. Brubaker, Elina 
Armstrong, Darryl McClintock, Dwight A. Bellinger, Linda B. Couto,
Timothy C. Nichols, Katherine A. High
Influence of vector dose on factor IX-specific T and B cell responses in
muscle directed gene therapy
Human Gene Therapy (2002) 13:1281-1291
Fields PA, Armstrong E, Hagstrom JN, Arruda VA, Murphy M, Farrell J, Hi 
Herzog RW
Intravenous administration of an E1/E3 deleted adenoviral vector induces 
tolerance to factor DC in C57BL/6 mice 
Gene Therapy (2001) 8: 354-361
Fields PA, Arruda VR, Armstrong EA, Chu K, Hagstrom JN, Herzog RW, 
HighKA
Risk and prevention of inhibitor formation in gene therapy for haemophilia B 
in context of a large gene deletion 
J  Mol Therapy (2001) 4: 201-210
Arruda VR, Hagstrom JN, Deitch J, Heiman Patterson T, Camire R, Chu K, 
Fields PA, Herzog RW, Couto LB, Larson PJ, High KA 
Post translational modifications of recombinant myotube synthesised human 
factor IX
Blood { im \)  91 \ 1
Fields PA, Kowalczyk DW, Arruda VR, Armstrong E, McCleland ML, 
Hagstrom JN, Pasi KJ, Ertl HCJ, Herzog RW, High KA.
Role of vector in activation of T cell subsets in immune responses against the 
secreted transgene product factor DC 
J  Mol Therapy (2000) 1: 225-235
Hagstrom JN, Couto L, Scallan C, Fields PA, Arruda VR, Herzog RW, High 
KA
Improved muscle-derived expression of human coagulation factor DC from a 
skeletal actin/CMV hybrid enhancer/promoter 
Blood (2000) 95: 2536-42
Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA, Burton 
M, Bellinger DA, Read MS, Brinkhous KM, Podsakoff G, Nichols TC, 
Kurtzmann G, High KA
Long-term Phenotypic correction of canine haemophilia B by gene transfer of 
blood coagulation factor DC mediated by an adeno-associated vector 
Nature Medicine (1999), 5: 56-6
X lll
Fields PA, High KA
Gene Therapy: Factor IX Deficiency
Science and Medicine (1999) 6: 4-5
Goldspink G, Skarli M, Fields PA
Gene transfer into muscle for the treatment of Muscular dystrophies and 
Haemophilia
Gene Ther Mol Biol (1999) 3: 233-241 
Fields PA, Pasi KJ
Gene Therapy for Haemophilia: How far have we come?
Haemophilia (1998) 4: 699-703
XIV
CHAPTER 1
INTRODUCTION
1.1 Haemophilia: Historical Perspectives
Haemophilia is an inherited bleeding disorder caused by defective production of either 
procoagulant protein factor VIII or DC. It is a monogenic disease caused by a 
molecular defect in either the factor VIE or DC gene on the X chromosome and is, 
therefore, transmitted in an X linked fashion. The word haemophilia is derived from 
the Greek word haima, blood, and philein, to love, meaning senseless bleeding. The 
first use of the word haemophilia was attributed to Schonlein (Virchow, 1854) but the 
first written use was by Hopf, a student of Schonlein, who gave a dissertation entitled 
“Die Hamophiliet” at Warzburg in 1828. Clinically the two disorders, deficiency of 
factor VIII (Haemophilia A) or factor DC (Haemophilia B) are indistinguishable and 
no differentiation can be made with regard to the bleeding tendency. The first 
described case of haemophilia as a bleeding disorder was documented over 1700 
years ago in the Babylonian Talmud. In early Jewish history the disorder was 
recognised following circumcision. At this time it was taught from the words of 
Rabbi Judah the Patriach:
“ For it was taught : i f  she circumcised her child and he died (as a result o f bleeding 
from the operation), and a second one also died, she must not circumcise her third 
child. ”
The decree of Rabbi Judah recognised the familial and sex linked nature of the 
bleeding defect and variations of his edict have been incorporated into Rabbinical law 
throughout the centuries and repeatedly commented on by others (Maimonnides, 12th 
century).
The first reported case of haemophilia in the USA was reported in the Massachusetts 
Gazette of March 22 1791, and described the case of Isaac Zoll who died in Frederick 
County, Virginia, at the age of 19 from
“A slight cut in one o f his feet, with an axe. From the time o f his receiving the wound, 
till he expired, no method could be devised to stop the bleeding. ”
This obituary describes five brothers who all had died of exsanguination following 
minor trauma: one received a prick with a thorn, another a scratch with a comb, a 
third a prick with a needle, a fourth, bruised his cheek against a stove, and a fifth 
received a cut in one of his thumbs. It is interesting to note that the boy’s father, 
Henry Zoll was twice married and only the children of the first wife were affected by 
the bleeding tendency.
In 1803, John C. Otto of Philadelphia described a family with a severe bleeding 
tendency. Otto recorded that only males were subject to a “strange affliction” and that 
females although exempt, were still capable of transmitting it to their male children. 
The first pedigree of haemophilia was described by Hay (1813), who followed the 
disease in the Appleton Swain family through six generations spanning 172 years. 
This family has since been reinvestigated (McKusick 1962) and been traced over 400 
years and 13 generations. The disease in this family originated from a male bom in 
Bristol, UK in 1630, and subsequently went to live in Newbury, Massachusetts in 
1639.
The first European series of the disease were case reports by the editor of Sammlung 
Auserlessener Abhandlungen (1805) and by Consbmch (1810, quoted by Bulloch and 
Fildes, 1911), followed by careful clinical and post mortem examinations by Blagden 
(1817) and Wilson (1819). Ward noted the first report of haemophilia being due to a 
coagulation defect in 1819 but his suggestion was ignored for 80 years. The next 
publication marked the transition from isolated case reports to describe the disease 
scientifically. Nasse in 1820 was of the opinion that the blood was of unusual fluidity 
and that this was due to hyperoxidation. From this study came Nasse's law that stated 
that haemophilia only occurs in males and is transmitted by unaffected females.
After 1820, the history of haemophilia is almost totally recorded in the German 
literature between 1830 and 1860. Complete descriptions of the diseases are seen in 
the German texts of Schonlein, Constatt, Neumann and Fuchs. At this time there was 
no real clue to the aetiology of the disease but it was thought by Schomnlein to be due 
to cyanosis and malformation of the heart, whilst others thought it to be due to 
anomalous gout or scrofula despite the adequate post mortem examinations (Virchow 
1854).
In 1893 Wright discovered that the clotting time of the patients blood was prolonged 
and in 1911 Addis, Minot and Lee (1916) observed that the addition of normal blood 
could correct the clotting defect in the haemophilic blood. Bulloch and Fildes (1911) 
surveyed the diseases in 235 patients and their relatives. They re-emphasised the 
limitation of the disease to males but gave no credence to earlier descriptions of 
haemophilia in the female, despite early case reports strongly suggesting a bleeding 
tendency. Indeed the female patient described by Treves in 1886 has been 
subsequently shown to belong a family afflicted with haemophilia.
In the first few years of the 20* century the diagnosis of haemophilia depended on the 
clinical and family history plus the finding of prolongation of the whole blood clotting 
time, (Listen 1839, Wright 1893) with normal levels of prothrombin. Treatment of 
bleeding episodes upto this point varied from the bizarre to the lethal, despite the 
demonstration by Lane (1840) of the beneficial effect of blood transfusion. This was 
rediscovered by Weal (1906) and Minot and Lee in 1916. The use of plasma was then 
shown by Feisly (1923) to be superior to whole blood, and this treatment then became 
standard practice for the next 30 years.
Until 1947 haemophilia was considered to be a single disease entity, then Pavlovsky 
observed that blood from one person with haemophilia could correct the defect in 
another. This phenomenon was demonstrable both in vitro and in vivo. Coincident 
with these investigations, the development of the thromboplastin generation test 
(Biggs et al, 1952) confirmed that there were indeed two separate groups of patients. 
This observation was confirmed clinically by the finding of a group of haemophilic 
patients whose defect could be corrected by the infusion of plasma from a 
haemophiliac (Aggeler et a l, 1952, Biggs et al., 1952). This new disease was called 
Christmas disease and is associated with a lack of a factor found in the serum called 
Christmas factor (CF, factor EX or PTC).
As knowledge increased and new clotting tests were devised, it became apparent that 
there were other bleeding disorders beside haemophilia. Further investigations have 
shown the need for two additional factors participating in the clotting with tissue 
thromboplastin, factor Vll (De Vries et al., 1949, Landwehr, 1951) and factor X
(Telfer et al, 1956). All these defects present with bleeding which is clinically 
indistinguishable from that of haemophilia and it is probable that early case records 
included patients with these defects.
As the pathways of blood coagulation have become more understood, it is apparent 
that other defects can be found in the laboratory which do not manifest clinically for 
example, Hageman factor (XII) deficiency (Ratnoff & Colopy, 1955) is not usually 
associated with bleeding, and deficiency of plasma thromboplastin antecedent (factor 
XI) (Rosenthal et al, 1953) is associated with bleeding in only about two thirds of 
cases. Deficiency of fibrinogen may be associated with only a mild bleeding defect.
Classical haemophilia probably exists in about 3-4 per 100,000 of the population in 
the UK (Biggs & Macfarlane, 1966). A similar incidence is found in Europe (Hardisty 
& Ingram, 1965) and in the US (Ratnoff, 1960, Lewis et al, 1963). Classic 
haemophilia is due to mutations in either the factor VIE or factor IX genes, classified 
as haemophilia A or B respectively. The clinical presentation of haemophilia B is 
indistinguishable from that of haemophilia A, though the two disorders may be easily 
separated by routine laboratory testing of FVIII and factor DC activity. The incidence 
of Haemophilia A is approximately -1:5000 male births, and for Haemophilia B is 
-1:30,000 births. Although the disease has been described in every racial group 
(Prentice & Ratnoff, 1967), it is said to be uncommon in the American Negro (Lewis 
et al, 1963), the Japanese (Yoshida, 1961) and the Bantu (Merskey, 1958).
The most famous family with Haemophilia is that of Queen Victoria, who gave birth 
to eight children, including Leopold Duke of Albany, who had haemophilia. In 
addition to this, two of her daughters proved to be carriers. It can be truly said that the 
result of transmission into the Royal Families of Europe had a profound effect on the 
course of European history. Nowhere is this more poignant than in the case of 
Alexandra, who became consort of Tsar Nicholas the second of Russia, whose son 
Alexis, bom in 1904, was affected with severe haemophilia. In Victoria’s family there 
was no evidence of any ancestor with haemophilia and it is presumed that the disease 
was due to a spontaneous mutation within her gene.
Haemophilia and The Royal Houses of Europe
Russia
Queen Victoria can be assumed to have been an obligate carrier, as over 20 relatives 
in successive generations subsequently inherited the condition. The third child of 
Queen Victoria, Princess Alice, married the Duke of Hesse at an early age and went 
onto have seven children, one of whom Frederick, had haemophilia and he died at the 
age of three years following a fall from a window. Alexandra, the younger daughter of 
Alice, whilst visiting Russia for the marriage of her elder sister Irene met the 
Tsarevich Nicholas for the first time as a 12 year old. Five years later they re-met and 
and were married in 1894 one week after the death of Nicholas’s father Alexander 111. 
The St Petersburg hierarchy did not consider the marriage undesirable even though 
Haemophilia was well recognised amongst Queen Victoria’s descendants.
Her youngest son, Leopold, had already died, as had Frederick her grandson. Despite 
this, the first reported Royal marriage to be declined because of the risk of 
haemophilia came as late as 1913, when the Queen of Romania decided against an 
association between that of her eldest son. Crown Prince Ferdinand, and Olga the 
eldest daughter of Alexandra and Nicholas. This was a little hypocritical since the 
Queen of Romania was a granddaughter of Queen Victoria and therefore a potential 
haemophilia carrier. Once Alexandra was received into the Russian Orthodox Church 
one of her first duties was to maintain the dynasty and produce a male heir.
Although her first children were female, on August 12^ 1904 Alexandra gave birth to 
a male called Alexis. For a month all seemed well with the young prince but it was 
then noticed that the young Tsarevitch was bleeding excessively and haemophilia was 
diagnosed, a fact that made Alexandra deeply depressed about transmitting the 
disease. Nicholas became embattled in the Russian revolution and Alexandra turned 
to Rasputin for spiritual help in dealing with Alexis’s illness. Unfortunately with the 
defeat in the Russian revolution Nicholas was forced to abdicate with his family 
including little Alexis. The imperial Royal Family was not granted asylum by any 
European governments, including Britain and were therefore forced to live in
Yekaterinberg until the summer of 1918 when the family were executed by firing 
squad in the early hours of July 17^^
Spain
Queen Victoria gave birth to nine children over a 17-year period {see Figure 1). The 
youngest, Beatrice, bom in 1857 proved to be a carrier for haemophilia and 
subsequently transmitted the gene to three of her four children. Her daughter Victoria 
Eugenie, had a significant effect on the political stability of Spain in the early 
twentieth century. The Spanish King’s choice of bride was important and the liberal 
Alphonso favoured a British queen and he decided to marry Eugenie even though he 
was armed with the knowledge that she might be a possible carrier. The marriage did 
not start well and a bomb was thrown at the young couple after their wedding, killing 
several people. Their first son Alponso had haemophilia and their second son Jaime 
was congenitally deaf. The third son died young and may well have had haemophilia. 
The fourth son Juan the father of the present king Juan Carlos was unaffected. There 
was a lot of anti British feelings in Spain because it was felt that these clinical 
catastrophes were a direct result of a genetically defective wife defiling Spanish royal 
blood.
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1.2 Clinical Features
Classical haemophilia is characterised by excessive haemorrhage into various parts of 
the body. The level of residual factor VIII or IX activity in plasma can accurately 
predict the severity of bleeding assoeiated with haemophilia A or B. Factor levels of 
<lu/dl are associated with severe hemorrhagie symptoms, 2-5u/dl levels with 
moderate haemophilia, and levels of 5-25u/dl with only mild disease.
Roughly 70% of haemophilia patients have severe disease, though this number may 
be overestimated since patients with severe haemophilia are more likely to seek 
medical care. Treatment of haemophilia with faetor VIII and IX replaeement has 
dramatically improved life expectancy. In the early 1900's the median life expeetancy 
was only 11.3 years whereas it is currently estimated at between 60-70 years.
Haematomas and haemarthroses are highly eharaeteristie of the disease. The severity 
of the bleeding tendeney varies markedly among families but there is little variation 
within kindreds. The table below shows the elinical elassification based on the 
severity of the clinical manifestations.
Table 1 Clinical features of Haemophilia
Classification
Factor level 
(normal range 
50-150u/dl)
Clinical features
Severe <lu/dl
Frequent spontaneous haemorrhages and 
haemarthrosis from early infancy
Moderate 2-5u/dl
Haemorrhage secondary to trauma or surgery 
Occasional spontaneous haemarthroses
Mild 6-50u/dl
Haemorrhage secondary to surgery or trauma 
Rare spontaneous haemorrhage
Severely affected haemophiliac individuals experience spontaneous bleeding. 
Haemarthroses become frequent at about the time the patient begins to walk and 
without effective treatment, chronic haemophilic arthropathy occurs by adulthood. 
Severely affected patients may sustain serious haemorrhages that dissect through 
tissue planes, ultimately leading to death as a result of compromise of vital organs. 
Despite the serious haemorrhagic tendency, bleeding episodes are intermittent, with 
some patients going for weeks or months without haemorrhage. Except for 
haemorrhage secondary to intracranial bleeding, sudden death due to haemorrhage is 
uncommon in individuals with severe haemophilia.
Moderately affected patients have occasional haematomas and haemarthroses usually 
associated with trauma. These patients may have factor activity of 2-5u/dl, just barely 
enough to limit the frequency of bleeding episodes. Although chronic haemophilic 
arthropathy may occur in moderately affected patients, it is usually less disabling than 
that of severely affected patients.
Mildly affected patients have infrequent bleeding episodes and the disease may go 
undiagnosed for many years, and be discovered because of excessive postoperative 
bleeding, following trauma, or after severe contact sports.
1.3 Coagulation Cascade
Blood coagulation is a host defence mechanism that protects the integrity of the 
vascular system after injury. After tissue injury the integrity of the vascular system is 
maintained by blood coagulation (haemostasis). Haemostasis involves the 
participation of coagulation proteins, platelets, vascular endothelium, and leucocytes, 
which lead to formation of platelet plug, fibrin based clot and deposition of white cells 
at the point of injury and activation of inflammatory and repair processes.
1.3.1 Classical coagulation
Classically the sequential activation of coagulation proteins that leads to the 
generation of thrombin has been described as two distinct pathways. The classic 
waterfall hypothesis for coagulation proposes the intrinsic and extrinsic pathways (see
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figure 2). Both these systems are routinely assessed in the laboratory. The activated 
partial thromplastin time measures the activity of the intrinsic system and is based on 
the contact activation of factor XII, whilst the extrinsic system function is measured 
by the prothrombin time. This scheme of the division into two pathways remains 
invaluable for the understanding of clot formation in vitro, in monitoring of clinical 
bleeding problems and monitoring anticoagulant therapy.
Figure 2 Classical Coagulation Pathway
INTRINSIC PATHWAY EXTRINSIC PATHWAY
XII — fc^XIIa
X I  ^  XIa VII
Tissue Factor
I X -----------► IXa
Ca^  ^ , Vila
vini ' i
I'
PROTHROMBIN ------------- ► THROMBIN XIII
Ca2+ i i
FIBRINOGEN------------------^  FIBRIN
^ ------------Xllla
Stable fibrin clot
Although the classical waterfall hypothesis is useful for measuring in vitro assessment 
of coagulation it fails to represent what happens in vivo. This may be pointed out by 
the following; patients with an inherited deficiency of factor XII, prekallikrien or high 
molecular kinogen manifest with no clinical bleeding problems, but they have 
prolonged activated partial thromboplastin times. These clinical observations
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demonstrate that these proteins are probably not important components of blood 
coagulation and should not therefore be considered an important component of in vivo 
blood coagulation.
Factor VII -  tissue factor is known to activate not only factor X but also factor XI. In 
the classic waterfall hypothesis this activation is not required. Tissue factor is a 
natural constituent of many non-vascular cells. Tissue factor on such cells is able to 
initiate blood coagulation. These points suggest a central role for the tissue factor- 
factor VII complex. Further evidence for a revised process of coagulation has been 
aided by the identification of an endogenous inhibitor of tissue factor induced 
coagulation (tissue factor pathway inhibitor).
1,3.2 Revised Hypothesis of Coagulation
The findings described above concerning the direct activation of factor EX by tissue 
factor-factor VII have lead to a revision of the coagulation cascade, with tissue factor- 
factor VII and factor X central to the model. The revised cascade is believed to more 
accurately represent what happens in vivo. Initiation of coagulation is brought about 
by exposure of blood to tissue factor, produced constitutively by cells beneath the 
endothelium.
When tissue factor comes into contact with circulating factor Vila, it forms a complex 
in the presence of calcium ions. Factor VII is converted to its active Vila serine 
protease by minor proteolysis (possible fi"om trace factor Xa or other protease). The 
now active factor Vlla-tissue factor complex, then converts factor IX to EXa and 
factor X to Xa. The newly generated EXa forms a complex with VEHa (activated by 
traces of thrombin generated slowly by Xa) in the presence of calcium and membrane 
phospholipid and subsequently also activates factor X to Xa. The complex is called 
“tenase”. Factor Xa binds to Va (activated by thrombin), which with calcium and 
phospholipid is called prothrombinase, the complex that rapidly converts prothrombin 
to thrombin.
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The initial TF-VIIa complex is enhanced by feedback activation of VII by factors Xa 
and IXa. However the complex is quickly inhibited by TPFI (tissue factor pathway 
inhibitor), a high affinity, low abundance protein found in plasma and on vascular 
cells. By this time the thrombin that has been produced activates factor XI as well 
factors V and VIII and therefore augments the formation of tenase and ultimately the 
production of more thrombin. Thus both the initial stage (TF-VIIa) and subsequent 
enhancement by intrinsic tenase are necessary to achieve optimal activation of the 
system.
Figure 3 Revised Hypothesis o f  Blood coagulation
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The revised hypothesis differs from the classical one in three main respects. It 
integrates all coagulation factors known to be involved in blood coagulation into a 
single pathway. It also assumes that contact activation is not required in vivo. Thirdly 
it also does not assume that initial generation of factor Xa and thrombin is the end of 
the haemostatic process.
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The revised hypothesis assumes that following initial generation, the haemostatic 
response must be reinforced and or consolidated by a further progressive generation 
of factor Xa and thrombin. The revised hypothesis (Rapaport & Rao, 1995) helps 
explain the bleeding seen in haemophilia, both spontaneous (intrinsic) and traumatic 
(extrinsic). From the revised hypothesis an absence of either factor VIII or EX will 
lead to a failure of amplification and consolidating generation of factor Xa, and lead 
to continued bleeding.
1.3.3 The role of factor IX
Factor EX and VIII are both critical components of the enzyme complex that catalyses 
the cleavage of factor X by the EXa-Villa complex to activated factor X (Xa). In the 
reaction factor IXa is the enzyme, and the factor Villa the cofactor that catalyses the 
conversion of factor X to factor Xa. The reaction also requires phospholipid and 
calcium. Activation of factor X involves the cleavage of Arg^^" -^ile'^  ^within the heavy 
chain. The cofactor probably serves to orientate the enzyme and substrate 
(Brandstetter et aL, 1995). Thus, under physiological conditions, the reaction does not 
proceed in the absence of functional factor Villa
1.4 Molecular Genetics of Haemophilia
The cDNAs for factor EX and VIE were cloned in 1982 (Kurachi et aL, 1992) and 
1984 (Gitschier et aL, 1985). The availability of this data has paved the way for rapid 
advances in the molecular characterisation of the defects responsible for the 
haemophilias (Giannelli & Green, 1996), the production of recombinant clotting 
factor concentrates for therapeutic use (White & Roberts, 1996), the generation of 
knockout animals to use as disease models of haemophilia (vide infra), and the 
production of wild type and mutant proteins for analysis of structure function analysis 
of proteins (Toole et aL, 1986, Yamaguchi et aL, 1993).
1.4.1 Factor IX gene
By contrast with the factor VIE gene, the factor IX gene is much smaller. The factor 
IX gene occupies 33.5 Kb of the long arm of chromosome X and is situated at
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position 27.1. The gene itself is composed of 8 exons and 7 introns. The structure of 
the vitamin K dependent clotting factors is strikingly similar at the protein level and at 
the level of gene organisation. Each of the 8 exons corresponds to a domain of the 
protein. Exon 1 encodes the signal peptide, exon 2 the propeptide and the amino 
terminal glutamic rich domain, the Gla domain, exon 3 an aromatic acid rich stack, 
exons 4 and 5 two epidermal growth factor like domains, exon 6 the activation 
peptide, exons 7 and 8 the catalytic domain.
The product of the factor IX gene is a polypeptide of 415 amino acids (AA) and 
proceeded by a pre pro signal peptide. The circulating factor IX consists of the GLA 
domain and two-epidermal growth factor like domains separated from the serine 
protease domain by an activation region. The polypeptide undergoes cleavage of the 
pre and pro segment of the signal peptide prior to secretion as well post translational 
modifications that include carboxylation of the first 12 glutamic acid residues, O 
linked glycosylation at Ser 53, Ser 61, Thr 159, and Thr 169 (Agarwal el aL, 1994), N 
linked glycosylation at Asn 157 and Asn 167, and B hydroxylation of Asp 164. 
Activation of factor IX entails excision of the peptide containing residues 146-180.
Figure 4 Factor IX Gene and Protein structure
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1.4.2 F actor IX  G ene M utations
Progress in molecular biology and the use of polymerase chain reaction has yielded a 
significant expansion in the detailed analysis of haemophilia B mutations. With the 
advent of PGR and rapid screening procedures based on PGR (e.g. single stranded 
conformation polymorphism) the pace of detection has increased dramatically. To
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utilise these data effectively, a database in a concise format is now published yearly in 
Nucleic Acids Research (Giannelli et aL, 1998) and available on the world-wide web 
(http://www.kcl.ac.uk/ip/petergreen/haemBdatabase.html). In the last published 
edition (7‘^  edition) of the database there are 1713 patient entries. The majority are 
accounted for by point mutations, 132 have short (<32nt) deletions or additions or 
both which are made up from 99 deletions, 25 additions and eight examples involving 
both additions and deletions. There are also 21 double mutations and one triple 
mutation. It should be noted that the database excludes patients with partial or 
complete gene deletions or more complex rearrangements. A pie chart showing the 
relative frequency of each mutation is shown below.
F igure 5 % Mutations in 1998 Haemophilia B database
Pie Chart : % frequency o f mutations in the 1998 
database
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Gross Gene Defects
Gross deletions are the main cause of gross gene defect in haemophilia B. Such 
mutations only account for 2-3 % of haemophilia B cases, and are usually associated 
with severe disease
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Small gene defects
There have now been reports of mutations in all regions of the factor IX gene. Many 
of the mutations have been noted to occur at CG doublets, resulting in a C-> T or G-> 
A transition (Koeberl et aL, 1989). This occurs because cytosines are often 
methlylated, which makes the protein unstable and susceptible to deamination. With 
deamination the methylated cytosine is converted to thymidine and since thymidine is 
a normal nucleotide it is not repaired and a mutation results. CG doublets appear to be 
hotspots for mutations and this may explain how the high number of sporadic 
mutation account for about one third of cases of haemophilia B. Some of the more 
frequent mutations do not involve CG doublets but are due to founder effect 
(Ketterling et aL, 1991a, Ketterling et aL, 1991b).
Promoter effect and mutations
Promoters are regions of the gene, which bind RNA polymerase and are therefore 
near the start site of transcription. Regulation of transcription occurs in the promoter 
region. Regulation can be mediated by CIS acting agents, which are endogenous DNA 
sequences, or by transacting elements. Transacting elements are exogenous factors, 
which bind to the promoter region and regulate transcription (Gilland & Tijian, 1992). 
These affect the transcription of the factor IX gene and have helped identify important 
elements of the factor EX gene promoter. These are nt+1 to +18, -14 to -1 , -27 to -16, 
and -32 to -22. The first, binds members of the C/EBP family of transcription factors, 
the second proteins are not yet well characterised and the third resembles an androgen 
response element (Crossley et aL, 1992).
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Figure 6 Factor IX Promoter Mutations
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The region in which results in the Leyden mutation is shown. The region binds trans acting 
elements, including the hepatic nuclear factor-4 (HNF-4), the CCAA T/enhancer binding protein 
(C/EBP), and an unknown protein (??). DBP= D site binding protein; NF-IL= nuclear factor 1- 
liver. (Updated and modified from High K.A and Roberts HR, Molecular Basis o f  Thrombosis 
and Haemostasis 1995).
Substitutions in the promoter region of factor IX have classically resulted in the factor 
Leyden phenotype. This phenotype was first described in 1970 by Veltkamp and 
colleagues (Veltkamp et aL, 1970). Most patients with the phenotype have a severe 
haemorrhagic disorder and lack factor IX antigen and activity at birth. At puberty, 
however, there is gradual increase in factor IX levels at a rate of 4-5 % per year until 
the patient reaches about age 20 when the increase in circulating factor IX alleviates 
the haemophilic condition.
1.4.3 Factor V III gene
The factor Vlll gene spans 186Kb across 26 exons near the tip of the X chromosome 
(Xq28). The factor Vlll RNA is approximately 9Kb in length and encodes an 
approximately 300kd protein. The factor Vlll protein circulates in the plasma at very 
low levels (approximately lOOmg/ml) where it serves as a critical cofactor for factor 
IX in the proteolytic activation of factor X to its active form (Xa). Factor Vlll is an 
intrinsically unstable protein, requiring strong electrostatic interaction with Von 
Willebrand factor (VWF) for stability in plasma. The two proteins circulate together 
as a tight complex in plasma. The extreme instability of factor Vlll in the absence of
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VWF accounts for the markedly reduced factor VIII levels observed in severe Von 
Willebrand disease (VWD) and in patients with variant type 2N VWD.
The Haldane hypothesis predicts that one third of all patients with an X linked lethal 
disorder should represent new mutations. This results from the fact that one third of 
all X-chromosomes reside in males and two thirds in females. The frequency of 
haemophilia A is generally estimated at between 1:10000 and 1:5000 males. Based on 
this gene frequency, approximately 1:25,000,000 to 1:100,000,000 females would be 
expected to be homozygous for a factor VIII deficient allele. Consistent with these 
predictions, classic haemophilia A in females has only very rarely been reported and 
other possible explanations should be considered whenever a female with this 
phenotype is encountered. Extreme skewing of X chromosome inactivation can result 
in unusually low factor VIII levels in female haemophilia carriers. Though this can 
produce reductions of factor VIII levels into the mild or even moderate haemophilia 
range, to reach levels <2u/dl is rare and therefore associated severe bleeding is 
extremely unlikely.
The exception are the rare individuals who carry a haemophilia A mutation associated 
with an X chromosome: autosome translocation or other cytogenetic abnormality, 
which may result in exclusive inactivation of the normal X chromosome. If the 
rearranged chromosome carries a haemophilia A mutation, this female could present 
with classic haemophilia. The diagnosis of homozygous type 2N VWD should also be 
considered in any female with very low factor VIH levels.
1.4.4 Intron 22 factor V lll gene inversion
A unique rearrangement within the factor VII gene has been identified as a common 
recurrent mechanism for haemophilia A (Naylor et aL, 1993). This rearrangement is 
an inversion within the factor VIII gene that is the result of unequal crossing over 
between a duplicated sequence within intron 22, termed gene A, and two highly 
homologous blocks of sequence located downstream of the factor VIII gene toward 
the telomere of the X chromosome arm. The rearranged gene is disrupted at intron 22. 
The resulting truncated protein product is presumed unstable and does not accumulate 
to significant levels. Thus the common factor VIII gene inversion is associated with
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undetectable levels of factor VIH (<lu/dl), and a typical severe haemophilia 
phenotype. It is thought that the specific configuration of the factor VIII gene and the 
repeated gene A elements, as well as their location on the on arm of the X 
chromosome, make this region particularly prone to rearrangement, leading to high 
frequency of this recurrent mutational event, which is now known to account for 
approximately 45% of all patients with severe haemophilia A.
Another interesting observation of the recurrent factor VIII intron inversion is the fact 
that the mutation always occurs during a male meiosis. This is presumably due to the 
large region of non-homology between the X and Y chromosome during meiotic 
pairing, favouring a misalignment between the gene repeated sequences and an 
illegitimate recombinant event, resulting in the gene inversion. The presence of a 
second X chromosome with full pairing in this region inhibits this event in a female 
meiosis, and this observation has important clinical implications. For a patient with an 
apparently new mutation in whom a gene inversion is identified, the mother can be 
generally assumed to be a carrier, with the recombination event often identified in the 
maternal grandfathers’ allele.
1.4.5 Other factor VIII gene mutations
The remaining 55% of severe haemophilia A patients who do not carry the intron 22 
inversion can generally be shown to have a more conventional defect in the factor 
VIII gene. Approximately 5% of patients have deletions removing varying sized 
segments of the factor VIII gene. The remaining defects comprise a small group of 
gene insertions/deletions and a much larger group (roughly 50%) of specific point 
mutations in exons or at splice junctions within the factor VIII gene. Additionally 
nearly all patients with mild or moderate haemophilia A (in which some residual level 
of factor Vin activity can be demonstrated) can be shown to have a point mutation 
within the factor VIII coding sequence, resulting in a single amino acid substitution.
Depending on the nature of the amino acid substitution, a range of residual factor VDI 
activities are observed accounting for the variation in severity among mild and 
moderate patients.
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Mutations which result from C (cytosine) to T (thymidine) transitions at the CpG 
dinucleotides are very common, accounting for approximately one quarter of single 
based substitutions. This hypermutability appears to result from the more frequent 
méthylation of Cs at CpG dinucleotides. Methylcytosine can spontaneously deaminate 
to Uracil, which will be converted by the cells DNA repair machinery to thymidine. A 
database of factor VIII gene mutations (Tuddenham et aL, 1994) has been maintained 
for haemophilia A that catalogues analysis from over 1000 DNA samples. Most 
recently in May 1999, 309 single based substitutions had been described with 264 
(85%) leading to a single amino acid substitutions (mis-sense mutations) and 45 
(15%) to premature stop codons (non sense mutations). An additional 38 mutations 
may lead to aberrant RNA splicing. Ninety two gene deletions have been reported 
ranging from 1Kb to 210Kb in size and overall accounting for about 5% of 
haemophilic patients.
1.5 Treatment of Haemophilia
Major progress in the treatment of haemophilia really took place in the last third of the 
20^ century. The development and availability of clotting factor concentrates 
(including Von Willebrand factor, factors VIII, DC, VII, XI, and XQI and fibrinogen) 
has revolutionised treatment. Increasingly during this period there was also 
widespread uptake of home treatment, which enabled haemophiliac individuals to lead 
more fully active normal lives with the freedom to integrate fully into society. The 
mainstay of treatment was the use of concentrates to simply replace the missing 
clotting factors and thereby lead to successful secondary prevention of a hitherto 
severe and disabling chronic disease. The term subsequently used for this form of 
therapy was “replacement therapy”. Replacement therapy with factor concentrates 
(factor Vm  or DC) is the most important part of haemophilia care. The development of 
plasma and then recombinant clotting factor concentrates has revolutionised 
haemophilia care. The problem of viral transmission by plasma-derived concentrates 
has been overcome by the use of plasma donor screening, virucidal killing methods 
and more recently the use of recombinant clotting factor concentrates.
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1.5.1 Replacement Therapy
The cornerstone of haemophilia treatment is replacement of the deficient clotting 
factor using a purified concentrate of factor VIII or DC preferably given as home 
therapy, by the patient himself or by a parent in the case of small children. Treatment 
may be given either on demand or as prophylaxis. On demand therapy is preferably 
given on the first evidence of a bleed. Home therapy ensures that the patient receives 
the treatment early in the course of a bleed.
Definition of Prophylaxis
Prophylaxis may be defined as intravenous injection of clotting factor concentrate in 
anticipation of and to prevent bleeding. Prophylaxis may be given as a single dose 
procedure that is given prior to an event that may either result in bleeding or be 
disrupted by it (i.e. surgery), as a short term procedure to counter a temporary increase 
in the fi*equency of bleeding, or a long term (primary, permanent, continuous) 
procedure in order to prevent haemarthrosis and the development of arthropathy.
The term secondary prophylaxis has been used to denote prophylaxis started afl;er the 
onset of serial bleeds when arthropathy is already manifest. Long-term prophylaxis is 
usually meant when the term prophylaxis is used.
Long Term prophylaxis
During the 1960 s and 1970 s a number of studies were published describing 
numerous attempts at the prevention of bleeding. Although some of the studies had 
obvious deficiencies such as lack of controls, low doses of concentrates, long 
treatment intervals, they showed that prophylactic treatment could reduce bleeding 
frequency (Kasper et aL, 1970; Ramsay & Parker, 1973).
Value of prophylaxis in children
One of the driving forces for prophylaxis in haemophilia is the prevention of 
haemophilic arthropathy. The most extensive experience of long-term prophylaxis 
was that of the series reviewed by Nilsson et al in 1992 (Nilsson, 1992). Prophylactic
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treatment of haemophilia A was started on a small scale in Sweden in 1958 and for 
haemophilia B in the late I960's. The rationale for prophylactic treatment was the 
observation that chronic arthropathy was less frequent and less severe in moderate 
haemophilia (i.e. factor VIII or IX concentrates l-4u/dl) than in severe (i.e. factor 
VIII/EX level <lu/dl) haemophilia.
In the 25-year survey carried out by Nilsson et al, a series of 65 patients with severe 
haemophilia A were divided into three age groups. In the group of oldest patients 
(n=25, bom 1958-72, age 21-35 at follow up) prophylactic treatment was started at 
various times between 3 and 13 years of age, and several patients already had 
arthropathy prior to the start of treatment. Initially they were given considerably less 
annual dosages than those in use today and the infusions were sometimes given only 
once a week. The treatment was successfully optimised and the mean annual 
incidence of joint bleeds being 5 (range 0.5-16), the mean orthopaedic joint score 5.1 
(range 0-15) and the mean radiological score 18 (range 0-41).
In the next group which was composed of 19 boys bom 1971-1981, (aged 13-20 at 
follow up) prophylaxis started at 1-4 years of age, usually being given twice weekly in 
dosages (800-2500 lU/kg/year) somewhat higher than those used in the previous 
group and successively increased to an average of 5400 lU/kg/year. The mean annual 
incidence of joint bleeds was reduced to 2.6 (range 0.2-17), the mean orthopaedic 
joint score was 1.2 9 range 0-7 and the mean radiological score 4.8 (0-22). Of the 19 
boys, 14 had orthopaedic scores of zero and 11 had radiological scores of zero i.e. this 
group had only minor non-disabling arthropathy.
The youngest group of 21 boys, bom between the years 1981-90, aged 3-12 at follow 
up started prophylactic treatment at the age of 1 or 2.The annual dosages ranged from 
400 to 9000 lU factor VIII per kg body weight. There were almost no bleeding 
episodes in these cases. The orthopaedic and radiological scores were zero in all 21 
patients. In this youngest group it was usually possible to maintain the factor Vm or 
IX concentrations above lu/dl between infusions.
Although a weakness of this study was the lack of a control, the findings clearly 
demonstrated that more intensive prophylactic treatment received by the youngest
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children designed to maintain plasma factor VIII or EX levels above lu/dl, yielded 
better results than earlier regimens with lower dosages.
Recommendations were then made by the international and national authorities at a 
joint WHO-WFH meeting in Geneva in 1994 (Lusher 1995). Since the main goal is to 
prevent joint bleeding and its sequelae, prophylaxis should be considered optimal 
management for persons with severe haemophilia A and B (baseline factor Vm/EX 
levels <2u/dl). Treatment should be started at the age of 1-2 years and be continued 
indefinitely. These recommendations have now been taken up by the United States 
National Haemophilia Foundation, Canadian Haemophilia Society and the United 
Kingdom Haemophilia Centre Directors Organisation, in addition to prophylaxis 
being the general policy in Sweden, Germany and a number of other European states. 
Where prophylaxis is not feasible or appropriate, on demand therapy should be given.
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1.6 Complications of Treatment
1.6.1 Inhibitor Formation
The development of an inhibitor, an alloantibody that blocks procoagulant function, is 
one of the most serious complications of haemophilia A or of haemophilia B 
treatment. Currently the incidence of inhibitor formation in the conventional protein 
based approach for haemophilia is roughly 20% for Haemophilia A (Briet et aL, 1994) 
and 4% for haemophilia B (Briet et aL, 1984).
The clinical impact of inhibitor formation has been recognised for over half a century, 
and only very recently have studies begun to clarify our understanding of inhibitor 
development. Recent studies have focussed on four main areas, a better understanding 
of the incidence of inhibitors following coagulation factor treatment, the identification 
of patients at the highest risk of inhibitor formation, the characterisation of the 
antibodies, and the development of better therapies.
Clinical features of inhibitor formation
The typical bleeding frequency or location of bleeding does not change in 
haemophiliac patients when an inhibitor develops, and joint haemorrhages continue to 
be a major problem. The development of an inhibitor should be suspected if  a patient 
does not respond appropriately to treatment.
Tests may reveal the rapid clotting factor disappearance from plasma by in vitro 
assays. The inhibitor level does not correlate well with the frequency of bleeding, but 
it does limit the kind of treatment, that is possible.
Inhibitor incidence
Clinically the development of inhibitors has significant implications for the patients, 
with resulting decreased life expectancy and increased morbidity. Inhibitors have not 
been recognised in haemophilia A patients before exposure to factor VIII. Although 
antibodies may be detected after as few as five treatments, the likelihood of
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developing an inhibitor appears to be related to the number of exposures (Ehrenforth 
et aL, 1992). Thus during the first 5-10 years of life, the incidence of inhibitors in 
haemophilia increases with the number of factor VIH infusions, and new inhibitors are 
rarely detected after 90-100 exposure days. The frequency of patient assessment is a 
key issue in evaluating inhibitor incidence. For example, several studies have detected 
low titre inhibitors that were not suspected on clinical grounds and that were only 
identified because of routine assessment every 3-6 months.
It is controversial whether the likelihood of inhibitor formation is related to the purity 
of the administered factor VIII or to its production process. The issue was originally 
raised when more highly purified factor VIII concentrates were introduced, and it has 
been of special interest since the introduction of recombinant concentrates, since there 
exists subtle differences in the processing of these products, which may alter 
immunogenicity.
There are some differences in the in the carbohydrate composition of recombinant 
factor VIII when compared to that purified from pooled normal plasma. However it is 
very uncommon for previously heavily transfused patients to develop an inhibitor 
when treatment was changed to monoclonal antibody purified or recombinant factor 
VIII (Schwartz et aL, 1990; Addiego et aL, 1993; Bray et aL, 1993).
As inhibitors develop early on in life most efforts to determine inhibitor incidence 
have looked at the response to factor VIII in previously untreated patients (PUPS). 
The interpretation of inhibitor incidence has been difficult for these new products 
since there are no previous prospective studies. Until the late 1980's, inhibitor 
assessments were retrospective, and were based on the development of resistance to 
factor v m  treatment -  with in vitro confirmation that a factor Vm inhibitor was 
responsible.
Unfortunately, the sequential introductions of intermediate purity concentrates, the 
monoclonal antibody purified factor FVIII concentrates and recombinant factor VHI 
were not systematically evaluated for possible product related changes in inhibitor 
risk. The various retrospective analyses have produced contrasting results. For 
example while inhibitor development was infi’equent in patients treated with
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cryoprecipitate in Belgium (7%) (Peerlinck et al, 1993b), patients treated in the US 
had a much higher incidence (35% Strauss et aL, 1969). In the case of intermediate 
purity products, inhibitor incidence has been reported to vary from less than 20% to 
almost 30% (de Biasi et aL, 1994). In a paper by Yee (Yee et al., 1997), an absence of 
inhibitors was demonstrated in previously untreated patients with severe haemophilia 
A after exposure to a single intermediate purity factor VIH product.
Briet (1994) summarised the key data for 8 of these studies, limiting the comparison 
to those patients at highest risk (severe haemophilia A) who developed a high 
response inhibitor. The cumulative incidence of high response inhibitors reached a 
plateau at 20 % for this group of 451 patients after 18 years of follow up (Briet et aL, 
1994). However, the individual studies had cumulative incidence values from 2 to 
46%, demonstrating the hazard of drawing conclusions from relatively small groups 
of patients.
Recent reports from the recombinant factor VIII trials provided the first detailed 
prospective characterisation of inhibitor development in previously untreated patients 
with severe haemophilia A. This multi institution study reported data from patients 
with severe haemophilia A, who had no prior exposure to any blood products and who 
were tested for inhibitor development every three months. At the times of publication, 
14 (29%) of the 49 patients treated with Kogenate had developed an inhibitor (Lusher 
et aL, 1993), as had 17 (24 %) of the 73 patients treated with Recombinate (Bray et 
aL, 1994).
Laboratory diagnosis o f Inhibitors
The slow kinetics of factor Yin inhibition must be kept in mind when evaluating 
patients suspected of having an inhibitor. Inhibitor screening is usually performed by 
incubating equal volumes of patient and normal plasma for one hour before the APPT 
measurement. If an inhibitory antibody is present, then factor VIII will be inactivated 
and the APTT prolonged. This assay is not sufficiently sensitive to detect some weak 
inhibitors.
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Quantitative inhibitor assays are an important guide to therapy and to detect changes 
in the inhibitor level. They are based on the measurement of the amount of factor VIII 
inactivated when the patient plasma is mixed with normal plasma. Most laboratories 
use the Bethesda method. In this assay patient plasma, undiluted or diluted with 
imidizole buffer, is added to an equal volume of pooled normal plasma. After a 2-hour 
incubation at 37°C, the factor VIII value for the mixture is compared to that of a 
control in which buffer replaced the patient plasma. One Bethesda unit is defined as 
the amount of antibody that causes a reduction in residual factor VIII to 50% of the 
control value (Kasper et aL, 1975). The patients’ levels are calculated by extrapolation 
from the plasma dilution that yields a 50% residual factor VIII level. Less commonly 
used variants include the New Oxford assay, where a factor VIII concentrate is the 
source of factor VIII, and the incubation is carried out for 4 hours at 37°C (Austen et 
aL, 1982). One Bethseda unit is equivalent of 1.21 New Oxford units (Austen et aL, 
1982)
1.6.2 Management of Inhibitors
As more inhibitors are seen in haemophilia A, most studies addressing the 
management of inhibitor formation have centred on haemophilia A. Most of the data 
reported in this section, therefore, discusses treatment for haemophilia A.
There are two issues to consider when managing inhibitor patients. Firstly attention is 
focussed on the management of acute bleeding. The options available depend on the 
inhibitor titre and the extent to which the patient’s inhibitor cross-reacts with porcine 
factor VIII. The treatment choice for the patient also depends on the inhibitor titre and 
whether the patient is a high responder, in whom an amnestic response is likely to 
follow a factor VIII infusion, or a low responder, where the titre remains in the 0.5-6 
BU range despite continued factor VIII exposure.
Low responder patients can be treated with factor VHI without the expectation that 
they will have an amnestic response that adversely affects further treatment. In some 
cases a temporary reduction in inhibitor titre can be achieved by plasma pheresis or 
immunoabsorption.
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The second issue that needs to be addressed is the feasibility of reducing the inhibitor 
titre by inducing immune tolerance or through immune suppression. This part of the 
treatment may require a long period of time and can only be addressed once the acute 
bleeding is under control.
a) Treatment with factor VIII concentrates
Bleeding can be most effectively controlled when sufficient factor VIII is given to 
achieve a level that supports normal haemostasis .For low titre responder patients, this 
can be achieved by infusing increasing amounts of a factor VIII concentrate, with the 
dose adjusted according to the assayed response.
In general, the effects of inhibitors as 5-10 BU can be neutralised in this way. It is 
essential to monitor the response with factor VIE assays to be sure that an adequate 
level has been achieved. Once the circulating inhibitor has been neutralised the 
amount of factor VIII needed for subsequent infusions may be similar to that for 
uncomplicated haemophilia A treatment -  or it may be impossibly large if a brisk 
amnestic response leads to enhanced antibody production.
b) Treatment with Porcine Factor VIII
Many factor FVHI inhibitors do not inhibit porcine factor VHI to the same extent as 
they do the human coagulation protein, and a high purity porcine factor VIII 
concentrate, Hyate: C has been used effectively in many haemophilia A inhibitor 
patients. It is important therefore to determine whether the patient’s plasma has a low 
or negligible inhibitor titre when incubated with porcine factor VIII.
For haemophilia A inhibitor patients, the titre vsdth porcine factor VHI is usually 15- 
30 % of that with human factor VIII, with a mean of 22%, for the 88 plasmas tested in 
the five largest series (Ciavarella et aL, 1984; Gatti & Mannucci, 1984; Kemoff, 
1984; Brettler et aL, 1989; Morrison et aL, 1993). Cross reactivity is even less for 
most auto antibodies i.e. for 69 patients, most reported in a single large series (Ludlam 
et aL, 1994), the mean cross reactivity was only 8 %. For most patients with 
haemophilia A, porcine factor VIII is an important treatment option when there is
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significant bleeding -  or a threat of serious bleeding and the patients antibody titre has 
low cross reactivity i.e. the titre is less than 10-15 BU against porcine factor VIII. 
Ideally before porcine factor VIE is used, the cross reactivity of the patients antibody 
should be determined by doing an inhibitor assay utilising porcine factor VIII 
concentrate. If the human inhibitor titre is high, most often cross reactivity will be 
present and porcine concentrate will not be effective.
c) Immune Tolerance Induction
Factor VIII inhibitors may be ablated in more than 80% of selected patients with 
severe haemophilia A subjected to immune tolerance induction (ITI), (Mariani et aL, 
1994, Kreuz et aL, 1995, Mauser-Bunschoten et aL, 1995). Successful ITI leads to 
normalisation of the factor VIII half-life, near normalisation of the patient’s quality of 
life and a reduction in the cost of treatment. The most important predictor of 
successful ITI is the inhibitor titre at the start of ITI, which affects both the likelihood 
of success and the time taken to achieve tolerance. An inhibitor titre of less than 
lOBU/ml at the time of induction of ITI significantly correlated with successful 
outcome in both the North American (NAITR) and the International Immune 
Tolerance registries (p=0.004, ans 0.001))(Mariani et aL, 1994a; Mariani & Kroner, 
1999). Tolerance may be achieved by the regular administration of factor VIII or DC 
over a period of time, which may vary fi"om a few months to two or more years in 
resistance cases until tolerance is achieved. The consensus on which dose is best for 
toleration is not widely agreed. The Van Creveld regimen uses low doses of factor 
VIII of 25 iu/kg three times weekly (Mauser-Bunschoten et aL, 1995).
At the other extreme, the Bonn Regimen uses doses of factor Vm of lOOiu/kg twice 
daily or even as high as 150iu/kg. In 1977 Brackmann and Gorsman were the first to 
report a curative treatment protocol for inhibitor patients using the Bonn protocol 
(Brackmann & Gormsen, 1977). This was based on administering high doses of factor 
FVIII (150iu/kg twice a day). The protocol was developed by Brackmann fi’om 1974 
to 1976 in an empirically based fashion, but the factors controlling the induction of 
immune tolerance toward the inhibitor antibodies and for predicting the success rate 
are still unknown. The high cost of the Bonn regimen has resulted in several studies 
using modifications of the dosage scheme.
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In a study by Oldenburg et al (Oldenburg et aL, 1999) the Bonn protocol was 
successful in 60 inhibitor patients, (36 high responders and 24 low responders) a 
response rate of 86.7 %. In 13.3 % (8 patients) of the patients the Bonn protocol was 
not successful. ITl therapy was curative therapy in all successfully treated patients. 
No inhibitor relapse has been reported and inhibitor free intervals were documented 
up to 20 years. Overall the median ITl duration to achieve partial or complete success 
was 5.4 months and 14.1 months respectively but there was a broad range of duration 
of ITl up to 100 months, mainly due to patients who were treated discontinuously 
(one or more interruptions of ITl). These patients needed about 2-3 fold the time to 
achieve partial or complete success of ITl, when compared to patients continuously on 
ITl. Interruptions must therefore be considered as one major factor causing a 
prolongation of ITl and therefore should be avoided. This study also examined 
whether the mutation type influenced the course of ITL In a limited number of 
patients the intron inversion 22 was compared to patients with other types of mutation 
and the ITl duration was considerably longer in those patients with intron 22 
inversion.
The outcome of success and dosages is a widely disputed and contentious area. The 
IITR suggest that larger doses of factor VIH have a significantly better outcome in 
patients with inhibitor titres >10BU/ml. In contrast, neither the NAITR nor GITR 
were able to demonstrate that such a relationship exists. Therefore optimal dosing for 
immune tolerance regimens has not been agreed. Currently, there is an ongoing 
clinical trial to look at the outcome between the regimens (Hay et al, 2001).
d) Use o f FEIBA in treatment o f Inhibitors
The management of bleeding in patients with inhibitors may use many different 
therapeutic modalities. Prothrombin complex concentrates and activated prothrombin 
complex concentrates have been successfully used in the treatment of bleeding 
complications in inhibitor developing patients. Despite the efficacy of these products, 
most physicians do not consider these activated products to be as effective as factor 
v m  replacement in patients without inhibitors and surgical procedures in high titre 
patients are often deferred. These activated or non-activated prothrombin concentrates
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seem to carry some thrombogenic risk, particularly after repeated dosing such as after 
surgery. FEIBA (Factor Eight Bypassing Activity, Immuno, Vienna, Austria) is an 
activated prothrombin complex concentrate widely used in patients with congenital 
haemophilia who have developed inhibitors, as in acquired haemophilia. Its efficacy 
for the treatment of bleeding episodes varies from 64% to 88% according to differing 
reports (Sjamsoedin et aL, 1981).
e) Recombinant Factor Vila
Recombinant FVIIA is an effective haemostatic agent that enhances the natural 
coagulation pathway and represents a significant advance in the management of 
patients with factor VIII or IX inhibitors. The unique mode of action rVIIa means it 
does not induce generalised coagulation. Additionally it has been shown to be non 
immunogenic in haemophilia A/B patients with inhibitors. Recombinant factor Vila 
has been studied extensively in phase II clinical trials. The largest clinical experience 
included a group of 41 haemophilia A patients who have been treated with 
recombinant factor Vila (Hedner et al., 1993). A therapeutic effect was achieved in 
most patients and there were no serious side effects or evidence of systemic 
coagulation activation.
1.6.3 Transfusion Transmitted Infection
Although the use of plasma derived concentrates were clearly efficacious, there were 
hidden dangers which had not been appreciated before their widespread use and 
uptake. As a consequence of manufacture fi*om large plasma pools they were 
contaminated with hepatitis and HIV viruses.
Hepatitis B and C
Before the development of virus inactivated factor concentrates, many patients with 
haemophilia became chronically infected with hepatitis B and C viruses. The high 
incidence of hepatitis following treatment with large pool plasma derived clotting 
factor concentrates was first recognised by Kasper and Kipnis in 1972 (Kasper & 
Kipnis, 1972). Before 1985 virtually all patients who received clotting factor
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concentrate for the first time developed non A non B hepatitis (Fletcher et al, 1983, 
Kemoff et al, 1985), which has now been identified as infection with hepatitis C 
vims (HCV).
Since 1991, all blood donations in the UK have been tested for antibodies to hepatitis 
C. It has now been shown that the vims is effectively inactivated by heat and solvent 
detergent treatment of factor concentrates. Approximately 70% of patients infected 
with HCV have a chronic elevation of liver enzymes and histological evidence of 
hepatitis. Patients with chronic HCV infection are at an increased risk of developing 
hepatocellular carcinoma. A world-wide questionnaire sent to 11801 patients, with 
haemophilia identified a risk 30 times higher than in the general population 
(Colombo et a l, 1991). Since it is possible to cure unifocal hepatocellular carcinoma, 
monitoring of haemophiliac patients by ultrasound may detect this complication early 
on. Additionally, haemophilia patients with hepatitis C infection have a high 
incidence of cryoglobinaemia, which is associated with clonal B lymphocyte 
proliferation, and chronic hepatitis C infection may also increase the risk of B cell non 
Hodgkin’s lymphomas.
HIV Infection
The optimistic perception of haemophilia dramatically changed in the early 1980's 
when in Western Europe and North Europe 60 -70 % of patients with severe disease 
became infected with the human immunodeficiency vims (HTV) that had 
contaminated concentrates. Long-term follow up of patients with haemophilia and 
HIV infection has been extremely informative about the progression of the disease 
because, in most patients the approximate time of seroconversion is known. Large 
cohort studies have shown that the probablilty of remaining AIDS fi*ee using Kaplan -  
Meier estimates up to 25 years from seroconversion is 18% (95% confidence interval 
1 l-25%)(Phillips et aL, 1994). Over the last 15 years of the last millennium, more and 
more efficacious vimcidal methods have been developed which, have markedly 
reduced the risk of transmission of blood borne infections.
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1.7 Gene Therapy
1.7.1 Introduction
The inherent side effects of treatment attributable to use of plasma derived 
concentrates, has lead to a drive to develop a better, safer, therapy for the treatment of 
haemophilia. Although recombinant products have reduced the risk of transfiision 
transmitted disease, this form of treatment is still expensive and only available in the 
developed world, still leaving up to 75% of the world’s haemophilia population 
inadequately treated. A treatment, which could be administered simply and 
infrequently, would be the ideal in these circumstances. It is strikingly appealing that 
the next stage on from recombinant technology is the administration of a simple in 
vivo form of gene replacement therapy.
Concept
A  conceptually new approach to the treatment of human disease has emerged during 
the past few decades. The concepts of gene therapy arose initially during the 1960's 
and the early 1970's. During this period cell lines were developed which could test the 
concept that foreign DNA could be introduced permanently, stably, functionally and 
heritably into mammalian cells to provide permanent new genetic functions. These 
studies were derived conceptually from the classical studies of Avery, McCleod and 
McCarty on DNA mediated genetic transformation, and since this, human geneticists 
have dreamed of the idea of using gene transfer to treat inherited diseases. However, it 
is only in the last decade that the advances made in recombinant DNA technology and 
cell biology have made it possible that this dream may become a reality. There are 
two main approaches, somatic and germline modification.
Somatic gene therapy: Any cells other than germ cells may have their genetic 
constitution altered. Therefore this only affects the individual’s genetic constitution 
during their lifetime and would not affect their children.
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Germline gene therapy: Alternatively, foreign genes can be injected into fertilised 
eggs. The inserted genes would be distributed amongst somatic and germ cells and 
will be permissive to transmission to future generations.
For a variety of technical and ethical considerations, current research is therefore 
restricted to somatic cell gene therapy. All the work described in this thesis is directed 
towards a somatic approach.
Definition of Gene Therapy
Gene therapy may be defined as the introduction of nucleic acids into cells for the 
purpose of altering the course of a medical condition or disease. In general, nucleic 
acids are DNA molecules, encoding gene products, or proteins. Although the simplest 
concept of gene therapy is for the treatment of monogenic gene disorders, it is 
possible that gene therapy can be considered as a new pharmaceutical tool for the 
treatment of many types of disease which have, as part of their aetiology, a genetic 
basis. There are many candidate diseases for a gene therapy approach, both genetic 
and acquired. In order to be considered for this approach, knowledge of the basic 
biology and science of the disease in question is required.
In particular, it needs to be understood that the phenotype of a particular disease can 
be readily explained by genotypic defect. In the case of haemophilia it is known that 
certain disease mutations result in a qualitative or quantitative defect of the respective 
clotting factor protein, resulting in an absence of circulating protein and haemophilia 
{see earlier). Candidate disorders where disease phenotypes manifest from the 
underlying genetic defects are shown in the table below. Theoretically, all these 
disorders may one day be amenable to a gene-based approach once the technology is 
optimised.
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Table 2 Candidate genetic diseases amenable to a Gene Based approach
D isease Defect Incidence T arget C ells
S evere com bined  
Im m unodeficiency  
( SC ID /A D A )
Adenosine
deaminase
Rare Bone marrow cells T 
lymphocytes
H aem ophilia  A ,B Clotting factor 
VIII or 
IX deficiency
A: 1: 10 000 
B: 1:30 000
Liver ,Muscle, 
Fibroblasts, Bone 
Marrow Cells
Fam ilial
H ypercholesterola-
em ia
Deficiency of low 
density lipoprotein 
receptor
1:1000000 Liver
C ystic F ibrosis Loss of CFTR 
gene
1:3000 Airway Epithelial 
Cells
H aem oglob inopath ies  
T halassaem ias/ S ickle  
cell d isease
Structural defects 
in
g/(3 genes
1:600 Bone marrow cells
G aucher s d isease Enzyme
Glucocerbrosidase
1:450 Bone marrow cells
a i  anti trypsin  
deficiency
Lack of anti 
trypsin
1:3500 Lung or Liver cells
1.7.2 E xperim ental considerations to address before developm ent o f  gene therapy  
protocols
In the consideration of a gene therapy treatment for hereditary disease, several 
processes have to be gone through and evaluated before it is possible to move into a 
clinical setting. First, the nature of the genetic defect leading to the disease in question 
should be completely understood. This will allow the appropriate cloning of the 
normal genes in question so they can be incorporated into prospective gene delivery 
vehicles. Equally important, is a detailed knowledge of the biology of the disease in 
question i.e. is the absence of a particular protein directly correlated with the 
manifestations of the disease in question? Will replacement of the missing protein 
ameliorate the disease manifestations? This knowledge is required so that appropriate 
target cells are selected for a gene-based approach.
This knowledge forms the basis of testing out the proof of principle for a gene-based 
approach i.e. in vitro transfection of appropriate target cells with expression of a
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biologically active protein product. Once in vitro efficacy has been established, the 
next phase of experimentation is the extrapolation of in vitro findings to an in vivo 
model. This will require the use of animal models of the disease in question to test the 
feasibility of the approach. Finally, once safe in vivo efficacy has been established, the 
stage is then set for testing out in human subjects. The scheme of testing is therefore 
shown as follows:
Invitro testing Invivo testing
Considerations Target cell choice Genes cloned (homologous)
Vectors Animal model available?
Biologically active protein? i.e. large and small model
Safety?
Toxicity?
Once these criteria have been met, and proof of principle has demonstrated in a safe 
and non-equivocal fashion, it is then safe to proceed to further testing in a clinical 
setting involving human subjects.
1.8 H aem ophilia  and G ene T herapy
1.8.1 In troduction
The concept of gene therapy treatment for haemophilia first came about in the late 
1980's. The possible use of a gene-based approach to treat haemophilia has been 
facilitated by the advances made in molecular biology over the last 20 years, which 
began with cloning of the clotting factor genes and which resulted in the capacity for 
advances in technology to develop recombinant clotting factor concentrates.
The relative disadvantages of protein-based therapy have fuelled interest in gene 
therapy for haemophilia. Gene therapy would potentially allow patients to realise the 
benefits of prophylaxis, including a reduced incidence of intracereberal haemorrhage 
and of haemophilic arthropathy, without the need for indwelling intravenous catheters
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or frequent factor infusion. The major advantage of such an approach would be that a 
constant level of clotting factor is maintained so that bleeds are prevented, and 
thereby form a safeguard not only against chronic joint injury but also against 
potentially fatal bleeding episodes such as intracranial haemorrhage. Thus it is 
possible that the relative ‘cure’ of haemophilia may be one of the first genetic 
therapies to evolve from molecular scientific advances made in the 20^ century.
1.8.2 Advantages of a gene based approach for haemophilia
Haemophilia is potentially a very attractive model for a gene-based approach for a 
number of reasons ;
1) Wide range o f  suitable target tissues with access to the circulation.
Clotting factors are normally synthesised in the liver, but several investigators have 
shown that biologically active clotting factors may be produced in several cell types, 
including fibroblasts (Palmer et al., 1989), myoblasts, (Yao et al., 1991), endothelial 
cells (Yao et al., 1991) and kératinocytes (Gerrard et al., 1993). These initial studies 
were important, since they provided the initial platform for proceeding from in vitro 
studies to proof of efficacy in animal models of disease. Therefore, the choice of 
target cell is not limited and the transgene can be inserted into any one of a number of 
tissues so long as the transgene product can gain access to the circulation.
2) Precise regulation o f  the transgene expression is not required.
A second advantage of haemophilia as a model for gene therapy is that precise 
regulation of expression of the transgene is probably not required. Most patients with 
haemophilia have severe disease with less than lu/dl. Patients vdth levels greater than 
5u/dl rarely experience spontaneous bleeding episodes (moderately affected).
Therefore, raising a patients level from > lu/dl to <5u/dl will result in amelioration of 
a severe disease phenotype. Similarly, it is clear from data based on infusion of 
clotting factor concentrates into patients with haemophilia that levels as high 150u/dl 
are not associated with ill effects since the proteins circulate as zymogens. Therefore,
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a remarkably wide range of levels of expression (3-150u/dl) falls within the 
therapeutic range. The situation in haemophilia is thus different from other medical 
disorders characterised by enzyme deficiency such as diabetes mellitus where loss of 
tight regulation of the process may lead to deleterious effects i.e. hypoglycaemic 
coma.
3) Clear endpoints fo r  efficacy available
For haemophilia this is straightforward and the following may assess the efficacy of 
the procedure
a) In vitro assays: Clotting based assays to determine correction of clotting, 
measurement of circulating clotting factor levels by clotting assays and Elisa 
assays.
b) Observation of clinical phenotype and bleeding frequency
c) Coagulation factor usage
4) Availability o f  animal models
A fourth advantage compared with other diseases, is the availability of small and large 
animal models that faithfully mirror the human disease. This has been facilitated by 
the cloning of the relevant species cDNA and the subsequent use in gene knockouts to 
produce clinically affected murine models of both Haemophilia A (Bi et aL, 1995) 
and Haemophilia B (Lin et aL, 1997, Wang et aL, 1997). Additionally there are well- 
characterised naturally occurring canine models of haemophilia (Evans et aL, 1989, 
Brooks et aL, 1997).
The development of animal models of haemophilia is essential to the development of 
a gene therapy protocol for two main reasons: to test the feasibility of a gene based 
approach in an animal model, and to demonstrate that scale up is achievable from a 
small animal model such as a mouse to a large animal model such as a canine one.
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L8.3 Approaches to Gene therapy fo r haemophilia
The introduction of the genetic material for factor VIII or factor IX into the 
appropriate targets is the only definitive approach to attempt to cure haemophilia. The 
genes may be delivered into target cells by two groups of vehicles: a) using 
recombinant viral vectors or b) using physical gene delivery methods. The 
requirements for a gene-based approach are easy to define, but are technically very 
demanding to achieve. The gene (or cDNA) is placed under the control of a strong 
(usually) viral promoter/enhancer, which may be modified to be specific for the tissue 
in which it is desired to express the gene.
Gene Delivery
Two approaches may be taken for the delivery of genes. In the ex vivo approach the 
gene of interested is introduced into cells in tissue culture and then transplanted back 
into the host animal. Alternatively the vector may be introduced into the recipient 
directly (in vivo approach). This approach does not generally attempt to target specific 
tissues.
Figure 7 Ex vivo and In vivo approaches 
Ex Vivo In Vivo
Defective g en e
Liver cellExtraction of 
liver ce ils
Cell nucleus 
Ctirom osom e
Stimulated to 
division in 
cell culture Viral vector witfi 
intact cDNA
Transfected liver cell
Intact cDNA integrated into ttie genom e
l i v e r /
in jection  of ttie  
re c o m b in a n t 
v e c to r into the  
p a tie n t’s b lood  
stream  
blood  
circulation  
system
in ta c t cD N A  in g e n e  t r a n s f e r  v e c to r
an
L8.4 Ex vivo approaches
The genetic modification in this approach is by transfecting cells to produce the 
desired protein in tissue culture, and then returning the functional cells to the patient. 
Ex vivo modifications allow for the optimisation and control of gene transfection. 
Additionally, unmodified cells can be eliminated prior to transplantation. The return 
of genetically modified cells to the body may be difficult. For the return of transduced 
haemopoietic cells, the process is straightforward with return to the blood stream. 
However, for other cells it may be necessary to establish a supporting matrix and 
blood supply to sustain the implanted cells and deliver the desired protein to the 
bloodstream. Facilitation of efficient transplantation of ex vivo cells may be achieved 
by the use of capsules with semipermeable membranes (Kingdon et al., 1993).
1.8.5 In vivo approaches
The alternative to ex vivo transfection is the direct modification of cells in the body {in 
vivo modification). The advantages of this approach are the simplicity, the ease with 
which it might be applied to patients and the fact that it eliminates the problem 
associated with transplantation of cells. This form of therapy would be the ideal, but it 
would need to be highly efficient, targeted, and not inactivated in vivo by inducing an 
immune response.
1.9 C hoice o f  G ene D elivery V ehicle
Several DNA vectors have been developed for gene therapy protocols. The vector 
must have the ability to enter a cell and be retained in the nucleus either as an episome 
(a separate DNA entity from the chromosomal DNA) or integrated into the 
chromosome, and be transcribed into mRNA in the nucleus. Vectors may be divided 
into viral vectors and non-viral vectors. Viral vectors have evolved efficient natural 
mechanisms of infecting cells such as retroviruses (Vile & Russell, 1994), adeno 
viruses and adeno-associated viruses (Kremer & Perricaudet, 1995). Non viral vectors 
(Shcofield & Caskey, 1995) such as plasmids or plasmid lipid mixtures (liposomes)
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which are artificially introduced into cells, or plasmid protein complex can bind to 
receptors on the surface of cells and enter by endocytosis.
Non Viral Vectors
Non-viral vector systems vary from direct injection of DNA to the mixing the DNA 
with polysine or cationic lipids that allow the gene to cross the cell membrane. Most 
of these approaches suffer from low efficiency of transduction and transient 
expression of the transgene due to episomal location within the nucleus. In relation to 
the haemophilia B gene therapy studies, factor IX containing plasmids have been 
electroporated into liposomes (Baru et aL, 1995) and injected intravenously into mice. 
They have also used been to ex vivo modify myoblast cell lines (Hortelano et aL, 
1996) and bone marrow stromal cells (Hurwitz et aL, 1997) before reintroducing the 
transduced cells into mice or dogs. Both of these approaches have yielded low and 
transient levels of factor DC.
More recently in vivo site directed mutagenesis using chimaeric RNA-DNA 
oligonucleotides has been reported to efficiently and specifically introduce single 
nucleotide changes in codons to the factor DC gene in rat hepatocytes, thereby 
changing the coagulation activity in plasma samples (Kren et aL, 1998). For 
correction of a genetic defect, this strategy requires that the mutation be characterised 
and that it be a point mutation. For all the non-viral strategies, further studies in large 
animals will be required to assess how competitive they are when compared with viral 
approaches.
Viral
Viral vectors include retroviral, lentiviral, adenoviral and adeno-associated vectors. 
Each vector system has its own advantages and limitations. Common to all the virus 
systems is the ability of each vector to transfer genetic material as part of the 
infectious process. In general, viral vector mediated gene transfer is more efficient 
than non-viral gene transfer, and at present is the method of choice. Viruses can bind 
to cellular receptors and introduce their genetic material into cells. When the viral 
genes are expressed in the target cell, new viral particles can be generated triggering a 
productive infection. Vectors may therefore exploit the same entry mechanisms as
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viruses from which they were derived. However, in vectors, some if not all of the viral 
genes required for replication have been replaced with potential therapeutic 
transgenes such as factor VIII or IX. Consequently, vectors cannot replicate within 
their target cell, and cannot initiate a productive infection but express the therapeutic 
protein instead (see figure 8).
Figure 8 Viral Infection o f target cells
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Retroviruses
Structure
Moloney murine leukaemia virus based retroviral vectors (MoMLV) have been the 
most commonly used vectors for gene therapy approaches. The RNA in the viral 
genome is converted to DNA in the infected cell. The genome comprises three genes 
termed gag, pol, and env, which are flanked by elements called long terminal repeats 
(LTRs). These are required for integration into the host genome and they also define 
the beginning and the end of the viral genome.
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The LTRs also serve as enhancer-promoter sequences and control the expression of 
viral genes. The final element of the genome, the packaging sequence (\j/), allows viral 
RNA to be distinguished from other RNAs in the cell. By manipulation of the viral 
genome, viral genes can be replaced with transgenes such as factor VIII and EX. 
Transcription o f the transgenes may be under the control of the viral LTRs or 
alternatively, enhancer promoter elements can be engineered in with the transgene. 
The chimaeric genome can then be introduced into a packaging cell, which produces 
all of the viral proteins (such as the products of the gag, pol, env genes). However, as 
these have been separated from the LTRs and the packaging sequence, only the 
chimaeric viral genomes are assembled to generate a replication-incompetent 
retroviral vector.
Advantages
These vectors can be produced at moderate titres in vector producer cell lines and 
have the capacity to transduce a wide variety of cell lines. Therefore in vivo, if the 
given target cells transduced can produce both active clotting factor and secrete it into 
the circulation, delivery of the vector during the appropriate part of the cell cycle 
should provide physiologically active clotting factor into the circulation. As the 
vectors integrate into the host cell genome, progeny cells will also express the vector 
sequence. Therefore, this allows long-term maintenance of the vector in the treated 
individual, and ensures that only a few transduced cells provide satisfactory levels of 
clotting factor.
Compared to adenoviral vectors {see below), retroviral vectors are relatively non- 
immunogenic, and do not directly induce immune responses to viral components or 
induce any adjuvant effects (McCormack et aL, 1997). Significant advances have 
been made in the production of retroviral vectors vsdth the development of high titre 
retroviral producer cell lines, leading to an increase of about 100 fold over those titres 
previously available and making production for human subjects attainable. To date 
there has been considerable experience with these vectors, and now well over 1500 
patients have been treated with these vectors giving increasing confidence in overall 
safety and clinical acceptability of these agents (Anderson, 1998).
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Disadvantages
Since these vectors integrate, there is potential for insertional mutagenesis resulting in 
possible oncogenic activation. Although this possibility cannot be excluded, so far in 
more than 1500 patients treated in clinical trials, no integration has been seen 
(Anderson, 1998). Special care will need to taken in the production of these vectors to 
ensure that replication competent virus is eliminated from the final product. Clinical 
batches of retroviral vector are stringently tested for replication competent 
retroviruses (RCR). New packaging cell lines are engineered to reduce homologous 
regions that might lead to homologous recombination. Another potential concern for 
retroviral vectors is their susceptibility to inactivation by primate complement 
(Takeuchi et ah, 1996). To this end, newer packaging cell lines are being developed to 
produce vector that is resistant to primate complement inactivation (Greengard & 
Jolly, 1999).
Uses o f Retroviruses in Haemophilia 
Haemophilia B
Because of their potential to transduce several different target cells and produce 
biologically active factor EX, a number of ex vivo approaches using these cells have 
been tried. These included primary fibroblasts (St Louis & Verma 1988, Palmer et ah, 
1989, Axelrod et ah, 1990), hepatocytes (Armentano et ah, 1990), endothelial cells 
(Yao et ah, 1991), and myoblasts (Dai et ah, 1992a, Yao et ah, 1994). Some early 
success was achieved transfecting murine myoblasts, with factor DC being expressed 
for up to six months, albeit with low levels. The reason for this was due to the host 
immune response (Yang et ah, 1994b) and inactivation of the viral promoters (Yang 
et ah, 1994b).
Studies were then extended into larger animals, but the results were even less 
successful, with levels being achieved which were clinically insignificant 
(unpublished observations). However, due to the initial promise of these studies, a 
human trial was undertaken in China using fibroblasts as the target cell which were 
subsequently transplanted subcutaneuosly back into two boys. One boy was reported
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to have an increase in factor DC activity with a decrease in requirement for 
replacement therapy whilst the other boy did not achieve any benefit (Lu et aL, 1993).
Subsequent in vivo approaches were tried but with little success. In this case using 
portal vein infusion, a retroviral vector expressing canine factor DC was infused via a 
splenic catheter. To induce cell division this animal underwent a two-thirds 
hepatectomy to enable the retrovirus to infect the target hepatocytes. This procedure 
produced only low levels of factor DC (0.lu/dl) for 9 months (Kay et aL, 1994). 
Clearly, this approach would be impratical and unacceptable in humans.
Haemophilia A
Ex vivo Approaches
Early progress with factor FVIII was problematic because of the presence of a 
transcriptional silencer (Hoeben et aL, 1995) or an inhibitory sequence (Koeberl et aL,
1995). This has been mapped to two independent regions of the A2 region of the 
factor VIII coding sequence (Lynch et aL, 1993). Despite mutation of these 
sequences, factor VIII expression failed to increase (Hoeben et aL, 1995). However, 
subsequent reports (Chuah et aL, 1998) showed that incorporation of an intron 
upstream of the factor VIII coding sequence lead to considerable improvement in 
vector titre and factor VIII expression.
Initially, several ex vivo approaches were tried using fibroblasts (Hoeben et aL, 1992a; 
Hoeben et aL, 1992b) and bone marrow cells (Hoeben et aL, 1993). However, this 
approach did not yield significant circulating levels of factor VIII. An improvement 
was made by Dwarki et al (Dwarki et aL, 1995) using an MFG viral backbone to 
transduce fibroblasts, which were then implanted as neo-organs into SCID mice 
resulting in transient (one-week) expression of factor VIII. The potential for using 
skin as a target cell has been clealy shown, and further studies have shown skin 
transplants from doubly transgenic mice that expressed factor VIII only under a 
dermis specific involucrin promoter were able to reconstitute normal clotting in Rag- 
17 FVni deficient double knockout mice (Fakharzadeh et aL, 2000).
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Other ex vivo cell targets were also tried, such bone marrow stromal cells (Chuah et 
aL, 1998) which, following transplantation into immunodeficient mice produced 
factor VIII activity of 20ng/ml.
In vivo Approaches
For this approach, hepatocytes are the favoured target cell but high titres of vector are 
required. A major technological barrier to the initial use of gene therapy vectors was 
the lack of technology, which could produce recombinant vectors in sufficient titre to 
enable high levels of gene expression to be attained. Considerable technological 
advances have been made in vector production and purity, enabling titres of virus to 
be produced several fold higher than first generation vectors, enhancing the 
desirabilty of the liver directed route.
Other advances in the liver route have been the use of antecedent infusion of 
hepatocyte growth factors that increase the number of cycling hepatocyte cells to 5- 
13% and increase the number of transduced cells to 1-2 % (fi-om untreated baseline 
0.1%) (Bosch et aL, 1996; Patijn et aL, 1998a; Patijn et aL, 1998b). The tropism of 
these vectors has been improved by the use of pseudotyping of the vector glycoprotein 
coat with a vesicular stomatitis envelope (VSV). Vanden-Driessche (Vanden- 
Driessche et aL, 1999) reported a significant advance in the use of these vectors, 
demonstrating that therapeutic levels of factor VIII in newborn mice could be reached 
using a pseudotyped retroviral vector (VSV). Six of 13 mice expressed factor VIII, 
with four mice expressing at levels higher >50% normal human plasma levels. The 
remaining mice developed antibodies to the non-species specific transgene. 
Importantly in these mice, expression was maintained for greater than 12 months. The 
high levels of expression observed in these studies may have been influenced by the 
age of the mice (newborn animals) in which the hepatocytes are in high rapid 
proliferation. These results bear out those of Greengard et al (Greengard & Jolly, 
1999) in larger animals (rabbits and dogs), where long term expression of factor VIII 
was obtained for six months.
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Adenovirususes
Human adenoviruses are responsible for mild illnesses such as respiratory infections. 
The more common serotypes 2 and 5 have been exploited for use in clinical gene 
therapy trials for cystic fibrosis and cancer (Wilson, 1993). The 36-Kb double 
stranded DNA virus contains genes that express more than one gene product during 
the life cycle. Like other DNA viruses, two main phases are distinguished during the 
course of an infection: an early phase with the expression of the early viral genes El 
to E4, and a late phase, after the onset of viral replication, characterised mainly by the 
production of structural proteins. A lytic infectious cycle requires two to three days, 
during which 1000 to 10000 infectious particles are produced per cell (Kochanek, 
1999).
By eliminating the El region of the vector, two goals are accomplished: space is made 
for the placing of gene sequences and in the absence of the El a protein the virus 
cannot replicate. The first generation adenoviral vectors have been shown to be very 
efficient at transferring genes into most tissues after in vivo administration. These 
vectors can transduce non-dividing cells and do not integrate into host DNA. These 
vectors have been shown to effect a temporary cure in a number of animal models 
with diseases like haemophilia and hypercholesterolaemia (Jaffe et aL, 1992), 
(Kozarsky et aL, 1993; Connelly & Kaleko, 1998). However, it was subsequently 
shown that low-level production of viral antigens from the vector elicited a strong 
immune response that eliminated the transduced cells and the transgene product 
(Yang et aL, 1994b; Yang et aL, 1994c). Also, re-administration was not possible due 
to the immune response (Kay et aL, 1997).
The immune response was potent at eliciting both a cytotoxic cellular response and an 
antibody producing humoral response. In the cellular response the virally infected 
cells were killed by cytotoxic T lymphocytes. The humoral response resulted in the 
generation of antibodies to adenoviral proteins and it prevented any subsequent 
infection if  the animal was given a second injection of the recombinant adenovirus. In 
order to overcome the problem of the immune response, second generation 
adenoviruses were developed in which additional genes implicated in viral replication 
were deleted.
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The idea has now been taken further with gutting the vectors (Fisher et aL, 1996a), 
deleting all the viral genes, leaving only the beginning and the end of the genome and 
the viral packaging sequence. The transgenes encoded by these viruses persisted up to 
84 days (Fisher et ah, 1996a). However even if the genes are removed there is still 
some level of immunity to the transgenes. Immunomodulatory agents that are 
selective may be useful in blocking these immune responses as demonstrated in 
several animal models (Wilson & Kay, 1995) {vide infra Chapter 7).
Adenoviruses in Haemophilia A
Adenoviral vectors have a lot of features, which make them attractive as gene delivery 
vehicles especially for hepatocytes. They are able to be produced in high titre, have 
broad infectivity, potential for a large payload, and have in vivo gene delivery 
capacity (Zhang et aL, 1998). Intravenous administration of B domain deleted 
constructs to mice dogs and primates have resulted in efficient transduction of liver 
tissue (Connelly & Kaleko, 1998), (Connelly et aL, 1996a; Connelly et aL, 1998; 
Connelly & Kaleko, 1998; Gallo-Penn et aL, 1999). High-level factor VIQ expression 
has been noted in mice with sustained phenotypic correction (Connelly et aL, 1998). 
In some mice, correction lasted longer than 12 months with levels of greater than 
2000mu/ml. When these studies were extended to haemophilic dogs, expression was 
short lived in the main due to a humoral response to human factor the VIE (Connelly 
et aL, 1996b). In studies with human primates when a tagged FVIII construct was 
used, therapeutic levels of factor VIII expression were obtained but these were short 
lived and only recorded at the high vector doses (Brann et aL, 1999). Transient 
elevation of liver enzymes was noted, with evidence of liver inflammation by 
histology.
The induction of a host immune response to these vectors has fuelled an interest in the 
development of vectors, which are devoid of all the viral coding sequences 
responsible for the immune response. These so called “gutless” vectors have resulted 
in the MiniAd vector constructs, which contain the minimal cis elements that are 
required, and contain a full length FVIII cDNA under the control of an albumin 
promoter (Zhang et aL, 1999). When injected into mice via the tail vein, these vectors
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encoding the full-length factor VIII cDNA, resulted in physiological levels of 
circulating factor VIII (100-800 ng/ml in 3/16 mice) sufficient to correct the 
haemophilic phenotype. Expression gradually declined, due to the presence of anti 
human factor VIII antibodies (Balague et aL, 2000).
Adeno-associated virus (AA
AAV vectors are engineered from human AAV, a non-pathogenic, replication 
defective parvovirus. Wild type AAV is composed of a single stranded DNA genome 
of 4800 nucleotides. The virus has both lytic and latent phases in its life cycle. The 
lytic phase requires a helper virus e.g. adenovirus or herpes virus. In the absence of a 
helper virus, wild type AAV integrates into the host cell genome. AAV integration 
shows site specificity with high proportion of events occurring at a specific site on 
chromosome 19.
To generate recombinant vector from the virus, the viral coding sequences are 
replaced by the gene of interest in a plasmid containing only the viral inverted 
terminal repeats (ITRs), and the necessary viral genes supplied in trans on a second 
plasmid. Following introduction of these plasmids into 293 cells, the cells are infected 
with helper adenovirus and lyse 48 hours later, and recombinant AAV is purified from 
the cell lysate (Samulski et aL, 1989, Snyder et al., 1993)
Most of the AAV vectors studied to date are based on the AAV-2 serotype. Since 
most humans are seropositive for AAV-2, it is possible that the presence of these 
AAV specific antibodies would interfere with AAV transduction in vivo. To 
circumvent this problem, other AAV serotypes could be used. The large scale 
production of high titre preparations of AAV is laborious and difficult, and efforts to 
enhance this are being developed to generate stable packaging cell lines by further 
improving vector purification strategies using high affinity chromatography (Clark et 
al., 1999; Anderson et al., 2000; Auricchio et al., 2001; Rabinowitz et al., 2002).
Replacing the structural and regulatory genes, cap and rep, with factor VIII or DC, 
produces the recombinant vector, rAAV. These inserts are flanked by two inverted 
terminal repeats (ITRs) which are the minimal cis elements necessary for integration,
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replication, encapsulation and rescue from the host cell genome. The wild type virus 
is not pathogenic in humans and is replication defective requiring a helper virus such 
as adenovirus to generate infectious particles. The outline of the process is shown in 
Figure 9.
The vector itself seems to have a distinct number of advantages, making it useful for 
gene therapy applications. Firstly, it has the ability to transduce non-dividing cells, 
such as brain, muscle and liver (Blau & Khavari, 1997, Fisher et ai., 1997, Kaplitt et 
al., 1994, Kessler et al., 1996, Snyder et al., 1997, Xiao et al., 1997).
Secondly, removal of all the viral coding sequences prevents the generation of wild 
type helper virus and eliminates the possibility of immune responses to residual viral 
genome expression. In place of the 4.4 KB coding region, the virus can carry and 
express non-viral genes up to 5Kb. Similar to Adenovirus, rAAV can infect both 
dividing and non-dividing cells.
Thirdly, and crucially for haemophilia, it appears that when the vector is used as a 
gene transfer vehicle, the length of expression achieved is good. An initial report 
using rAAV lac Z containing the bacterial p galactosidase gene demonstrated stable 
muscle based expression in Balb C mice for at least 32 weeks after IM administration 
of the vector. (Kessler et ah, 1996). Long-term persistence of P galactosidase protein 
expression was demonstrated for greater than 1.5 years in healthy mice (Kessler et al.,
1996). A highly significant finding in this early work was the fact that rAAV did not 
induce substantial cell mediated immune responses. It was found that the rAAV 
vector did not elicit a CTL response to the vector transduced cells and in particular to 
the p galactosidase. These results are in stark contrast to Adenoviral vectors using the 
same transgene (Yang et al., 1996a). This result would be very desirable for using a 
secretable transgene such as factor IX.
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Figure 9 Generation o f Recombinant AA V vectors
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To generate recombinant AA V vector particles, human or primate cells (HeLa, 293 or 
COS) are first transfected with the recombinant AA V vector DNA and a 
complementing plasmid, which supplies the Cap and Rep proteins, but that cannot be 
packaged into AAV virions because the ITRs are missing. The transfected cells are 
subsequently infected with helper adenovirus, which initiates a productive lytic 
infection, or transfected with a plasmid encoding the essential adenoviral genes 
required for AA V replication
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Summary
It can be seen therefore that each individual vector has properties that may be 
advantageous or disadvantageous in a gene based setting. These properties are 
outlined in the following table:
Table 3 Comparison of vectors
Retroviral A d en oviru ses A deno-associated
Titre Low High Good
Integration Yes No Uncertain
Maximum 
insert size
-6K b >30Kb (Gut -less) 4.7Kb
Ability to enter 
non dividing cells
No Yes Yes
Safety Possibly oncogenic Not oncogenic Not known to be 
oncogenic
Vector stability Moderate Good Very good
Host range Wide Wide Wide
1.9.1 Potential C om plications o f  a G ene B ased  A pproach
The treatment of haemophilia by a gene based approach represents a new form of 
treatment for the disease and brings with it new concerns about the possible 
complications of treatment. The complications of a gene transfer therapy centre 
around three main issues:
1) Inadvertent germ line transmission
2) Insertional mutagenesis
3) Inhibitor formation
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1) Inadvertent Germ line Transmission
Here, there exists the possibility that the injected vectors instead of just inserting into 
their target tissues could theoretically disseminate inadvertently to the germline 
tissues of recipients. This could result in the transmission of the donated gene 
sequences to subsequent generations. If this were to result in permanent correction of 
the genetic defect this would be useful, but because most vectors integrate randomly, 
concern exists that the donated gene sequences may result in harm to the offspring i.e. 
if the site of integration disrupts a critical gene sequence for the developing embryo or 
if expression of the donated gene somehow disrupts the normal program of 
development.
Therefore, part of the work up for any gene-based strategy is an assessment of the 
likelihood that the donated gene sequences will be transmitted to future generations. 
Generally, the risks are lower for ex vivo strategies than in vivo strategies but this 
possible complication needs to be explored in pre-clinical studies prior to undertaking 
clinical studies.
2) Insertional mutagenesis
The risks of random insertion of integrating vectors into the host genome may lead to 
severe deleterious consequences such as the activation of proto-oncogenes and 
oncogenes which may alter the neoplastic propensity of any given cell. This could 
result in devastating long-term neoplastic complications of a gene-based approach. 
Data specifically addressing this point continue to accrue as the number of long term 
survivors of gene therapy approaches with integrating vectors increases (Ye et aL, 
1998).
Ideally, integration into the host cell genome should be ordered and predictable (to 
avoid oncogenicity) to allow for long-term production of the gene product when the 
target cell undergoes division. A useful approach to adopt for the time being until 
more data becomes available would be to limit initial trials with integrating vectors to 
older subjects who have less life expectancy. Such an approach would allow accrual
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of more data on the effects of integrating vectors while protecting the population that 
would be most affected by late appearing complications.
3) Formation o f Inhibitory antibodies
An important issue facing all gene therapy trials for haemophilia is the risk of forming 
antibodies to the transgene product. The formation of neutralising antibodies is the 
most common complication of protein-based replacement therapy, occurring in 
approximately 20% of patients with haemophilia A and 3% of those with haemophilia 
B (Brettler, 1996; Kay & High, 1999). Despite several years of study it is still not 
possible to predict which patients will develop inhibitory antibodies, but certain risk 
factors have been identified, such as the nature of the underlying mutation, inherited 
characteristics of the individuals immune response, and the circumstances 
surrounding exposure to the clotting factor protein i.e. the presence of tissue injury or 
inflammation.
A major concern for a gene-based approach is, what will the incidence of inhibitor 
formation be, using such a novel therapy? At the initiation of gene therapy protocols 
in the mid 90's no study had addressed these issues. In particular, the mechanism of 
inhibitor formation in this approach is important since knowledge of this will facilitate 
intervention strategies to deal with this complication. Factors that are likely to 
influence inhibitor formation in a gene based approach include the vector itself, 
target-tissue selected, and inclusion of tissue specific promoter elements.
Another important consideration for a gene based approach, and the development of 
inhibitor formation is the mode of antigen delivery to effect satisfactory therapeutic 
clotting factor levels. In the conventional protein based approach, delivery of antigen 
is by intermittent intravenous infusion. This in turn will lead to peak and trough levels 
of infused protein and the relationship of this situation to inhibitor formation is not 
well understood. However, for a gene-based approach the situation is different, since 
gene expression from the target tissue is constant, protein expression will be 
continuous. The effect of this on inhibitor formation will be different, from the 
protein-based situation, and some investigators have argued that continuous 
expression of antigen may be more tolerogenic, leading to less inhibitor formation,
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and that a gene based approach may even be used as a treatment for inhibitor 
formation (Evans & Morgan, 1998).
The mechanism of inhibitor formation and immune responses in a gene-based 
approach requires characterisation. The emphasis and objectives of this thesis is the 
characterisation of the immune responses and the possible development of inhibitory 
antibodies and strategies to modify such responses. These issues are expanded upon in 
chapter 2, which outlines the problem and strategies to tackle it.
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CHAPTER 2
INITIAL AIMS AND OBJECTIVES
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2.1 T he Im m une R esponse to a G ene T ransfer A pproach  
The problem
One of the biggest concerns for a gene-based approach for the treatment of a human 
disease is the development of an immune response to the process. This happens in the 
conventional approach for haemophilia, where an immune response results in a 
antibody mediated humoral response to the infused clotting factor protein. Clinically, 
such inhibitory antibodies (inhibitors) complicate therapy, and can make affected 
patients very difficult to treat.
The occunence of an immune response may be anticipated, since the introduction of 
any new protein (or transgene product) will be seen as foreign by a naive host and 
therefore trigger an immune response. For a gene-based approach to be successful, 
gene expression must continue and not be down regulated by an immune response. If 
this were to occur, gene expression may be lost and the treatment aims fail. Figure 10 
stylises the appearance of an immune response and consequent loss of gene 
expression.
Figure 10 Immune response and Gene Expression
G ene
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The mediators of this response may be cellular (CD4, CDS) or humoral 
(immunoglobulins), and there are several components of the treatment process where 
an immune response may occur. The components may broadly be divided into 
external factors (characteristics of the vector and the transgene) and internal factors
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(characteristics of the host to receive gene therapy). The immune response may occur 
to one, both (or more) of the components as illustrated in Figure 11.
Figure 11 Immunological components in a Gene Based Approach
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(Key: T = Transgene, V= Vector)
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2.2 Immunological Components of a Gene Based Approach which may limit 
success
There are several points at which the immune response may limit overall efficacy of a 
gene transfer approach. The immune response may occur to endogenous host factors 
or exogenous factors, as outlined in the figure above {Figure 11).
2,2.1 External Factors
a) Transgene Selection
With the introduction of any new form of therapy for haemophilia it is important to 
anticipate the consequences of a possible immune response to the transgene product 
of the factor IX gene. It is known from previous introductions of new forms of 
therapy, that this is likely to occur. In the conventional protein based approach, 
intravenous infusion of either recombinant or plasma derived clotting factor 
concentrate may generate an inhibitory antibody response mediated by an MHC II 
pathway. This results from the activation of CD4 positive cells and their subsequent 
cognate interaction with B cells (Singer et al., 1996; Reding et al., 1999), resulting in 
antibody production. Therefore a humoral antibody mediated response may result 
from the transgene product human factor DC once it is secreted from the target cells 
into the circulation.
However, in a gene based approach an added layer of complexity is introduced, since 
the protein is manufactured intracellularly. The resultant peptides of the produced 
protein will be presented to the effector immune system on the surface of the target 
cell via a MHC I class pathway. This could theoretically lead to a chance of eliciting a 
cytotoxic T cell response (CTL) response to the peptide fragments presented on the 
cell surface and lead to elimination of the target cells manufacturing the novel 
proteins. This is in addition to the immune response, which may also occur to the 
proteins once they are secreted from the target cell, which is mediated via MHC class 
II pathways. Thus, in any gene therapy approach for haemophilia, one has to consider 
the additional interaction of an MHC class I response. Figure 12 illustrates the
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pathways involved in MHC presentation, with the differences between the protein 
based and gene based approach emphasised.
Figure 12 Gene versus Protein based
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Intrinsic properties o f  the transgene
The properties of the transgene itself are also crucial to the overall outcome. With 
reference to haemophilia, the transgene product (factor VIII or IX) needs to be 
secretable. However, most gene transfer studies addressing the possible problem of a 
CTL response to the transgene product have used the p galactosidase gene as a 
reporter gene. This gene is bacterially derived and non-seeretable, and is clearly not 
representative of what may happen to a species-specific homologous transgene, which 
is required for use in haemophilia. Prior to undertaking this thesis there was no 
published work examining a possible CTL response to a secretable protein.
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Fortunately, the recent availability of the relevant homologous transgenes and 
haemophilic animal models allows these questions to be addressed.
b) Vector selection
The vector used for gene transfer may influence the immune response to the vector 
itself and the transgene that it encodes. If the vector is highly immunogenic, it may 
trigger an immune response to the vector and possibly, even the transgene it encodes. 
The immune response may once again be cellular or humoral. In a humoral driven 
response the antibodies generated may lead to enhanced clearance of a vector, and 
more importantly, may preclude vector readministration.
2,2.2 Internal Host Factors
In the evaluation of an immune response to a new form of therapy for haemophilia, 
host cell factors play a critical role in predicting whether or not an immune response 
occurs. This is well demonstrated in the pathogenesis of inhibitor formation, where it 
is clear from numerous studies in replacement therapy of haemophilia, that underlying 
mutation plays a role in inhibitor formation. For these reasons stated above, there is 
more complexity in the gene-based approach.
2.3 Primary Objectives and Experimental Approaches Adopted
The primary objective of this thesis was to define the role of an immune response in a 
gene based approach, by characterising its occurrence both at a cellular and humoral 
level. In particular, a specific aim was to ascertain whether the process was T cell 
dependent or, independent.
Experiments were designed to investigate the humoral immune response in a muscle 
directed approach in both normal immune competent animals and in disease models 
of haemophilia B. The influence of vector selection was also examined and the effect 
it may have had on the resulting immune response. Additionally, for a gene-based 
approach to treating haemophilia, there also exists the potential for a cellular based 
response, as the protein is produced intracellularly and therefore affords the
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opportunity of a CTL response to the produced protein. A second objective therefore, 
was to examine whether a CTL response could be elicited to the secretable transgene 
product human factor EX.
In the conventional replacement therapy one of the likely factors, which is associated 
with the development of an inhibitory immune response, is the nature of the 
underlying mutation causing haemophilia. A further objective was to examine the role 
of inhibitor formation in an animal model where the disease was caused by a large 
gene deletion, and one where the disease results from a missense mutation.
In designing these experiments, other factors considered were the route of gene 
delivery and its relationship to the likelihood of an immune response, and in particular 
whether certain routes of administration lead to a more tolerant state. In studying this, 
possible mechanisms were explored to explain the results observed. A final aim of the 
thesis was to explore ways of overcoming the immune response if it occurred, by 
means of immunomodulatory drug or antibody therapies specifically designed to 
block activation pathways of the immune system. In summary therefore, the thesis 
had three main objectives to:
1) To define the role and outcome of the immune response to a gene-based approach 
for the treatment of haemophilia B. The main emphasis, was to study humoral 
and cellular responses to the human transgene product factor IX in the context of 
AAV directed muscle based gene transfer.
2) To define factors both exogenous and endogenous, to the process, which may 
affect outcome of the response.
3) To try to overcome any possible response by the design of immunomodulatory 
strategies.
The thesis does not set out, or attempt to cover, all the aspects of the immune 
response, but primarily the work was performed to define some of these responses, 
which were not known about at the outset of these studies.
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CHAPTER 3
MATERIALS AND METHODS
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This chapter is divided into three primary sections, according to whether the 
techniques fell into one of three categories listed.
• Clotting based assays
• Immunological assays
• Molecular assays
3.1 Clotting Based Assays: Murine Assays
3.1.1 Modified APTT
The assay was performed by mixing 50 pi of murine test plasma and citrate buffer 
with 50pl FIX deficient plasma (Organon Technika, Durham, NC) and incubating 
with SOpl APTT reagent (Organon Techninka) for 3 minutes at 37°C. 50pl of 25mM 
CaClz was then added and the time to clot formation was measured with a fibrometer 
(Fibrosystem Cockeysville MD)(Kung et al., 1998).
3.1.2 Bethesda Assay
The test plasma was taken and serial dilutions were made in Factor IX deficient 
plasma. 50pl of test plasma was incubated with 50pl normal mouse pooled plasma for 
2 hours at 37°C. Following the incubation, 50pl of the mixture was added to 50pl of 
factor DC deficient plasma and incubated with 50pl APTT reagent. The APTT was 
then recorded and the residual factor DC was calculated by using a standard curve, 
which was generated from normal mouse plasma. The Bethesda titre was then 
calculated and adjusted according to the dilution of the test plasma.
3.2 Canine Assays
3.2.1 Whole blood clotting time
The whole blood clotting time was determined as follows: 2ml of freshly drawn 
venous blood was added to separate 5ml red top tubes. The first tube was inverted
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every 2 minutes and inspected for clotting. When a solid clot was observed in the first 
tube, the second tube was inverted and inspected at 1-minute intervals. The time at 
which a solid clot formed in the second tube was recorded as the WBCT.
3,2,2 APTT clotting time
Activated partial thromboplastin time (APTT) of plasma samples were measured with 
a fibrometer (Fibrosystem, BBL, Cockeysville, Maryland). 50pl plasma samples and 
APTT reagent (Organon Teknika, Durham, North Carolina) were mixed each and 
incubated at 37^C for 3 minutes, before addition of 50pl of 25mM CaCl] and 
measurement of the clotting time with the fibrometer.
3.3 Immunological Assays
Murine
3,3,1 Factor DC Ag elisa for mouse
For coating 6.5pl, of A300 rabbit anti hFIX (Dako corp, US) was diluted into 6.5ml of 
coating buffer and 50pl of this was added to each well, using a multichannel pipetter. 
The plate was left to incubate overnight at 4®C. The plate was then washed 4 times 
using washing buffer (IxPBS w/Tween). 200 pi of diluting buffer was then added to 
each well, using multichannel pipetter as the blocking stage and the plate incubated at 
room temperure for 1 hour.
The standards were thawed: (Factor DC: 200, 100, 50, 25, 12.5, 6 and 3 ng/ml) and 
placed on ice. The serum samples tested (or media collected from cell culture) were 
then thawed. The plate was washed 4 times using washing buffer (1 x PBS w/ 
Tween), tapping the plate on the last wash onto a paper towel to empty the wells. The 
standards (lOOpl) were added to each well in the first 2 columns (in duplicate). A 
blank was added (diluting buffer) to the last row. lOOpl of each sample was added in 
duplicate in each well. The plate was incubated at 37°C for 2 hours, and then washed.
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The detection stage was carried out by diluting 4.5pl HPO-conjugated goat anti- 
human factor EX into 10.5 ml diluting buffer and adding 100 |rl to each well. The plate 
was incubated at 37°C for 2 hours and then washed. The substrate was made up using 
12-mg 0-phenylenediamine + 12 ml 0.0 IM Na-citrate, and placed on ice. The 
substrate was then activated with 2.5 pi of hydrogen peroxide and a 100 pi of 
substrate was added to each well, incubated at room temperature for -10-15 minutes, 
before reading recording the optical density at 450 nm.
3.3.2 Subclass specific Elisa (for anti Human IgG subclasses in mouse plasma)
96 well Elisa plates were coated with human derived plasma factor EX (1 pg /ml, 
mononine. Armour Pharmaceutical Co, Kankaee, IL) overnight at 4° C. The following 
morning the plates were washed and serum from the test mice was added at a dilution 
of 1/32. Following a 2-hour incubation at 37°C, the plates were washed and anti 
human factor EX was detected with horseradish peroxidase conjugated antibodies 
mouse monoclonal antibodies (1:2000) specific for mouse IgGl, IgG2a (cross 
reacting with IgG2c), IgG2b, IgG3 or IgGM (Boehringer- Mannheim, Indianapolis, 
IN). Following a 2-hour incubation the plates were washed. The detection was carried 
out using a peroxidase enzyme system, with the substrate reagent o-phenylene 
diamine (12 mg o-phenylenediamine + 12 ml O.OIM Na-citrate). The OD was read at 
450nm.
Antibody titres in pg IgG /ml were determined by standard curves for wells coated 
with serially diluted purified murine IgG proteins (IgGl, IgG2a, or IgG2b, starting at 
16 pg IgG /ml; Sigma, St Louis, MO).
3.3.3 Subclass specific Elisa to measure antibody subclasses to murine Factor IX
To perform this Elisa, wells were coated with mouse Factor EX (1 pg/ml), blocked, 
and then incubated with mouse plasma (1:16). Parallel wells were coated with two 
fold dilutions of purified immunoglobulins (Sigma, St Louis, MO) starting at 
lOOng/ml for generation of the standard curve. Secondary antibodies were specific for 
mouse IgM, IgGl, IgG2a, IgG2b, and IgG3 (Horseradish peroxidase label, Boeringer
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Mannheim). Optical density was read at 450 nm after incubation with substrate o- 
phenylene diamine (12 mg o-phenylenediamine + 12 ml O.OIM Na-citrate).
3.3,4 Cytokine Elisa for Murine Cytokine assays
These assays were performed as per manufacturers instructions (Pharmingen, US). 
Coating -  Capture antibody:
The purified anti-cytokine capture antibody was diluted to 1-4 pg/ml in coating buffer 
(CB) and 50pl added into each well (repeat by mixing and removing with 50 pi to 
ensure uniform coating. The plate was subsequently incubated at +4°C overnight (in 
the cold room). The dilutions for each cytokine capture antibody are shown in the 
table below.
Cytokine dilutions for capture antibody (purified rat anti-mouse monoclonal 
antibody):
___________ Final Cone" : Stock:___________Dilution: For 2ml CB:
IL-2 2 pg/ml 100 pg/ml 1:50 40 pi
IL-4 2 pg/ml 500 pg/ml 1:250 8 pi
IL-10 4 pg/ml 200 pg/ml 1:50 40 pi
IFNy 4 pg/ml 1000 pg/ml 1:250 8 pi
The plate was removed fi*om the cold room, and washed 4 times. Finally 200 pi of 
diluting buffer was added to each well and incubated for 1 hour at room temperature 
prior to sample loading.
Loading samples and cytokine standards
Prior to loading the samples, the cytokine standards were prepared as follows.
IFNy/IL-2
To make up these standards, serial dilutions were made fi’om a stock solution of 1 
pg/ml, starting with a highest concentration of 5000 pg/ml (1:200 dilution) and then 
performing doubling dilutions down to a concentration of 39 pg/ml.
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IL-4, IL-10
To make up these standards serial dilutions were made from a stock solution of 
50 pg/ml starting with a highest concentration of 2000 pg/ml (1:25000 dilution) and 
then performing doubling dilutions down to a concentration of 15 pg/ml. Before 
adding either the standards or test samples, the plates were washed three times. Then 
the standards and test samples are added at 100 pi per well in duplicate and left to 
incubate room temperature for 2 hours. The plate was then washed 4 times and the 
detection antibody added as follows:
Detection-antibody
The biotinylated anti-cytokine detecting antibody was diluted to 0.25-2.0 pg/ml in DB 
(Diluting buffer, PBS, 0.05% Tween, 6% Bovine serum albumin):
1 OOpl of the antibody was added to each well and the sample allowed to incubate for 
1 hour at room temperature. The plate was washed 6 times.
Final cone: Stock: Dilution: For 2ml CB:
IL-2 1 pg/ml 100 pg/ml 1:100 20  pi
IL-4 0.5 pg/ml 100 pg/ml 1:200 10 pi
IL-10 1 pg/ml 500 pg/ml 1:500 4 pi
IFNy 1 pg/ml 100 pg/ml 1:100 20  pi
Avidin-Peroxidase
The avidin- or streptavidin-HRP conjugated enzyme was diluted to the manufacturers 
optimal concentration in DB (1:1000), and 100 pi added to each well and incubated at 
room temperature for 30 minutes. The plate was then washed 8 times prior to the 
detection stage.
Substrate and Detection
The substrate was made with 12 mg o-phenylenediamine + 12 ml O.OIM Na-citrate 
and placed on ice. The substrate was then activated with 2.5 pi of hydrogen peroxide
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and 100  of substrate added to each well, and incubated at room temperature, 
looking for the colour change (~ 10-15 min). The wells optical density was then read 
on a photodetector at 450 nm.
3,3.5 Western blot
The western blot was performed by electrophoresing Ipg of murine factor protein 
onto a 7.5% polyacrylamide gel, and transferring it onto a nitrocellulose membrane 
using an electroblot system (Biorad). Subsequently, the test plasma, at a dilution of 
1/500 was added and then incubated for 1 hour. A secondary antibody, anti-mouse 
IgG conjugated to horseradish peroxidase (Boehringer Mannheim, Indianapolis, IN) 
was used at 1:1000 dilution and was allowed to incubate for 1 hour. The strips were 
subsequently washed 6 times and then substrate was added for 5 minutes before 
detection by autoradiography.
3.4 Murine Proliferation Assays
The technique used for the murine lymphocyte proliferation assay was as follows :
1, Dissection of tissues
The mice were euthanised, and then prepared for removal of the spleen and draining 
lymph nodes (popliteal and inguinal). The spleen was dissected out and placed in 
complete medium (Iscove’s MDM w/ 25mM Hepes, L-glutamine, P/S, 5-10% FBS, 
pyruvate and 2x10'^ M 2-ME [180 pi 5.5x10'^ M 2-ME into 500 ml Iscove’s makes 
2x10'^ M] using a 6 -well plate, transferring on ice until the beginning of the 
proliferation procedure. Similarly, the draining lymph nodes (Inguinal and popliteal) 
were dissected away from the injected animals and placed in completing medium and 
allowed to sit on ice, and the fat cells allowed to collect at the top of the tube. The 
cells were subsequently removed and the lymph node cells were kept on ice
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2. Preparation of cell fractions
The tissues were homogenised using a fine wire mesh and sterilised by burning in 
C2H5OH. The sterilised mesh was placed in a 6 -well plate containing 3 mis of wash 
medium (Iscove’s MDM w/ 25 mM Hepes, L-glutamine, P/S and 5% FBS). The 
tissue was placed between the two layers of the mesh and homogenised using a 3-ml 
sterile syringe plunger (max 2 spleens/mesh) to crush the tissue. The cell suspension 
was transferred into a 15-ml conical flask and repeated once again with fresh wash 
medium to collect the remaining cells, equalising the tubes with wash medium prior to 
centrifuging. The samples were transferred on ice.
The samples were spun at 500 g at +4 °C for 5 min. The supernatant was removed. 
The side of the conical flask was then tapped to displace the pellet, and 6 ml AKC 
(lysing) buffer was added to the dislodged pellet. The lymph node and spleen cells 
were then combined and left on ice for 2-3 minutes, to lyse the red cell component 
away from the harvested tissues. The samples were respun and the fractions were 
washed with 5-mls of wash medium, resuspended and centrifuged. Finally, the 
supernatant was removed and the cells were resuspended in 5 ml of complete medium 
prior to cell count being performed.
3. Cell count
A cell count was performed using a 1:1 dilution of cells in Tryptan blue (20pl dye + 
2 0 pl cell suspension) and then placing 2 0pl of the mixture into the counting chamber 
- haematocytometer. Using a counting microscope, a cell count was performed.
4. Plating out cells -  proliferation plate (96 well)
For the cell proliferation assay, Concanavalin A (lOug/ml) was used as the positive 
control (Concanavalin A is a proliferating agent, which works by crosslinking B- and 
T cell receptors).
The test stimulator for the proliferation assay was human factor IX. The factor DC has 
to be added to the effector cells in serial dilutions. The factor IX was prepared by
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making doubling dilutions starting from the highest concentration of 20(ig/ml down to 
0.3)Lig/ml. For a negative control, lOOpl mock medium was used i.e. complete medium 
without any added antigen (last row of the plate). The cells were added to the 
proliferating medium at a density of 100 pi (which equalled a density of 5x10^ 
cells/well). The final volume per well was therefore 200 pi. (All mediums used for the 
plating out stage were in complete medium -  i.e medium containing 2ME, 5% FBS, 
Sodium pyruvate, P/S, Icoves). The cells were then left to proliferate with the factor 
IX and Concanavalin A in the 5% CO2 incubatorat 37°C, for five days, prior to cell 
labelling with tritiated thymidine.
5. Cell Labelling
After day 5 of the proliferation,  ^H Thymidine was added to each well of the culture. 
1 pCi is added to each well in a volume of 20pl using the radioactive multipipetter. 
The cells were pulsed overnight and harvested onto glass fibre filters using a 96 
channel cell harvester (Nunc Gibco), washing 4 times with distilled water. Filters 
were air-dried and the Thymidine content was determined by liquid scintillation 
counting.
6. Cytokine release assay
The cytokine release assay was carried out in a 24 well plate. First, the stimulating 
antigen was added to the plate in complete medium by starting with the highest 
concentration of 20pg /ml human factor EX (Mononine, Alpha therapeutics, US) and 
making doubling dilutions down to 1.2pg/ml. Concanavalin A (con A) was used for 
the positive control at a concentration of 6pg/ml. The negative control was mock 
medium, i.e. complete medium without any added antigen (last row of the plate). 
Finally, the effector cells were added at a density of 5x10^ cells per ml. The final 
volume per well was therefore 1.5ml. The cells were incubated at +37°C in a cell 
culture incubator with CO2 at 10 % for 72-120 hours. The supernatants were 
harvested and stored at -80°C until analysis via cytokine Elisa as described above.
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3.5 Canine Assays
3.5.1 Canine Factor IX Elisa
Canine factor IX Ag levels were determined by Elisa using a mouse monoclonal anti 
human factor DC (Boehringer) as the capture antibody (this antibody cross-reacts with 
canine factor DC). Plates were coated with 1.5pg/ml antibody per ml coating buffer. 
The detection immunocomplex was a rabbit anti canine factor DC (Affinity biological, 
Hamilton Ontario, Canada) at a 1:1400 dilution using a stock solution of lOmg/ml 
(total IgG) and a horse-radish peroxidase conjugated swine anti rabbit 
immunoglobulin (with no cross reactivity with canine or murine Immunoglobulin, 
1:2000 dilution, Dako, Carpinteria, California). Purified plasma derived canine factor 
DC (Enzyme Research laboratories. South Bend, Indiana) was used as the standard. 
The lower limit of detection of the assay was approximately 1.5 pg/ml
Anti canine Ab assays
Antibodies against canine factor DC were detected either by Western Blot or Elisa.
3.5.2 Elisa
Wells of a microtitre plate were coated with purified canine factor DC protein 
(lug/ml), blocked with 6% bovine serum albumin (BSA) in PBS, pH 7.4 solution, and 
dilute serum samples were added (1: 16 in BSA/PBS). Antigen antibody complexes 
were detected in horseradish peroxidase conjugated antibodies specific to canine IgM 
(1:1000), IgGl (1:2000), IgG2 subclasses (1:2000) (Bethyl Laboratories, 
Montgomery, Texas). For the detection step, the substrate was made up as follows: 12 
mg o-phenylenediamine + 12 ml O.OIM Na-citrate, place on ice. The substrate was 
activated with 2.5 pi of hydrogen peroxide. 100 pi of substrate was added to each 
well, and the incubation was carried out at room temperature for -10-15 min. The 
optical density was read at 450nm. For the quantitation of results, wells were coated 
in parallel, using two fold serial dilutions of canine reference serum with known 
concentrations of immunoglobulins (Bethyl laboratories).
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3.5.3 Western Blot anti cFIXAb
Membrane strips with Ipg of purified canine factor DC were incubated (Enzyme 
Research laboratories, South Bend, Indiana) with canine test serum dilutes 1:200. 
Rabbit anti canine IgG (with a horse radish peroxidase label) diluted 1:1000 (Sigma) 
was used as the antibody for chemiluminescent detection.
3.6 Canine Proliferation assay
This assay was designed to look for the presence of proliferation in the CD4 cellular 
fractions to cFDC antigen in a canine model of haemophilia injected with 
intramuscular Adeno- associated vectors {see Chapter 8). I wish to acknowledge the 
helpful comments of Professor P Felsburg (University of Pennsylvania Veterinary 
School) and Dr J Brubaker (Wistar Institute) in the setting up of this assay.
Method
Blood samples (15 ml) were collected in preservative-free heparin as the 
anticoagulant and maintained at room temperature prior to isolation of lymphocytes. 
Blood samples were separated by centrifugation in HEPES-buffered Hanks Balanced 
Salt Solution followed by a ficoll gradient (Sigma Hypaque Ficoll 1.077, Sigma 
Chemical Company, St. Louis, MO) to remove platelets and red blood cells. Banded 
peripheral blood mononuclear cells (PBMCs) were washed twice in HEPES-buffered 
Iscove’s medium (GIBCO BRL, 25 mM HEPES) and remaining red blood cells were 
removed by lysis. PBMCs were cultured in lymphocyte proliferation medium 
(Iscove’s medium including glutamine, 1 mM sodium pyruvate, 5x10'^ M 2- 
mercaptoethanol, 5% fetal bovine serum, and antibiotics) in microtiter plates at 5x10^ 
cells/well.
After five days of culture (37°C, 10% CO2 in air) in the absence (mock) or presence 
of canine factor DC (two-fold serial dilutions of purified plasma-derived protein. 
Enzyme Research Laboratories, South Bend, ID, starting with 20 pg cFIX/ml 
medium), or presence of the mitogen concanavalin A (1 pg/ml), cells were pulsed 
with ^H-thymidine for 16 hours. Proliferation for each concentration of canine factor
lA
IX was assayed in quadruplicate. The cells were then harvested the following morning 
using a Tomotec harvester (Harvester 96 Mach III).
The cells were harvested onto glass filter mats (Wallac 1450-421). Once the mats had 
dried, the mat was placed in bag containing Scinti fluid and the degree of triated 
thymidine uptake was measured using a Beta lux cell scintillation counter (Nunc). The 
stimulation index was calculated as the ratio of the average proliferation of canine IX- 
stimulated cells vs. mock-stimulated cells. A stimulation index >2 was recorded as a 
positive result.
3.7 Histological analysis
3.7.7 Murine
Haematoxylin and eosin staining
Frozen sections were rehydrated by incubating in decreasing concentrations of alcohol 
(100-100-95-80-75%), before placing them in de-ionised water. They were then 
placed in Elrich's haematoxylin for 10 minutes. The slides were then rinsed in 
running tap water for 2-5 minutes and transferred in acid-alcohol (1% ethanoic acid, 
70% ethanol) for 30 seconds. They were then rinsed again in running tap water and 
were transferred in eosin for 1-5 minutes. They were then placed in de-ionised water 
and incubated in a series of alcohols (70-80-95-100-105%) before placing them in 
histoclear for 5 minutes. Following this, the slides were coverslipped-using DePex 
(BDH).
Immunofluorescence staining for CD8 deposition in mouse muscle
Cryosections were fixed in acetone, air-dried and subsequently blocked in 1% serum/ 
Ix PBS for 10 min. FITC-conjugated anti-CD8 (Pharmingen, San Diego, CA) was 
applied at a 1:25 dilution in 1% serum/Ix PBS and incubated for 1 hour. Cryosections 
of draining lymph nodes of the injected muscle were also stained with peanut 
agglutinin (PNA)-biotin (Caamono, et al., 1998).
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3.7.2 Canine
Muscle biopsies (100-200mg of tissue) of injected and non-injected tissue were 
excised with a sterile scalpel from dogs sedated by general anaesthesia with coverage 
with normal canine plasma that began before the procedure. Excised tissue was snap 
frozen and cryosections were prepared (6pm) and stained with haematoxylin and 
eosin. To look for the presence of canine factor antigen, a primary antibody dilute 
1:100 (Affinity Biologicals, Hamilton Ontario) was applied and a secondary antibody 
FITC -conjugated swine anti rabbit immunoglobulin diluted 1:30 (Dako, Carpinteria, 
California) was applied.
3.8 Generic Molecular Techniques
In order to start the construction of a vector for any gene transfer protocol, a number 
of molecular techniques are required in the cloning steps for the production of suitable 
plasmid vectors, either for use as vectors themselves or for use later in viral vector 
preparations.
Techniques acquired for Cloning of Vectors
3.8.1 Restriction Digests
These were required to manipulate various cDNA sequences from the provided 
plasmids i.e. from other investigators and the ATCC. The plasmid map was studied 
and the appropriate restriction sites identified. Then, under conditions as dictated by 
the individual restriction endonucleases, restriction digests were carried out. The 
endonucleases were supplied by Boeringher Mannheim, GIBCO, or Promega. 
Reactions were typically carried out using lOU of enzyme in a 20pl reaction with the 
relevant buffer. In any one reaction usually about l-2pg of DNA was digested.
3.8.2 Ligation Reactions
Reactions were set up in 20pl volumes containing approximately 10 ng of vector and 
50-200ng of insert in Ix ligation buffer (10 mM rATP, 1 M Tris -HCL pH 7.4, 1 M 
MgCl] and 0.3 M DTT). One pi of T4 DNA ligase (lU Boeringer) was added, the
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reaction mixture made up to 20pl with sterile distilled water (SDW) and the reaction 
was carried out ovemightat 16° C.
3.8.3 Alkaline phosphatase reaction
This reaction was carried out to dephosphorylate the vector in order to prevent re 
ligation of linearised DNA molecules during cloning procedures. Briefly, calf 
intestinal phosphatase (CIP) was used to remove the 5' terminal phosphate group of 
the digested DNA fragments. One pi of CIP was added to the restriction digest 
mixture, and incubated for 1 hour at 37°C. Then, 5mM EDTA pH 8 was added and 
the mixture heated to 65°C for 20 minute to inactivate the CIP. The DNA was then 
phenol chloroform extracted. The aqueous phase containing the DNA was 
subsequently ethanol precipitated and resupended in TE 20pl.
3.8.4 Agarose gel electrophoresis
Agarose gel of the various required percentages were made by dissolving Agarose in 
either IX Tris-borate (TBE) buffer (90mM Tris pH 8, 90mM orothoboric acid, 
2.5mM EDTA) or Ix Tris acetate (TAE) buffer (x 50 buffer contains 242 g Tris base,
57.1 ml glacial acetic acid, 100 ml 0.5 M EDTA (pH 8.0) made up to 1 litre with de­
ionised water). To visualise DNA, ethidium bromide was added at a final 
concentration of 0.5 pg/ml. The gel was the then poured into a running tray and a 
comb was added to the tray, which was then removed when wells formed prior to the 
DNA samples being added. Once the tape and comb were removed the, appropriate 
buffer xl was added (depending upon what the gel was made fi"om), 10 1^ of sample 
was mixed with 5 gl of x 6 loading buffer (0.25% bromophenol blue, 0.25% xylene 
cyanol FF and 40%, (w/v) sucrose in water). An appropriate molecular weight marker 
was used to determine the size of the DNA fragments. Typically, 0.7% w/v agarose 
was used for separation of fi*agment sizes between 0.8Kb-12Kb, whereas 0.5% w/v 
agarose separated between 0.1Kb-30Kb and 1.5% w/v between 0.2Kb-3Kb. The gels 
were run at 45-55mA and the negatively charged DNA then migrated towards the 
anode. The DNA was visualised using a UV transilluminator and photographed with a 
Polaroid black and white camera.
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3.8.5 Bacterial transformations
A lOOpl of competent cells (Epicurian Coll SURE 2 supercompetent Cells, 
Stratagene) were taken and thawed on ice in an eppendorf tube. In a volume of 50 pi, 
a maximum amount of 50 ng of DNA taken and mixed with the competent cells and 
left on ice for a maximum of 30 minutes. In a 42°C water bath, the cells were then 
heated shocked for 90seconds and then placed on ice for 2 minutes. 900 pi of LB SoC 
medium (50mls LB medium, 0.5mls IM MgSo4, 0.1 mis 20% Glucose) was added to 
the cells and the mixture was incubated for 1 hour at 37 ° C. The cells were then spun 
down and streaked out over LB/Ampicillin (Amp) plates. LB/Amp plates were made 
up from a autoclaved mixture of: 500ml de-ionised water, 5g tryptone, 2.5g yeast 
extract, 5g NaCl, 7.5g Agar. The mixture was allowed to cool, and ampicillin was 
added at a final concentration of 50pg/ml. The mixture was the added to 90 mm petri 
dishes and allowed to set. The streaked out bacteria were the incubated at 37°C 
overnight.
3.8.6 Minipreps: (Requiredfor Colony Screens of cloning vectors)
The petri dishes were removed from the incubator and a discrete colony was picked 
off the plate using a sterile toothpick and aseptic technique, and inoculated into 4mls 
LB/Amp. The mixture was placed in a shaker at 225 rpm overnight at 37°C. 1.5 mis of 
the mixture was centrifuged and the supernatant removed. The pellet was resuspended 
into lOOpl of solution I (43.75ml H2O, 1.25ml Tris Stock IM, 5ml lOOmM EDTA, 
0.45g glucose) and resuspended. Then 200 pi of solution II (lOOpl 10% SDS, 20pl 
lOM NaOH, 880pl H2O) was added to the mixture, inverting several times.
150pl of solution III (30 ml 5M Potaasium acetate, 5.75ml Glacial acetic acid, 
14.25ml H2O) was added, and the solution was shaken vigorously. The mixture was 
centrifuged in a microfuge (1300rpm) for 2 minutes. The supernatant was removed to 
a tube containing 400pl phenol/chloroform. The tube was shaken vigorously for 1 
minute and then centrifuged again for 2 minutes. The supernatant was removed and 
added to a tube containing 200 pi of chloroform and centrifuged for 2 minutes. The 
supernatant was removed and added to 800pl of ethanol 100%, vortexed and
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centrifuged for 2 minutes. The ethanol was removed and the pellet washed in 70% 
ethanol. The ethanol was removed and the pellet left to air diy and finally resupended 
in TE.
3.8.7 Maxiprep (for large scale production of DNA)
Once the DNA was deemed to be correct, a sample was then grown up by 
maxipreping according to the Quiagen protocol. 150 mis of grown culture was taken 
and spun down to create a bacterial pellet, which was resupended in lOmls of buffer 
PI (43.75mls H2O, 1.25mls Tris Stock IM, 5mls lOOmM EDTA, 0.45g glucose). The 
bacteria were completely redissolved and lOmls of buffer P2 (lOOpl 10% SDS, 20pl 
lOM NaOH, 880pl H2O) were added and incubated at room temperature for 5 
minutes. The solution was mixed thoroughly by inverting the tube 5-6 times. Then 10 
mis of buffer P3 (30 ml 5M Potaasium acetate, 5.75ml Glacial acetic acid, 14.25ml 
H2O) was added and the solution mixed by inverting 5-6 times. The solution was then 
incubated on ice for 20 minutes. After incubation, the sample was mixed again before 
centrifugation was carried out at 15000 RPM for 30 minutes at 4°C.
After centrifugation the supernatant was removed promptly and applied over a Qiagen 
tip 500 which had been equilibrated by applying 10 mis of buffer QBT (750mM 
NaCl, 50 mM MOPS, pH 7.0, 15% isopropranol, 0.15% Triton X-100. The 
supernatant was applied and allowed to drain through the column by gravity flow. 
Once drained, the column was washed twice with 30 mis of buffer QC (l.OM NaCl, 
50mM MOPS, pH 7.0, 15% isopropranol). The DNA was then eluted off the column 
with 15 mis of buffer QF (1.25M NaCl, 50mM Tris Cl, pH 8.5, 15% isopropranol). 
The DNA was then precipitated with 0.7 volumes of isopropanol previously 
equilibrated to room temperature. The mixture was centrifuged immediately at 
> 15000g at 4°C for 30 minutes and the supernatant carefully removed. The DNA was 
washed in 15 mis of cold 70 % ethanol and redissolved in TE. The yield of DNA was 
calculated by measuring the DNA concentration on a UV spectrophotometer at 
260nm.
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3,8.8 Transfections
For the transfection, the cationic lipid lipofectamine was used. Lipofectamine 
interacts with DNA to form a lipid DNA complex. The resulting lipid -  DNA 
complex fuses with the tissue culture cells under test and results in uptake and 
expression of the DNA to the target cells.
3.9 Specific Molecular Assays
PCR reactions
The polymerase chain reaction (PCR) was used for a variety of purposes: 1) To detect 
the presence or absence of specific DNA sequences, using DNA extracted from cells 
(murine, canine) or tissues. 2) To amplify specific sequences for further downstream 
manipulations (i.e. inserts for cloning), engineering convenient restriction sites within 
the primers. 3) For use in RT-PCR reactions on RNA extracted from various tissues.
For routine PCR reactions, the Taq DNA polymerase was used. Preliminary reactions 
were carried out to optimise reaction conditions, with variables such as primer 
annealing temperature, extension time and Mg^^ concentration. In all reactions, a 
control was included as a negative control to detect contamination if present. 
Additionally, a control was included that was not known to contain the target DNA 
sequence or that contained an amplifiable sequence of different length to the primary 
target sequence. PCR products were visualised either by agarose or polyacrylamide 
gel electrophoresis. Routine PCR reactions of 20 pL were set up in Ix Taq reaction 
buffer (Promega), 0.2mM dNTP's, 2-10 pmol of each primer (forward and reverse), 
1-2.5 mM MgCl], DNA template (2pl) and 2.5U of Taq polymerase (0.5pl, Promega). 
The DNA template varied from 10 ng (plasmids) to lOOng- 400ng (DNA from 
tissues). Mineral oil (Sigma) was placed on top of the mix and the tubes were placed 
on a Biometra Trioblock PCR machine. Generally, 30-35 cycles were carried out, 
with an initial 95°C template dénaturation step (1 min), 55-72° C primer annealing (1 
minute) and 72 extension (1-3 minutes) .The reactions were placed on ice or at 4°C.
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3.91 PCR Analysis of murine injected muscle
In three animals, at two months post injection, a RT-PCR reaction was performed on 
extracted muscle from the injected legs to look for the presence of factor IX cDNA. 
Total RNA was isolated from muscle using Trizol reagent (Gibco/BRL). RNA Ipg 
was reverse transcribed using a kit from Gibco/ BRL. PCR primers specific for 
murine factor EX cDNA were used to amplify 434 bp of the mouse factor EX transcript 
using one fifth of the cDNA product as the template (annealing temperature of 54°C, 
35 amplification cycles). The primers used were as follows:
Forward prim er 5 - GATTGTAACTGCTGCCCACTGTCT-3 
Reverse prim er 5 - AATCTTTGCCTCCTTCCGGGTAGC-3
No amplification product was obtained from uninjected muscle that was reverse 
transcribed.
3.92 RT- PCR protocol for Isolation of Canine cytokines from peripheral blood 
mononuclear cells
An assay was devised to measure the intracellular cell cytokine levels via an RT-PCR 
assay, due to the lack of available reagents to measure canine cytokines levels in the 
cell supernatants. PBMCs were cultured in 24-well plates at 2x10^ cells/well, and 
stimulated with canine factor EX (10 pg/ml) for 4 days. Subsequently, cells were 
harvested, and total RNA was isolated using the Trizol reagent kit from Gibco/BRL. 
RNA was reverse transcribed (1 pg/sample) using the Superscript kit from 
Gibco/BRL. 1/10th of the cDNA product served as a template for PCR amplification 
with “ready-to-go” PCR beads (Pharmacia Biotech, Piscataway, NJ).
PCR conditions were as follows: 5 minutes initial dénaturation at 94°C, 40 cycles of 
94°C (1 minute), 52°C for 1 minute (annealing for primer pairs for IFNy or IL-2) or 
60°C for 1 minute (IL-10 or P-actin primer pairs), and 72°C for I minute (extension), 
followed by a final extension step of 72°C for 10 minutes. PCR products were 
separated on an ethidium bromide stained 1.5% agarose gel.
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PCR primer pairs for canine cytokines were as follows:
• IL-2: 5’-CATCGCACTGACGCTTGTA-3’(forward primer)
5’-CTTGTTTCAGATCCCTTTAGTTTC-3’(reverse primer) yielding 
a 345-bp PCR product
• IL-10: 5’-CAGCCGACACCAGAGCACCCTACT-3’(forward primer)
5’-AAATGCGCTCTTCACCTGCTCCAC-3’(reverse primer) yielding 
a 391-bp PCR product
• IFN-y: 5’-CGGTGGGTCTCTTTTCGTAG-3’(forward primer)
5’-GCCTTGCGCTGGACCTG-3’ (reverse primer) yielding a 255-bp 
PCR product
• P-actin 5 -GCGATGAGGCCCAGAGCAAGAGG-3' (forward primer)
5’-GTCCCGGCCAGCCAGGTCCAG-3’(reverse primer) yielding a 
426-bp PCR product.
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CHAPTER 4
VECTOR CONSTRUCTION AND
PRODUCTION
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Introduction
In any gene transfer protocol, the choice of vector to deliver the transgene product is 
crucial. Vectors all have individual properties, which may or may not make them 
attractive to any given protocol. As summarised earlier, the initial studies for 
expression of clotting factors in muscle were carried out using plasmid vectors as a 
vehicle for gene delivery.
For the process to be successful, efficacy must first be achieved in vitro before 
attempting to try those vectors in vivo to prove that the selected target tissues are 
capable of producing biologically active clotting factor genes. With respect to 
haemophilia, any tissue that can produce clotting factor genes is a potential target. 
Several authors have shown that it is possible to obtain clotting factor gene expression 
from a number of tissues: fibroblasts (Palmer et al., 1989), myoblasts, (Yao et al., 
1991), endothelial cells Yao 1991. (Yao et al., 1991) and kératinocytes (Gerrard et al., 
1993).
The early in vitro work in this chapter describes the strategy of using plasmid systems 
for assessment of the optimal expression cassette, prior to incorporation into a viral 
vector (AAV) system.
4.1 Plasmid Vectors
Initially because of lack of availability of the factor IX (FIX) gene, early work was 
performed using the factor VII (FVII) gene. The purpose of these experiments was to 
demonstrate proof of principle to show that the chosen target cells could secrete FVII 
in vitro. When FIX cDNA became available the studies were extended to test FIX 
cDNA expression cassettes in vitro. The majority of the experimental work performed 
in this thesis is using the factor EX gene either as a plasmid vector or in viral vector 
systems.
84
4.1.1 FVII Plasmid Vector: FVII/PCDNA3
A  FVII vector was made by inserting the FVII cDNA into a commercially available 
I  expression vector PCDNA 3. Before these vectors were used in vivo, the vectors were 
I transfected into a muscle cell line C2CI2 and also other cell lines (Cos 7) to test 
expression capacity. The expression vector has a CMV promoter inserted which 
facilitates high-level transgene expression in muscle as a target tissue (Dai et aL, 
1992a).
The FVII cDNA insert was cut away from its PUG 19 supply plasmid (via ECORl 
restriction digest) and extracted via a gene clean kit (Quiagen, MinElute Gel 
Extraction Protocol) from the agarose gel electrophoresis gel. The PCDNA3 plasmid 
was linearised with an ECORl digest and then dephosphorylated to avoid religation 
(as described in materials and methods). The vector and insert were then set up 
overnight in ligation mix at 16°C. The following day, the ligation mix was 
transformed into competent cells and then streaked onto agar plates overnight. The 
following day the colonies grown were picked from the plates and minipreps were 
screened to analyze the extracted DNA. The DNA was run out on a gel and the 
orientation of the construct was checked by a double restriction digest. The miniprep 
gel is shown below, which shows the correct 1.9-Kb and 5.9 Kb fragments in the 
correct orientation.
5.9 Kb
fragment
1.9 Kb
fragment
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The colonies in the correct orientation were then madeup in large in quantities by 
growing up the vector using a maxiprep technique (Quiagen, Germany, Chapter 3, 
page 79). The DNA concentration produced was analysed by standard 260nm 
spectroscopic absorbance. The DNA was then stored and resuspended in glycerol 
buffer (15%) in small aliquots at -70°C.
The resulting vector produced is shown in the plasmid map below:
Figure 13 FVII/PCDNA-3 vector
P (CMV)
%  hF.VIIcDNA
ampR
pcD N A 3-F .V II
7  .80 Kb
BGH pApUC o ri 
V SV4Ü pA f1 o ri
neoR
SV40 ori
4.1.2 AAVmFIXconstruct
In order to perform experiments with a species-specific homologous transgene a 
murine FIX AAV plasmid was constructed. A 1.7Kb mFIXcDNA insert was removed 
from its supply plasmid as shown below:
1.7 Kb mFIX 
Insert
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The insert was then excised from the gel and the DNA extracted by a gene clean 
method. The insert was ligated and cloned into an AAV-2 plasmid which resulted in a 
plasmid containing mFIX under transcriptional control of a cytomegalovirus IE 
enhancer/promoter, a chimeric CMV/ (3 globin mini intron (5 to the mouse FIX 
cDNA), and the human growth hormone polyadenylation sequence. The plasmid map 
is shown below:
Figure 14 AAVmFIX plasmid
N ot I
D ra in
P (CMV)
C M V / b -g lo b in  in tro n  
^V^NPamHI
ITR
p A A V - m F . I X
7 .3 5  Kb
m o u se  F IX cDNA
ITR
hGH p o ly  A
Xbal
N ot I
XbalXbal
BamHI
The AAV mFIX plasmid was then grown up in a maxiprep (Quiagen) (as described in 
materials and methods Chapter 3, page 79) and stored in glycerol buffer at -70°C.
4.1.3 AL4 VhFIXS construct
The AAV hFIX construct used for these experiments was gift to the laboratory from 
Avigen Inc (California, USA). This construct has a CMV promoter and contains the 
intron 1 of factor IX gene. The construct integrity was checked by performing a 
restriction digest to release the 1.9 Kb factor IX cDNA insert as shown below:
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Digest
f^^ents
_ 5.4 Kh
— 1 RKh
The resultant expression AAVhFIX expression vector used for some of the 
experiments is shown below:
Figure 15 AA VhFIXS
ITR p  (CMV)
pA A V -CM V -hF.IX -3
7 .2 0  Kb
ITR SV4Ü poly A
BamHI
intron
Further FIX expression vectors studied
Other vectors were used PCEPIV/ FIX intron and PCEP IV. These were produced 
some years earlier and plasmid maps are shown below:
Figure 16 PCEP PV/FIX construct
^ a l  I 0 .80
F.IX cDNA TK pA
P(CMV)
BamHI 10.40
Sal I 10.00
pCEP4“ F.IX P(TK) 
SV40 pA 13.40 Kb
pUC o n
EBNA-1
Figure 17 PCEPPV/FIX intron construct
F.IX cDNA
in tro n  I 
BamHI 1 0 .4 0
Sal I 1 0 .0 0
nl 0 .0 0
a I I 0 .8 0
TK pA
P(CMV)
PCTK)
SV 40
EBNA
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4.2 In Vitro Studies
The vectors described above were tested in vitro in cell culture under the following 
conditions. Typically the in vitro tests were carried out using a standard transfection 
technique incorporating the use of lipofectamine (see materials and methods chapter 
3, page 80).
Method
For the FVII plasmid transfections, the reactions were carried out in 6 well plates at 
60-70% cell confluence. The ratio of (DNA vector : Lipofectamine) was 1:3 for all 
experiments. For the FIX studies with the three vectors were used a) 
pFIXCEPlV/intron b) pFIXCEPlV, c) pAAVFIX. The ratios of DNA vector to 
lipofectamine is shown in the table below: The FIX constructs were then tested out in 
C2C12 cell lines as shown below.
V ector D N A  V ector L ipofectam ine
P F IX C E P lV  intron 18ng
PE m pty V ector 18ng
M ock - -
P F IX C E P lV 6 |ig 18ng
PE m pty V ector 6n g 18ng
M ock - -
P A A V F IX  intron 6n g 18ng
P E m pty V ector 6n g 18ng
M ock - -
4.3 In Vitro R esults
The FVII construct (PCDNA-3/FVII) produced was tested in vitro in C2C12 and Cos 
7 cell lines. In order to study the transfection of target cells it is necessary to test the 
vectors with and without an insert, i.e. an empty vector.
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4.3.1 FVII: C2CI2
The results of the transfections are shown in the figure below. The graph shows the 
results for the vector containing the FVIIcDNA insert, and for the vectors with no 
insert (EV), which acts as the negative control for these experiments.
Figure 18 FVII levels post transfection C2C12
FVII levels in vitro following transfection 
of C2C12and 293 cells
FVII Ag
(ng/ml)
C2C12
e  293 
^  C2C12EV
100
Time (Hours)
As can be seen for the FVII plasmid results, it was possible to transfect the two tested 
cell lines but the resulting FVII antigen levels were low. A better result was obtained 
in the 293-cell line.
4.3.2 FIX C2CI2
The three vectors described above were tested in C2C12 cell lines and the results are 
shown in the graph below:
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Fig 19 FIX Ag post transfection C2CI2
RX L B /a 3  F=OLUmTW\NBFHmCNC2C12 C B ±S 
AT 48 AND 96 HOURS
50 1000
FMMT
FD€V
• FDÎPCEPIV 
AAVFMNT
Time (Hours)
Amount o f  FIX produced
In calculating the amount of factor IX produced per 24 hours the size of the plasmid 
has to be taken into account.
For plasm id  1 {pCEPIV/Intron): lOpg/24/10^/cells 
Started with 13.4 Kb PCEPIV plasmid using 6pg = 0.63pmol 
Therefore produced lOpg per 24 hours from 0.63pmol
Amount = 14.7pgFIX/24HOURS / 10  ^ cells/ pmol plasmid
For plasm id  2 (pCEPIV): 4pg /24/lQ^/ cells
Amount = 5.9pg FIX/24HOURS / 10  ^ cells/ pmol plasmid
For plasm id  3 {pAA VFIXintron)
31pg/24/10^/cells
Started with 6pg 7.2 Kb plasmid =1.26pmol 
Therefore 31 pg per 24 hours from 1.26pmol
Amount = 24.6pgFIX/24hours/10^ cells/pmol plasmid
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Summary
As can be seen from the above, the best results were obtained with both the intron 
containing plasmids. The levels attained were considerably higher with the intron- 
containing construct, which was in keeping with previously published data (Kurachi 
et aL, 1995). It is presumed that intron-containing constructs stabilize mRNA 
available for translation of the FIX protein, hence improving production of protein. As 
increased efficacy was demonstrated with the intron containing constructs in vitro, 
these constructs were selected for in vivo use.
4.4 Viral Vector Production 
Adeno Associated Vector (AAV)
Adeno-associated viruses (AAV) are non-pathogenic, replication defective 
parvoviruses that usually require coinfection with a helper virus to generate new 
infectious virus particles. AAV infection in humans and other animals is 
asymptomatic and non-pathogenic. AAV has several advantages, when considering its 
potential use as a gene therapy vector. Infection is asymptomatic and AAV will infect 
a wide variety of cells. The 4.7 Kb genome of wild type AAV undergoes targeted 
integration on chromosome 19 after infection (Kotin et aL, 1990; Kotin et aL, 1991; 
Samulski et aL, 1991; Kotin et aL, 1992). Most recombinant AAV vectors do not 
include the rep gene (which would severely limit packaging capacity), and therefore, 
site specific integration is lost (Walsh et aL, 1992; Kearns et aL, 1996; Yang et aL, 
1997; Russell & Hirata, 1998).
The pro-viral genome can be rescued for viral replication from pro-viral DNA and 
cloned into a plasmid, thereby making construction of recombinant genomes feasible. 
(Samulski et aL, 1982). AAVs are the smallest DNA animal virus, and the single 
stranded linear genome is encapsulated in an icosahedral structure, approximately 
20nm in diameter. The organisation of the genome is as follows. There are two open 
reading frames (ORFs) .The ORF that extends over the 5 left half of the genome 
encodes for replication {Rep) proteins, and the 3 right encodes for structural {Cap) 
proteins. There are three promoters located at 5, 19, 40 map units respectively. The
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genome is flanked by two inverted terminal repeats (ITRs) of 145 Bp (Koczot et al 
1973, Lushby et al 1980).
Figure 20 AAV genome
I T R  -   C a p  iT
R e p 6 8
VP1 _  J
VP2
V P 3
î i
Map o f the wild-type AAV genome, including Rep (solid) and Cap (open) reading 
frames, promoters (p5, p i  9, and p40), polyadenylation site (pA), and inverted 
terminal repeats (ITR). The viral transcripts encoding the different Rep and Cap 
(VP 1-3) proteins are shown below the genome. The smaller Rep proteins, VP2 and 
VPS, are translatedfrom internal initiation sites.
The terminal 125 bases are palindromic, but the overall palindrome is interrupted by 
two shorter palindromes in the centre of the larger palindrome, forming a T shape 
structure after maximum base pairing. This hairpin structure is used a primer for DNA 
replication. The ITRs do not appear to contain dominant promoter or enhancer 
activity. It has been shown that the ITRs are the only elements required in cis for 
integration, rescue, replication, and encapsulation of the AAV genome. Since the Rep 
and Cap proteins can be provided in trans, this has allowed the generation of viable 
rAAV vectors that can transduce a foreign gene into a target cells chromosome in a 
stable manner.
Principles o f AA V Vector Production
AAV vectors are derived from the naturally occurring virus by recombinant DNA 
techniques. The AAV viral genome is cloned into a series of bacterial plasmids to
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facilitate modification. The viral rep and cap genes are excised from the viral genome 
and cloned into AAV helper plasmid. The human factor IX gene is flanked by the 
inverted terminal repeats (ITRs) and cloned into an AAV vector plasmid. These 
plasmids are then used to transfect human embryonal kidney cells 293 in the presence 
of an adenoviral viral helper plasmid that contains the E2A and E4 genes and the VA 
RNAs from adenovirus type 2. Following the transfection with CaCh co precipitation, 
the transfection buffer is replaced with serum free medium and the flasks are 
incubated further to get virus amplification. Following the incubation period the cells 
are removed from the transfection plates by gentle pipetting and are then pelleted by 
low speed centrifugation and resuspended in pre chilled 10 Mm Tris Cl pFl 8. The 
cell extract can then be stored at -  80 ° C until the virus extraction. An outline of the 
procedure is shown below:
Figure 21 Triple Transfection AAV
3 Helper 
Plasmids
pKep/Cap
pAdcno
Helper
Triple Transfection
293 Cells
Recombinant AAVFl
Lyze cells
Purification o f  
recom binant AAV
Purified Recom binant A A V -F IX  ► intram uscular Injection
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4,4,1 Research Preparation made in the laboratory
In order to conduct the small animal experiments (murine) it was necessary to produce 
a recombinant adeno associated viral vector in the laboratory. Commercially, these 
vectors are produced by the triple transfection method as described above, and these 
methods are now used routinely in the laboratory as well. The first preparations made 
for the production of rAAV vectors were made with the use of an adenovirus 
providing the adeno-helper functions. In the later preparations, this was substituted 
with the use of an adenoviral plasmid. The method of this preparation is described 
below, which describes the protocol using an adenovirus to provide the helper 
functions. The process is laborious and takes approximately 1 month from start to 
completion. A diagram describing the process is shown below:
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Figure 22 rAÂ Vproduction with Ad helper virus
293 cells
Allow to grow 
60 -70 % confluence
Add Adenovirus to 293 
cells : provides helper 
function
CaCb Transfection
AAV PLASMID
]TG PLASMID
Virus Purification 
with Caesium Chloride 
banding
Caesium Chlori 
entrifugation
Dialysis Purification
Vector purification 
via dialysis across cell 
membrane
Dot Blot quantitation
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Method
a) Expansion of the HEK 293 cells
293 cells were expanded in 150 mm plates in DMEM/ 10 % FBS / 1% P/S 1%, 
glutamine (20 ml/plate), 37%, 5% CO2 . A total of 100 plates were prepared and 
allowed to reach 80-90% confluence. Infections were performed in 2% FBS / DMEM.
b) Viral Infection with Adeno helper virus
The helper virus utilised for the prep was Adlac z, and the infection was carried out at 
an MOI (multiplicity of infection) of 2 (based on a previous experiment to elucidate 
optimal MOI).
The calculation performed for the number of particles required was:
2 (MOI) X 100 (No of plates) x 5 x 10  ^ (No of cells per 150mm plate) x 0.7 
(confluency) x 25 (assuming 1 infectious particle / 25 virions)
= 1,75x10^  ^particles
Therefore 8.75 x 10 particles / litre of medium (1 litre will be enough for 50 plates) 
was required to infect the plates. The cells were then infected with 20mls of infectious 
medium per plate for 2 hours at 37°C. At 2 hours post infection the transfection 
cocktail is added.
c) Transfection cocktail
The transfection cocktail consisted of a mix of: CaCb, x2 Hepes buffer, and the DNA. 
The initial research preps consisted of preparing a transfection cocktail of the two 
plasmids containing the trans plasmid, which contained the AAV elements, and the 
cis plasmid, which contained the transgene. The adeno helper functions were provided 
by prior infection of the packaging cells with adenovirus. At 2 hours post viral 
infection the transfection cocktail was added.
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Transfection cocktail mix
In 50ml conical tube:
4.5 ml 2M CaCh
750 |Lig trans plasmid (625pi)
250 pg cis plasmid (157pl)
Sterile Hi 0 to a final volume of 36 ml
In this case, the trans plasmid concentration was 1.2 pg/ml and the cis plasmid 
concentration was 1.6pg/ml. Therefore, for a 20-plate preparation, 625 pi of Trans 
and 157 pi of cis plasmid were used. So each conical contained 4.5ml 2 M CaCli 
30.7ml water plus the cis and trans plasmids.
In a 200mls conical tube, 36mls of x 2 Hepes was added, vortexed in the hood, 
adjusting the speed to avoid splashing. Then the CaCl 2 / DNA mixture was added 
drop wise from 25ml pipette while vortexing. The 72mls mixture was incubated for 
25-30 minutes at room temperature. This mix of 72mls was sufficient for 20 plates. A 
total of 5 transfection cocktails were prepared at approximately 5 minute intervals, so 
that the first cocktail had been incubating for 20-25 minutes when the last cocktail 
was prepared. The cocktail was then shaken up after the incubation period was up and 
added drop wise onto the 293 cells using 3.5mls of transfection cocktail per plate. The 
plates were then returned to the incubator overnight at conditions of 5 % CO2, 37°C. 
The following morning the transfection medium removed and replaced with DMEM 
1% Pen /Strep.
The cells, which developed CPE after 48 hours, were harvested after 72 hours. To 
each plate, 0.5mls 0.5M EDTA, pH 8.0 was added. The cells were harvested with a 10 
ml pipette and transferred to an autoclaved 500mls centrifuge tube. The tubes were 
placed on ice and spun at lOOOg for 20-30 minutes. The supernatant was decanted into 
a flask, which had been sterilised with bleach. The cells were resuspended in cold 
sterile Tris 10 mM, pH 8.0. The final volume of the cell suspension was 30-40ml and 
was frozen at -80° C before isolation of the AAV vector.
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d) Virus extraction from transfection plates
The cell extract was then lysed in order to release the virus. This was performed by 3 
1-minute rounds of sonication at an output of 2.5. Once the sonication was completed, 
RNAase was added to a final concentration of 0.2mg/ml. Additionally Bovine 
Pancreatic DNAase I was added; for the 50 plate prep, 5mg of lyophilised powder was 
added. The sample was gently mixed and incubated at 37°C for 30 minutes. Sodium 
deoxycholate was then added to solubilise the membranes at a final concentration of 
0.5%. The tube was immediately removed and placed in ice water for 10 minutes. The 
sample was then ready for virus purification by performing caesium chloride 
centrifugation.
e) Caesium Chloride centrifugations 
Spin 1
For every ml of sample 0.454 grams of CsCl was added. The volume of the sample 
was measured with a 50-mls pipette. The volume is then made up to 40mls with 1.3 
grams/ml CsCl. The sample was then ready for loading into the centrifuge tube. The 
bottom tier of the caesium chloride consists of 9ml 1.6 grams/ml CsCl. The middle 
tier consists of 9 ml 1.45 grams/ml CsCl. Finally, 20 mis of the sample is added to the 
top of the gradient. The tubes were spun at 25000 RPM at 4°C for 18-24 hours.
Harvesting the fractions
Using the Beckman recovery system, the first 12-ml of the sample was collected into 
a 12ml snap cap tube. Once the 12-ml has come through, fractions of 1ml are 
collected. Fractions are collected until the entire Adenoviral AD band had come 
through. The fractions are placed on ice and are subjected to a PCR analysis to 
confirm the presence of AAV vector. The AD band was found in fractions 14 and 15, 
and the AAV fractions 9-13.
Spin 2
CsCl at 1.41 grams/ml was added to a final volume of 12ml and spun in a 70.1 rotor, 
ultra clear heat seal tubes, at 60000RPM overnight. The first 4 fractions were 
collected in 1ml fractions, and then as 0.5ml fractions.
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Analysis o f  the fractions
Once the relevant fractions were collected, the remaining fractions were discarded. 
The refractive index for the remaining fractions was calculated using a refractometer 
using a total of 6 \i\ of sample to analyse the refractive index. The density of the 
fraction was calculated using the formula:
Density (gtn/ml) = R Ix  10.8601 - 13.4974
Centrifugation ( 1994) : D Rickwood, T C Ford, J  Speensgeard 
(John Wiley)
The desired fractions containing the AAV particles should fall within a density range 
of 1.41 to 1.38 gm/ml. At this stage 1 pi of each fraction with a density of 1.35- 1.43 
gm/ml is removed and mixed with 1 ml H2 O and was used for later PCR analysis (1 pi)
Spin 3
The fractions from the second centrifugation with densities of 1.38-1.41 (i.e. where 
AAV fractions are) were pooled. This was done by pooling 0.5-ml samples (total 2ml) 
and adding 2 mis of 10 mM Tris pH 8.0 to make a final volume of 3.8-4ml. A 
gradient was set up as follows in an ultra clear 12-ml centrifuge tube (SW41). 3.9 mis 
of 1.45g/ml CsCl (in 10 mM Tris, pH 8.0, filter sterilised) was added to each tube.
Slowly the sample was underlayed with 3.9 ml 1.6gm/ml CsCl (in 10 Mm Tris, pH 
8.0, filter sterilised). The ultra centrifuge was cooled prior to loading up the samples. 
The pooled fractions were then loaded onto the gradient. The centrifuge tubes were 
placed into cooled SW41 rotor buckets. The ultracentrifuge was balanced and started 
up to spin at 35000 RPM at 4°C overnight. The tube below represents the layered 
gradients prior to centrifugation. The tube is then loaded into the Beckmann rotor and 
the rotor balanced prior to centrifugation.
4 mis Pooled samples 
Le. AA Vpreps
4 mis CsCl 1.4 g/ml 
4 mis CsCl 1.6 g/ml
101
At the end of the third centrifugation, the fractions were collected initially in 1 ml 
fractions and then in 0.5 ml fractions. Subsequently for each fraction the refractive 
index was measured and the density for each fraction calculated. The AAV fraction 
(vector) will be contained in the fractions with the density ranging between 1.36g/ml 
to 1.41 g/ml. (The fractions collected with densities corresponding to these readings 
were fractions 9,10, and 11, see table 4, p i  05)
f) Dialysis step
Subsequently the selected AAV fractions were subjected to dialysis, the principle 
being to remove any residual caesium chloride contaminating the fractions. This was 
done by dialysis extraction of vector by taking the pooled fractions (i.e. 9,10,11) 
containing the bulk of the AAV vector and injecting into a slide a lyzer cassette 
dialysis cassette (Pierce, 0.5-3ml, MWCO = 10,000). Prior to injection some of the air 
from the cassette was removed with an 18 gauge needle / 3 ml sterile syringe. The 
pooled fractions were then injected into the cassette using a different hole. A flotation 
device was attached to the cassette, and the cassette placed in a cold Hepes buffered 
Saline (HBS) in a beaker, pH 7.8 in cold room (600- 800ml (HBS) in beaker). The 
mixture was stirred at slow speed (using a magnet) at 4°C for 6 hours, changing the 
buffer every 2 hours.
Finally the vector suspension was removed from the cassette with a fresh syringe 
using an 18-gauge needle, and transferred to a sterile eppendorf tube in the hood and 
the volume determined, and the tube placed on ice. The vector was stored with a 5% 
volume of heat sterilised glycerol (microwaved for 20-30 sec) ensuring the vector is 
mixed well. The vector was then distributed to cyrovials (200 pi / cryovial) and 
eppendorf tubes. The vector was freezed in dry ice and placed in -  80 ° C freezer until 
required for future analysis.
Volumes obtained post dialysis
Volume___________ Glvcerol vol (5%)
Fraction 9 560pl 30pl
10 520pl 28pl
11 460pl 25pl
1 0 2
g) Dot -B lot quantitation to caclculate rAA V concentration
From each fraction (i.e. 9,10,11) 5 fil was kept to perform a dot blot quantitation. The 
5 pi samples were then for prepared for the dot blot quantitation procedure to estimate 
the amount of vector generated.
Labelling o f radioactive probe
Prior to the dot blot quantitation, a probe was labelled according to the protocol using 
a random primer labelling kit (Strategene, Primeit II, US). lOpl of DNA (lOng/ul) was 
taken and mixed with a primer lOpl and water 14pl. The mixture was heated for 5 
minutes in boiling water and centrifuged; this opens up the DNA for labelling. Then 
lOpl of x5 buffer, 5pi of p32 labelled (dCTP), Ipl Klenow (DNA polymerase) was 
added to the mixture making a total of 50pl .The mixture was incubated at 37-40 ° C 
for 2 to 10 minutes. At the end of the incubation, the mixture was checked for 
radioactive activity to see the probe had been labelled. The probe was subsequently 
placed in the radioactive fridge.
Extraction o f DNA from AA Vfractions
2pl of sample was diluted into a 178 pi of water. Then 20 pi of x 2 proteinase K was 
added and the mixture and incubated for 1 hour at 37° C. The mixture was then 
allowed to cool to room temperature, and subjected to a Phenol/Chloroform- isoamyl 
alcohol (25:24:1). Extraction was carried out with chloroform-isoamyl alcohol (24:1). 
8pl of glycogen (5mg/ml, Ambion), 20pl 3 M sodium acetate, pH 5.2, and 450pl 
ethanol. Precipitation was then carried out at - 80° C for 1 hour. The mixture was 
subsequently spun at maximum speed in the cold room for 20 minutes and the 
supematatant was carefully removed. The pellet was dried in a speed vacuum and 
resuspended in x l T.E buffer (lOpl). Then 5pi, 2.5pl, Ipl, and 0.5pl was added to 
150pl of spotting solution respectively. Serial dilutions of plasmid standards (5pl, 
c3.2ng/ml) were made with the spotting solution (150pl). Each plasmid standard 
covered the equivalent of 20ng, lOng, 5 ng, Ing and 0.5ng DNA each resupended in 
5pl.
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Slot blot hybridisation
Once the standards (x6) and test samples (x6) were made up in the spotting solution 
(0.4M NaOH, 25mM EDTA, 0.00008% Bromothymol blue), the next stage was to 
prepare the membrane, which was used in the binding of the DNA. The spotting 
solution is alkali and denatures the DNA (-vely charged) to allow it to bind to the 
positively charged membrane. The pre cut Biodyne membrane (0.4M NaOH, 25mM 
EDTA, 0.00008% Bromothymol blue), is wetted along with pre cut filter paper for 1- 
30 minutes. The slot blot apparatus is assembled and a vacuum applied. The standards 
and samples are then applied and the vacuum turned off once the samples have passed 
through. The membrane is subsequently transferred to a hybridisation tray (Perkin 
Elmer) containing 100ml pre warmed pre hybridisation solution. The mixture is 
placed in a shaking water bath at 50°C for 20 minutes. At the end of this period the 
pre hybridisation buffer was removed and 30 mis of hybridisation solution and the 
denatured probe were added. The mixture was incubated in a shaking water bath for 
20 minutes. Subsequently the membrane was rinsed in 100 mis pre warmed wash 
solution. A wash was then carried out in lOOmls wash solution at 65°C for 10-15 
minutes and two further rinses were carried out for 1-2 minutes in 100 ml of wash 
solution. The membrane was then placed in a seal a meal bag removing the excess 
liquid and placed in an X-ray cassette. The film was exposed at -  80° C overnight and 
the film developed the next day.
PCR Reactions
The PCR reactions were set up as follows: 2pi per dilute fi*action as template, primers 
specific for vector. For the PCR beads: 2pl template. 0.5pl forward primer (50 Um). 
0.5pl reverse primer (50 Um), 22pl H2O. PCR reaction: 94 ° C for 5 minutes, 94 ° C 
(1 minute) / 52-53 ° C (1 minute) for 25 cycles, 72° C for 7-10 minutes. The PCR 
products were run out on a 1.5- % agarose gel and visualised. The lanes were labelled 
with their corresponding fi*actions.
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4.4.2 Results 
Density gradients
The table shown below gives the density results obtained from the second and third 
centrifugation spins. The refractive index for each fraction is measured using a 
refractometer and the density calculated according to the following formula:
Density = RI x 10.8601- 13.4974
Centrifugation (1994) : D Rickwood, T C Ford, J Speensgeard 
(John WUey)
T able 4 Densities centrifugations 2 & 3
Fraction RI C2 RI C3
1 1.3936 1.64 1.3957 1.66
2 1.389' r.59” “ 0 9 1 7 1.62
3 1.3857 1.55 1.3881 1.58
4 ' T .383~ 1.52 1.3846 1.54
5 1.381” ' O 1.3821 1.51
6 1.3791 0 8 “ 1.38 0 9
7 0 7 6 8 “ \~aJ 0 7 8  ' ” 1.47
8 1.375 1.44 1.3755 1.44
9 1.3737 1.42 1.3731 ~ T 4 1 ^ ^
10 1.3716 1.4 1.37 1.38
11 1.3699 1.38 1.3677 1.36
~  I T 1.369 1.37 1.3654 1.33
13 1.3679 1.36 1.3635 1.31
14 1.3664 1.34 1.3606 1.28
15 1.3657 1.33 1.3592 1.26
16 1.3644 1.32 1.3566 1.24
17 1.3635 1.31 1.3547 1.21
18 1.3626 1.3 1.3531 1.2
l 9 “ 0 6 1 7 1.29 1.3519 1.18
20 1.3611 1.28 1.3755 1.17
Density results o f the AA V 
fractions from 2"^  ^and 3'^  ^
centrifugation steps
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The following plotted graph shows the results obtained for the densities of the second 
and third centrifugation steps:
Fig 23 Densities post 3rd centrifugation
Q
Density o f AAV fractions after 2nd  
and 3rd centfrifugation steps
1.6
1.5
1.4
1.3
1.2
1.1
10 15
Fraction
20 25
Centrifugation 2 Centrifugation 3
PCR 2^^ Gradient AAV Prep
The gel represents the PCR analysis for examination of the fractions 9 to 13. The 
numbers represent the fraction numbers.
Fig 24 PCR A A V fractions
DNA Ladder 9 10 11 12 13
From the predicted density results fractions 9 to 12 were analysed by a PCR reaction 
to confirm the presence of AAV vector in the fractions. The above gel shows a very 
strong signal obtained for fractions 11 and 12. These bands correlate strongly with the
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predicted bands from the density results. Although not clearly shown here, bands 10 
and 13 were also weakly positive. Therefore preps 10,11,12,13 were harvested and 
loaded for the third centrifugation.
Dot blot quantitation
From the dot blot quantitation the amount of vector produced from the prep is 
calculated.
Fig 25 Dot Blot 
20 10 2.5 0.5 C ontrol Standards : ng /D N A
Fraction 8 10 11 12 13 (old prep)
The dot blot above shows that fraction 10 at 1 pi volume is approximately half the 
intensity of the control standard at 2.5 ng (lul volume) .lug DNA approximates to 
5Kb equating to 0.3 pmol. Therefore 2.5 ng of 7.3 Kb plasmid equates to 5.1 x 10 ^  
pmol = 5.1 xlO’’^ mois. Therefore 6.023 x10^^x5.1 xlO ''^=3x 10  ^plasmid particles 
= 6x10^ vector genomes per pi = 6x 10 ‘ * /ml
4.5 A denovirus Preparation
The stages required in an Adenovirus preparation are relatively straightforward when 
compared to the AAV preparation. The stages required are infection of 293 cells with 
the adeno virus in question, and then incubation prior to virus harvest and purification 
through caesium chloride banding. The stages are outlined in the following diagram:
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Figure 26 Acknovims production
Allow to grow 
60-70 ®/o confluence
Add Adenovirus to 293 
cells
Virus Purification
with Caesium Chloride 
handing
293 cells
1
i
Caesium Chloride 
trifugati
I
Vector Collection 
and quantitation
Aliqout out and store at -80°C  
till further use
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4,5,1 Method
a) Preparation o f HEK 293 cells
To make an adenoviral vector HEK 293 cells (provided by the vector core at the 
University of Pennsylvania) were grown out and split into 150 mm petri dishes using 
25 ml DMEM, 10 % FBS, 1% P/S for each plate. After reaching confluence the cells 
were further split and expanded.
b) Infection o f cells
Each 150 mm dish requires a total of Ix 10^ ® particles of virus suspended in 10 ml 
DMEM, 1% Pen/ Strep (serum free). A total of 5 x 10^  ^particles were suspended in 
1/2 litre of medium, (enough to infect 50 plates). The medium was aspirated from the 
dishes and 10 mis of medium containing the virus was added to the cells in each plate. 
The incubation was allowed to proceed for 2 hours at 37 ° C. At 2 hours 15mls of 
DMEM + 10% FBS + 1% Pen/ Strep was added to each plate. After 30 hours the 
cytopathic effect (CPE) was visible (the cells appear round and refractile and begin 
themselves to lift off the plate Avith very little agitation). At this stage by pipetting the 
media over the growth surface the cells were removed from the plate. The cells were 
collected in into 1-litre autoclaved centrifuge bottles. The bottles were centrifuged at 
4000RPM for 10 minutes at 4° C. The supernatant was removed into bleach being 
careful not to dislodge the pellet.
Virus Extraction
The pellet was resuspended in lOmM Tris HCL (pH 8.1), using 0.5ml of Tris per plate 
harvested. (At this stage the pellet may be stored prior to the next stage of the 
procedure). The pellet was then freeze thawed three times in alcohol dry ice / 37 ° C 
to release the virus from the cells. The lysate was subsequently spun for 10 minutes at 
3000 rpm at 4° C. The supernatant is saved avoiding the pellet. The pellet was then 
resuspended in a small amount of 10-mM Tris -HCl, pH 8.1 to rinse the cell debris of 
any residual virus. The solution was then respun for 10 minutes at 4° C and the 
supernatants are then pooled together.
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c) Caesium chloride layering
10 ml of light caesium chloride solution was pipetted into an ultracentrifuge tube of a 
Beckmann SW 28 rotor. Slowly and gently the light Caesium chloride (1.45g/ml) was 
underlayed with a solution of heavy caesium chloride ( 1.6g/ml). The light caesium 
floats to the top of the heavy caesium and the interface between the two layers should 
be very sharp. The viral supernatant was then carefully layered onto the top of the 
caesium gradient and the tubes were loaded into a SW 28 rotor ensuring the tubes 
were carefully balanced. The tubes were then spun for 2 hours at 20000 rpm at 4° C. 
The centrifuge tube was removed from the centrifuge and clamped onto a ring stand 
in a sterile fume cupboard. The virus appears as a narrow opaque white band 2/3 of 
the way down the heavy- light caesium chloride gradient. The tube is then punctured 
under the band with a sterile needle to allow the caesium chloride to drip out until the 
band is collected. Care is taken not to collect any of the bands above.
Figure 27 Collection procedure for Virus
Defective Virus
* Virus to be harvested
I
^  Puncture with sterile needle to 
Collect harvests
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d) Viral Extraction
The collected bands (2mls) is then diluted with an equal volume of 10 mM Tris (2 
mis). In an ultra centrifuge tube (a Beckmann SW 40) 4ml of light caesium chloride is 
added. A further 4ml of heavy caesium chloride is carefully layered under the light 
caesium chloride. Finally the 4 mis of viral supernatant diluted in Tris is added on top 
of the gradient. The tubes are then loaded into the SW40 rotor and were spun 
overnight at 20000 rpm at 4°C. The Adenoviral band is then collected by puncturing 
the side of the tube with a needle and syringe. The band is then desalted over a Hepes 
column manufactured by Biorad (Econ Pac lODG column, 7322010) and fractions of 
the collected bands are diluted 1:50 and an OD reading 260nm is recorded.
The amount of particles per ml is then calculated by the formula:
OD 260 X Dilution xlO  = particles/ml
Yield of Fractions collected (QD (260 nm)
Fraction 1 0.053
Fraction 2 0.0157
Fraction 3 0.017
Fraction 4 0.0.17
Fraction 1 = 0.053 x 50 = 2.63 xlO'^/ml
Had 0.5ml (added 25pl glycerol), therefore aliquots made of 40pl = 1x10*'  particles / 
eppendorf
Fractions 2^,4  (were pooled together)
Had 1.52 ml (add 80pl glycerol). Aliquots of 125pl = IxlO" particles / eppendorf 
Glycerol was added to a final concentration of 5% and at stored at -80°C once 
aliquoted out.
II
Summary
The work described above shows that the production of recombinant viral vectors is 
not a trivial procedure. The process involves several intricate methods, and often the 
final outcome of a procedure that may last 4-6 weeks is not known right until the 
point of vector purification and yield quantitation. The early stages of rAAV 
production required the use of an Adenovirus as a helper virus. The procedure in the 
laboratory has now been modified because of fears of viral contamination with 
Adenovirus, and this incoporates the use of an Adeno viral plasmid providing the 
helper ftmctions instead of an Adenovirus (Matsushita et al., 1998). Other issues in 
recombinant vector production include obtaining a satisfactory yield of vector. Newer 
ways of vector purification have been developed to improve this process, such as 
using High performance liquid chromatography to purify the vector.
1 1 2
CHAPTER 5
GENE BASED TRANSFER TO MICE:
PARAMETERS AFFECTING THE
IMMUNE RESPONSE
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5.1 Introduction
In order to demonstrate a proof of principle for a gene therapy concept it is necessary 
to demonstrate efficacy in a small animal setting before progressing to a large animal 
model. At the time of commencing these studies no animal models of the disease were 
available. Consequently, initial studies were performed in normal mice, both immune 
competent and incompetent. As outlined earlier, the immune response observed to a 
gene-based approach may involve separate responses to each component of the 
system i.e. to either the vector or transgene or both (Chapter 2, page 58).
Experimental design must therefore address each component in turn to dissect out the 
possible immune responses, which may be observed. The initial experiments in this 
chapter examine the response to vector selection. The three vectors used were 
Plasmids, Adenovirus (Ad) and adeno-associated vectors (AAV). The early studies 
were performed in normal immune competent mice. With the development of murine 
models of Haemophilia B, these studies were repeated in these affected mice. When 
these studies were conceived, there were no assay systems in place to study cellular 
responses (i.e. CTL response) to vector selection. Consequently, the work in this 
chapter makes use of antibody isotype profiles generated to different vectors to 
investigate the type of immune response that occurred to each vector. These results 
are informative since previous murine studies had defined that different isotype 
profiles correlate with different immune responses and in particular whether the CD4 
T helper response was a Thl or Th2 driven response (Severinson et al., 1982).
The second set of experiments was designed to study the effects of transgene selection 
on the immune response. Prevoiusly published work addressing the immune response 
to the transgene product, involved the use of non homologous reporter genes such as 
Beta Galctosidase (a bacterial gene) encoding a non secretable transgene product 
(Yang & Wilson, 1995; Yang et al., 1995c,(Fisher et al., 1997) . Therefore, it would 
be conceptually difficult to extrapolate these findings to Haemophilia B, where the 
desired transgene product is secretable. Within the context of this part of the study 
three different transgenes (human, murine, and canine) were used in both murine and 
canine models of Haemophilia B.
114
The objectives o f  this work were to:
a) To characterise the humoral response to transgene product with emphasis 
on the temporal appearance of antibody formation
b) The nature and specificity of antibodies produced
c) To study the effect of underlying mutation on the resulting immune 
response
5.2 Vector Selection 
Experimental design
Three cohorts of mice were injected intramuscularly with one of three vectors 
encoding human FIX as described below. At 2 weekly intervals, mice were bled and 
the serum harvested for analysis of FIX Ag expression and antibody production to 
human FIX Ag by subclass specific Elisa. At 12 weeks the mice were sacrificed and 
the injected limbs analysed histologically for FIX Ag expression, and for evidence of 
inflammatory infiltrates determined by Haematoxylin and Eosin staining, and 
immunofiouresence for CDS infiltration. In further injected cohorts some mice were 
sacrificed at earlier time points to study the injected limbs histologically. For 
comparison with a non-secretable transgene a further cohort of mice were injected 
with Adp gal and AAV p gal.
Animals
Normal 8-week-old C57BL/6 male mice (Charles River Breeding Laboratories) were 
anaesthetised by inhalation of mefofane, and a 1cm incision of the skin of one 
hindlimb was made. Three cohorts of C57BL/6 mice received IM injections of AAV 
(n=10), E1/E3-deleted adenoviral (n=7), or plasmid (n=8) vector at a single time point 
(numbers of animals reflect the sum of two independent experiments). The viral and 
plasmid vectors (diluted in sterile PBS) were injected with a Hamilton syringe at two 
IM sites (25 pi into tibialis anterior and 50 pi into quadriceps muscle). For AAV and
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adenoviral vector, 4x10^^ viral particles were injected per animal. 100 pg DNA was 
infused for the plasmid vector. The skin was closed with a suture. The mice were bled 
retro-orbitally on a biweekly schedule up to 12 weeks post-injection using 
heamatocapillary tubes.
Vector Preparations
All vectors contained an expression cassette containing the human FIX cDNA and the 
CMV IE enhancer/promoter. Similarly, the vectors encoding the p gal transgene were 
contained in an expression cassette containing CMV IE enhancer/promoter. The 
vectors used for these experiments were produced by the methodology described 
previously (Chapter 4, page 96-103). The plasmid vectors were made in large 
quantities by using the maxi prep (Quiagen) method as described. (Chapter 3, 
page79).
Assays for human FIX antigen and anti-hFIX
An ELISA specific for hF DC in murine plasma samples was carried out as described 
(Chapter 3, page 66)(Walter et aL, 1996). Antibodies against human FIX were 
detected by subclass specific ELISA (Chapter 3, page67).
Histological Analysis
Mouse muscle tissue was snap-frozen in liquid nitrogen-cooled isopentene and stored 
at -80 C till the sections were ready to be analysed. Cryosections (5-6 pm) were 
prepared and stained with haematoxylin/eosin (H&E) or with a goat anti-human FIX 
for immunofluorescent detection. Immunohistochemical detection of CD8^ cells was 
carried out as detailed (Chapter 3, page 75)
Results
Antibody profiles
All of the injected mice developed anti-hFIX by 2 weeks post-injection which was 
maximal by 4-8 weeks. Analysis of the antibody isotypes revealed that all three
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vectors induced antibodies of the T helper cell-dependent subclasses IgGl, IgG2b, 
and IgG2c). T helper cell-independent antibodies (IgM and IgG3) were not detected. 
C57BL/6 mice produce IgG2c instead of the highly homologous lgG2a subclass 
(Jouvin-Marche et aL, 1989a; Jouvin-Marche et aL, 1989b; Morgado et aL, 1989). 
Human FIX antigen was undetectable in plasma samples by ELISA with the 
exception of two adenovirus-injected mice that showed transient antigen levels during 
the first month after vector administration {data not shown). The results for the AAV 
injected animals are demonstrated \n figure 28. For these animals, the most dominant 
isotype profile induced was an IgGl profile {Ratio lgGl/IgG2h =5.7). The AAV- 
treated mice showed the lowest proportion of class IgG2 production of the three 
injected eohorts. Furthermore, 3 of 10 AAV-injected mice had undetectable IgG2c 
anti-hFIX while all adenovirus or plasmid injected mice developed IgG2c. I  he results 
suggest a bias towards an IgGl profile in the AAV injected cohort.
Fig 28 i) Antibody Isotype profiles o f  AAV injected animals
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ii) Antibody profiles o f Adenoviral injected Animals
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The results for the Adenoviral injeeted animals are shown in figure 28 ii). The 
Adenovirus injected animals displayed the most dominant IgG2 (Ratio IgGl/IgG2b 
=1.1) response with the lowest amounts of IgGl subclass induction being shown for 
this cohort of animals.
in) Antibody profiles o f Plasmid injected animals
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The plasmid injected animals displayed high amounts of IgGl, which was 
intermediate between the Ad and AAV injected animals {Ratio IgGl/IgG2b =2.1).
The calculated ratios of IgGl to IgG2b and IgG2c subclasses for all three injected 
cohorts are shown in the graph below at 8 weeks post injection.
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Calculated proportions o f IgGl: IgG2 subtype induction in three injected cohorts
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The calculated ratio of the average antibody titre of IgGl over lg02b or Ig02c (at 8 
weeks post-injection) shows a bias for IgGl for the AAV vector-injected mice and for 
IgG2c for adenovirus-injected mice. Plasmid-injected mice showed an IgGl/IgG2b 
ratio subclass profile intermediate between AAV and adenovirus-treated mice, but 
displayed the overall strongest anti-hFIX immune response.
The data suggest that subsets of T helper cells activated by the secreted transgene 
product human FIX, might differ depending on vector selection. The data do not 
reveal any marked quantitative differences in the immune responses against hFIX 
because of variability in induction of IgG subclasses among different animals.
Histology of Injected muscle
1) Normal Muscle
Sections of muscle were removed from an uninjected animal and analysed for the 
presence of factor IX expression, inflammatory infiltrates by H& E staining (Chapter 
3, page 73) and if indicated further staining by immunofluoresence for CDS cell 
deposition (Chapter 3, page 75).
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Fig 29 Normal Muscle
Haematoxylin and Eosin FIX Ag expression
As can be observed from the appearances the muscle displays normal architecture 
with no disruption. The dark blue basophilic areas represent the muscle nuclei. No 
expression of human factor IX Ag is seen.
2) AA V injected animals
The histological sections for the AAV injected animals are shown below: 
Fig 30 A A V Injected animals
Haematoxylin and Eosin FIX Ag expression
FIX Ag expression
For the AAV based transduction clear expression of factor IX was seen as evident the 
immunoflouresent staining which is indicated by the yellow arrow (green 
tluorochrome (FITC) anti-factor IX antibody). No evidence of any inflammatory
12,
infiltrates was seen, both on H & E staining and staining by immunofluorescence for 
the presence of CDS and CD4 T cells.
Although the presence of cellular factor IX expression is evident histologically, no 
circulating detectable factor IX Ag is evident due to the formation of antibodies to the 
protein. The subclass of the antibody was predominantly of an IgGl subclass (see 
earlier) indicating a predominantly a Th2 cellular driven response. It therefore 
appeared that long-tenu expression was achievable using an AAV vector with no 
cellular immune (CTL) responses being observed hisologically.
Figure 31 Plasmid Injected animals 
Haematoxylin and Eosin CDS expression
Inflammatory
Infiltrates
CD8 infiltrates
In the plasmid injected animals, no detectable circulating levels of factor IX could be 
found. As seen above, histological analysis revealed the presence of inflammatory 
infiltrates in the muscle sections on H&E staining. The presence of inflammatory 
infiltrates suggests that a cytotoxic T cell response was occurring in the plasmid 
injected animals. The presence of these cellular infiltrates and the strong Ig02 
responses observed to the human factor IX transgene product suggested the possibility 
of a CTL response occurring. Further immunofluoresecent staining confirmed the 
inflammatory infiltrates to be composed of a high proportion of CD8 cells {see figure 
31).
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Figure 32 Adenoviral based transduction
The histology results for the adenoviral injected animals are shown below:
Haemotoxylin and Eosin CD8 expression
Inflammatory cell infiltrates CDS expression
The adenonviral-injected animals did initially express some circulating factor IX Ag, 
which was detectable in the plasma as early as 2 weeks post injection (data not 
shown). However, this had disappeared by 2 weeks post injection. Therefore, a further 
cohort of animals was analysed at 3 weeks to study why expression was lost early. 
This is shown in the images above, which show the dense presence of strong 
inflammatory infiltrates at 3 weeks post injection. Confirmatory immunofluoresent 
staining confirmed the presence of CD8 positive cells amongst these infiltrates, 
suggesting the presence of a strong cytotoxic T cell response occurring in the muscle.
Mechanisms of intram uscular immune responses
Plasmid Injected animals
The results presented here for plasmid mediated gene transfer were disappointing. 
Direct plasmid injection lead to the production of profound inflammatory responses 
and no transgene expression. The humoral response to the transgene product 
displayed an immune profile in keeping with a Thl cellular response. For non-viral
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vectors such as plasmid injection of naked DNA, there is evidence to suggest that the 
actual plasmid backbone may act as a powerful adjuvant to the stimulation of a 
powerful host immune response. The basis of the immune response centres around the 
presence of non coding immunostimulatory sequences (“ISS”) within the plasmid 
backbone which contain hypomethylated CpG basepairs (Sato et aL, 1996). These 
hypomethylated motifs rapidly stimulate the innate immune response with production 
of IFNy by NK cells and IFN a  and p, il-12 and IL-18 by macrophages.
This response is important phylogenetically as it acts as the host’s first line of defence 
against bacterial infection. In the adaptive immune response, bacterial DNA favours 
the development of a Thl driven response and secretion of IFNy, which favours 
immunoglobulin class switching to the IgG2a subtype. For this reason, because of the 
strong and persistent cell mediated and humoral immune response to the plasmid 
backbone and encoded transgene, the use of plasmid DNA vaccines has enormous 
future potential in infectious diseases, allergy, and cancer tumour vaccines. However, 
for use in gene replacement expression work, to generate a secretable protein, this 
strong immune response is counter productive (vide infra). Therefore, for plasmid 
vectors to be effective in gene replacement strategies for secretable proteins, vectors 
will be needed to be designed which lack these ISS sequences. However, in DNA 
vaccines, these adjuvant properties would appear to be beneficial.
Adenoviral injected animals
For Adenoviral based transduction the pattern suggested by the antibody profile 
(IgG2) to the human factor IX suggested the presence of a cellular immune response 
to factor IX. Most adenoviral vectors are derived fi'om the Ad type 5 (Ad5) virus in 
which a foreign expression cassette has been introduced in place of the early region 1 
(El). Such El deleted vectors can easily be produced at high titres in 
complementation cell lines, providing the El functions in trans. The deletion of the 
regulatory El genes prevents viral propagation in infected organisms and dramatically 
reduces the expression of all viral genes. Further deletion of the non essential early 
region 3 (E3) genes allow insertion of larger segments of foreign DNA (up to 8 Kb) in 
the viral genome. However, in vivo application of these E1/E3 vectors has shown that 
expression of the transgene is only transient, demonstrated in these experiments.
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Other investigators have shown that the short lived in vivo expression of the transgene 
was related to the induction of a host specific cytotoxic T lymphocyte (CTL) immune 
response directed against viral antigens synthesised at low levels in the transduced 
tissues (Dai et aL, 1995), (Yang et aL, 1996b), (Engelhardt et aL, 1994a; Engelhardt 
et aL, 1994b). However, it has also been shown that cytotoxic cellular response could 
be elicited to the transgene itself, which could also account for the rapid elimination 
of transduced cells ((Juillard et aL, 1995), (Michou et aL, 1997).
Most of the early studies performed in adenoviral based transduction experiments 
used Beta galactosidase as the transgene. This protein is of bacterial origin and 
therefore theoretically could be expected to induce an immune response either 
cellular, humoral or both. When studied in muscle based transduction, Yang et aL, 
(1996) demonstrated that destructive cellular responses were directed to Beta 
galactosidase protein, i.e. the transgene product. Interestingly, however, the response 
was dependent on the method of gene transfer with plasmid or adenoviral vector 
enhancing the immune response by infecting antigen presenting cells located within 
the injured muscle or in the regional lymph nodes. The results shown here also show 
the presence of a cytotoxic cellular immune response to adenoviral and plasmid 
transduced muscle. It is unclear however, whether this response is directed to the 
transgene (i.e. human factor DC) as well as the vector. The only way to definitively 
answer this is to devise a CTL assay to the transgene product and study whether this 
phenomena occurs. This subject is discussed further in chapter 6.
AA V injected animals
The results fi'om the AAV injected cohort suggest that a dominant CD4 Th2 immnue 
response was occuring, with a relative lack of a CD4 Thl (CTL) response. When the 
work was begun with using the AAV vectors, it was hoped the expression obtained 
would be better than that observed in the Ad and plasmid injected animals. This was 
predicted, based on reports in the literature suggesting the relative lack of an immune 
response against these vectors, resulting in long term transgene expression. The work 
in one of these reports (Fisher et aL, 1997) demonstrated that using the lac z reporter 
gene, which produces the highly immunogenic bacterial protein 13 galactosidase, long­
term stable gene expression was observed for at least 32 weeks after IM injection.
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suggesting the relative lack of an immune response. It is noteworthy within this study 
that none of the injected mice demonstrated any signs of tissue inflammation. This at 
the time, was a major break through since it represented the first finding of a vector 
which was capable of inducing long term gene expression with a relative absence of 
being immnunostimulatory (“blunting” of the immune response).
Subsequent reports using the AAV-lacZ or AAV-hEpo vectors showed that dose- 
dependent levels of p-galactosidase or human erythropoietin were obtained after 
single-dose administration of vector (Tripathy et al., 1994), indicating an apparent 
lack of immunogenicity by AAV based transduction with a non-homologous 
transgene in this model.
Summary
From the above studies it is clear that the humoral profiles induced were influenced 
by vector selection. The Adenoviral and plasmid injections induce a more biased 
response towards a Thl driven response whereas the AAV injected animals induce a 
stronger response with the production of IgGl antibodies in keeping with a Th2 
response. This would therefore, predict that the adenoviral and plasmid injected 
animals will produce a cellular immune response to the transduced tissue. This is 
borne out by the histology results, which showed evidence of inflammatory 
infiltration in the plasmid and adenoviral injected animals with loss of expression of 
human factor IX. The profile suggested by the AAV injected animals induced less of a 
cellular response (lack of Ig02 class induction), and this is again borne out by the 
histological findings of factor EX expression in the muscle sections studied. However 
no circulating factor EX could be detected due to the presence of a humoral response 
to the non species-specific transgene product (human factor EX).
5.3 Effect of Transgene
The preceding studies suggested that choice of vector alone influenced the resulting 
immune response, but it is clear that the expression of bacterial or human transgene
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products could also constitute potential antigens and be recognised as foreign by the 
host immune system.
It is logical that a non-homologous transgene that leads to the production of a non- 
homologous protein will induce an innate immune response. Equally, comparison of 
vectors will also be influenced by the presence of transgenes coding for immunogenic 
proteins. Therefore, extrapolation of these findings to the homologous situation will 
be difficult. The subsequent cloning and availability of homologous transgenes 
facilitated more accurate interpretation of the immunological responses and allowed 
the following experiments to be performed with the requisite transgenes in their 
cognate homologous animal models.
5,3,1 Species versus Non Species specific Transgene
Aim
As outlined above, because of the observed antibody formation to the human 
transgene in normal immune competent mice, similar experiments were carried out in 
normal immune competent mice using the species specific transgene murine factor IX 
instead.
Method
Immunocompetent 5 month old male CD-I mice, 5 month old male C57BL/6 mice 
(both strains fi'om Charles River Breeding Laboratories, Wilmington, MA) and 5 
week old male BALB/c mice (The Jackson Laboratory) (n=3 for each strain) were 
used in this study. The quadriceps and tibialis anterior muscles of both hind limbs 
were injected with a total dose of 1x10^  ^AAV-mFIX. The positive control mice used 
for these experiments was injection of the same AAVmFIX construct into knockout 
haemophilia B mice.
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AAV mFIX Vector
AA V vector construction.
The plasmid encoding AAV-2 vector AAV-CMV-mFIX, contained the murine FIX 
cDNA (2.7-Kb Bam HI fragment) under the transcriptional control of a 
cytomegalovirus IE enhancer/promoter, and also included a chimeric CMV/p-globin 
mini-intron (5’ to the mFIX cDNA), and the human growth hormone polyadenylation 
signal. The expression cassette is flanked by AAV serotype-2 inverted terminal 
repeats (ITRs). AAV-CMV-mFIX was produced by triple transfection of HEK-293 
cells in a helper virus-free system, and purified by repeated CsCl gradient 
centrifugation (as described in chapter 4, page 110). Vector titres were quantitated by 
slot blot hybridisation. Purified vector was stored at -80°C in PBS containing an 
osmotic stabiliser, and further diluted with sterile PBS prior to injection of the mice.
Antibody detection
The presence of antibodies was detected by Western blot. Murine factor EX was 
transferred onto a nitrocellulose membrane and incubated with various mouse plasma 
samples, followed by incubation with horseradish peroxidase conjugate anti-mouse 
IgG and autoradiographic detection.
Results
Anti mFIX antibody detection
None of the mice injected with AAV-mFEX developed antibody against murine factor 
EX when assayed by Western blot at 18 days (data not shown) and 60 days post­
injection {Figure 33, lanes 2-10).
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Figure 33 Western Blot Normal mice with AA VmFIX transgene
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Lane 1. Plasma from haemophilia B mouse bred on CD-I background that had 
developed antibodies against human factor DC after intravenous injection o f Ad- 
hFIX. These antibodies cross-reacted with murine factor DC. Lanes 2-10. Plasma 
from mice injected IM with AAV-mFIX. Lanes 2-4. BALB/c mice. Lanes 5-7. 
C57BL/6 mice. Lanes 8-10. CD-I mice. All samples were from day 60 post­
injection.
Clotting times by APTT on plasma samples of all vector injected mice were within 
the normal range (approximately 25 seconds) when measured 60 days post-injection. 
Factor IX inhibitor assays on all the injected mice also demonstrated the absence of 
Factor IX inhibitors. The control mice injected with AAV-mFIX all developed 
antibodies against murine factor IX within the first 4 weeks of injection, 
demonstrating the immunocompetence of these animals.
Summary
Although an innate expectation, the critical importance of these studies demonstrates 
that normal immune competent mice do not make antibodies to the transgene product 
murine factor IX. This is in contrast to using human factor IX as the transgene, where 
all injected animals made antibodies to the transgene product. These studies 
emphasise the importance of selecting a species-specific transgene in any proposed 
gene transfer studies.
The majority, if not all of the early gene therapy studies performed, employed the use 
of non-species specific transgenes (usually human). This clearly made interpretation
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of the results difficult, since immune responses (as would be predicted) frequently 
occurred. The design of future gene therapy experiments needs to consider this, and 
emphasises the importance of selection of the relevant homologous transgene, and 
that when planning gene transfer strategies the choice of transgene is critical.
5.4 Other Factors That May Affect the Immune Response
5.4,1 Route o f Administration of the vector
The route of administration of antigen delivery clearly influences the outcome of 
immune responses. In a gene-based approach, an important element of how much 
gene expression takes place will depend on the target tissue reached and the 
immunological cell populations present. For example, tissues rich in antigen 
presenting cells (APCs) may effectively induce immune responses more than tissues 
not rich in APCs.
It is known that individual immunogens exhibit particular dose response curves, 
which may be determined by measuring the immune response observed with various 
doses and administered route of delivery. An insufficient dose does not lead to 
immunogenic stimulation, either because it fails to activate sufficient lymphocytes or 
because it induces a non-responsive state. Conversely, an excessively high dose can 
also fail to induce a response because it can cause lymphocytes to enter a non- 
responsive state. In mice, the immune response to purified pneumoccal capsular 
polysaccharide illustrates the importance of dose. A dose of 0.5mg fails to induce an 
immune response in mice, whereas a thousand fold lower dose (5 x 10"^  mg) induces a 
humoral antibody response (Kuby f  Immunology, (WH Freeman, 2000) pages91-92). 
A single dose of most experimental immunogens will not induce a strong response. 
Rather, repeated administration, over a period of weeks is required to stimulate a 
strong response. Such repeated administrations or boosters increase the clonal 
proliferation of antigen specific T or B cells.
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Experimental immunogens are generally administered parentally, that is by routes 
other than the digestive tract. The following routes of administration are common:
Intravenous 
Intradermal 
Subcutaneous 
Intramuscular 
Intraperitoneal
The administration route determines which immune organs and cell populations will 
be involved in the response. Antigen administered intravenously is a very effective 
route to the spleen because the blood vessels open into this organ and antigen is 
effectively filtered from the blood. Antigen administered subcutaneously and 
intramuscularly moves first to the local lymph nodes but may also reach the spleen by 
lymph flow and the thoracic duct. Differences in the lymphoid cells populating these 
organs generate differences in the quality of the subsequent immune response. 
Therefore the route of administration is critical to the outcome of an immune response 
to a particular immunogen, and variation in route vrill influence outcome.
In the conventional protein based replacement therapy for haemophilia, infusion of 
clotting factor concentrates results in initial presentation in the spleen and antigen 
presentation occurs at this site. However, when antigen delivery is via a peripheral 
route such intramuscular or subcutaneous injection antigen presentation occurs via 
antigen presenting cells in regional draining lymph nodes. In a gene based approach 
the target tissue selected will influence outcome, as the draining lymph nodes of that 
particular tissue will first present antigen to the immune system. In the case of an 
intramuscular approach in the hindlimbs of a mouse, the draining lymph nodes will be 
the inguinal and popliteal nodes of the injected limb.
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Route of Administration and Gene Transfer
Introduction
It has been observed by a number of investigators (Walter et aL, 1996; Michou et aL, 
1997), that when an adenoviral vector expressing a non homologous transgene, such 
as human factor DC is injected intravenously into C57BL6 mice, a failure of antibody 
production is observed, with high circulating levels of human factor DC antigen being 
produced (Connelly & Kaleko, 1998), (Kung et aL, 1998). This seems a rather 
unexpected result given the high immunogenicity of Adenoviral vectors (Yang et aL, 
1994a; Yang et aL, 1994b; Yang et aL, 1994c) and the use of a non-species specific 
transgene in the vector.
If the same injection is performed intramuscularly in the same strain of mice, no 
circulating FIX antigen is found in the serum of the injected animals and all the 
animals make antibodies to the human factor transgene product, which is 
predominantly an lgG2 subclass. Close analysis of the injected muscle reveals that 
although expression of factor DC can be demonstrated at a tissue level for a transient 
time (2-3 weeks), there is a gradual build up of inflammatory infiltrates in the muscle 
precluding further expression of the transgene and the ultimate destruction of the 
target tissue by a cytotoxic T cell infiltrate (as noted in the histological sections shown 
above, see page 123).
It is puzzling therefore, why the introduction of a human transgene product should 
result in long-term expression in normal and in knock out mice that are deficient in 
F.Vin or FDC using a vector that is well-characterised for its immunogenicity (Yang 
et aL, 1994a; Yang et aL, 1994b; Yang et aL, 1996a; Yang et aL, 1996d). Studies have 
shown that haemophilic C57BL/6 mice are not tolerant to human coagulation factors, 
since they rapidly develop high titre antibodies against human FVlll or FDC when 
these proteins are introduced as intravenously infused protein concentrates or when 
the vector is injected intramuscularly (lM)(Qian et aL, 2000).lt is therefore unclear 
why long-term expression of coagulation factor DC is achieved in C57BL/6 following 
systemic delivery of adenoviral vector, and how the intravenous route of 
administration fails to result in production of antibodies in the C57BL6 strain. Other 
investigators have commented on the ability of the C57BL6 to demonstrate prolonged
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expression with other transgenes, such as human antitrypsin, (Barr et aL, 1995), when 
compared with other strains of mice.
5.4,2 Experimental strategies to address route of administration
The aim of the studies in this section was designed to examine the influence of route 
gene delivery in the C57BL6 strain and, examine the mechanisms, which may be 
involved in the paradoxical immune responses observed in the C57BL6 strain of 
animals. The experimental strategy taken was to compare the effects of route of 
administration in two different wild type strains of mice (C57BL6, Balb/C).
Method
4-6 week old male inbred C57BL6 and Balb/C mice (n=4) were purchased from the 
Jackson Laboratories (Bar Harbour, ME, USA) and injected intravenously via the tail 
vein with an Adeno viral vector encoding human factor EX. The mice were bled at 
days 0, 7, and 14 days after injection and bi weekly thereafter.
Vectors
The vectors used for these experiments contained an expression cassette encoding the 
human FIX cDNA under the control of a CMV IE enhancer/promoter. The vectors 
used for these experiments were produced using the methodology described 
previously (Chapter 4, page 106). The dose of vector injected was 4x10^^ vector 
genomes per animal.
Human FIX antigen and anti human factor IX measurement
Human FIX antigen in plasma samples of mice was measured by Elisa as described 
(Chapters, page 66). This assay does not detect murine FIX. Antibodies against 
human FIX were detected in plasma samples (1:32 dilution) by subclass specific Elisa 
as described. (Chapters, page 67).
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Results
The figures below show Factor IX antigen expression and anti FIX antibody 
production in C57BL6 and Balb/C miceachieved after intravenous injection (tail vein) 
of an adeno virus encoding human FIX into wild type Balb/C or C57BL6 mice.
Figure 34 FIX Ag expression in WT C57BL6 and Balb/C mice
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As demonstrated from the above graph, expression reached in the Balb/C mice is very 
low and lost quickly in this strain. However, in the in the C57BL6 mice the expression 
levels reached are logarithmically higher and sustained. When analysed at much later 
time points, the C57BL6 mice continue to express high amounts of circulating FIX 
antigen, {data not shown)
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Figure 35 Antibody titres Balb/C mice
c
3  1 
û
d
AbTitre : Balb/C Ad l/V
100 5
Time (W eeks)
M1 M2 M3
The presence of antibodies is easily demonstrated in the Balb/C animals serum, but 
not in the C57BL6 strain {data not shown), thus reflecting the antigen levels obtained.
Sum m ary
These results demonstrate that these two strains respond significantly differently when 
challenged by gene transfer when vector administration is via the same route. The 
inference from these results is that strain specificity directly influences the response 
to gene transfer. These results pose the question as to why therefore the C57BL6 
strain is permissive (and produces large amounts of FIX antigen) to a highly 
immunogenic challenge with Adenoviral human factor IX when administered 
intravenously compared to Balb/C mice. The following experiments were conducted 
to answer some of these questions.
Are the C57BL6 injected mice truly tolerised?
Aim
As shown above, the C57BL6 injected mice continue to express large amounts of 
factor IX and suggesting that these mice may truly be tolerant to the circulating 
human factor IX. If this were the case, it might be expected that further
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immunological challenge to these animals, with human FIX, would result in continued 
expression of circulating factor EX. This hypothesis was tested out in the following 
experiment.
Method
A cohort of mice, who initially received Adenovirus encoding hPEX IV, were later 
challenged (8 weeks) with an AAV vector IM encoding human factor EX. Normally 
immune competent mice receiving AAV IM injections produce an antibody to factor 
EX that results in no circulating FEX levels being detectable. If the mice injected with 
Adenovirus encoding factor EX were truly tolerised, then later challenge with the 
AAV IM injection should not result in the production of antibodies to factor EX after 
injection.
At day 0, four C57BL6 mice received a dose of AdhFEX at a dose of 4x10^® vector 
genomes via tail vein injection. The mice were then analysed for factor EX antigen and 
antibody production by the methods previously described. (Chapter 3, page 65). At 8 
weeks (cross over point) the mice then received AAVhFEX at a dose of 4x10^^ vector 
genomes given intramuscularly into the hindlimbs. The mice were again followed up 
serially at 2 weekly intervals post injection for FEX Ag and antibody formation to 
circulating human factor EX.
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Results
The following figure shows the antigen levels before and after the mice received the 
AAV intramuscular injection
Figure 36 Adenovirus IVfollowed by AA V I/M
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As demonstrated from the above results, these mice continued to produce significant 
amounts of circulating factor IX and did not drop their levels after the AAV I/M 
injection suggesting that the animals were truly tolerant to the circulating human 
factor IX.
Further confirmation o f tolerance induction:
Lack o f  HFIX-specific T cell proliferation in C57BL/6 mice that had received IV  
injection o f adenoviral vector.
C57BL/6 mice (n=3) that had received adenoviral vector via the IV route were 
challenged twice by IP injection of hFIX protein formulated in complete Freund’s 
adjuvant (cFA) 5-6 months after adenoviral vector administration. The injections were 
one month apart, and the animals did not show antihFIX as measured by ELISA, up to 
two weeks after the last boost with hFIX/cFA /data not shown). Subsequently, the 
mice were sacrificed and in vitro proliferation of lymphocytes in response to hFIX 
antigen was assessed. C57BL/6 that had received IM injection of the adenoviral
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vector (but not cFA) were analyzed in parallel. As documented in the table below no 
evidence for T lymphocyte proliferation was obtained for mice that were IV injected 
with adenoviral vector, despite the repeated boost with hFIX antigen in cFA, while IM 
injected mice showed mild proliferation with a stimulation index of 2-3.5.
Table 5 Mouse Stimulation indexes
Mouse SI
Ad-hFEX IM 2.1
Ad-hFEX IM 3.5
AAV-hFEX IM + Ad-hFIX IV + 
hFEX/cFA
<1
Ad-hFEX IV + AAV-hFEX IM + 
hFEX/cFA
<1
Ad-hFEX IV + AAV-hFEX IM + 
hFEX/cFA
1.6
Lymphocyte proliferation following in vitro stimulation with human FIX 
protein. Shown are the stimulation indexes (SI) for individual C57BL/6 mice 
that had received ad-hFIX vector IM (first two rows) or IV (last three rows). 
Mice injected IV with Ad-hFIX vector had received IM infusions o f AA V-hFIX 
8 weeks before or after IV administration o f the adenoviral vector, and were 
boosted twice in a 1 month interval with hFIX protein formulated in complete 
Freund's adjuvant (cFA) and infused intraperitoneal (IP). SI was calculated 
based on the hFIX concentration that gave the highest proliferative response, 
which was generally, 5-10 pg hFIX/ml medium.
Summaiy
The failure of the splenocytes, in the intravenously injected animals, to proliferate to 
the potent resimulation challenge of human factor EX in complete Freunds adjuvant 
indicates tolerance has been induced to hFIX in these animals. The mechanisms of 
why this occurred is outlined in thefbllovying section.
Possible mechanisms to explain the observed C57BL6 tolerance
If the C57BL6 strain is truly tolerant to circulating factor EX Ag (after intravenous 
administration), it may be that this antigen is inefficiently presented to the effector
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immune system and result in T cell anergy. The failure of efficient presentation can 
occur for several reasons in the antigen-presenting pathway. The APCs may carry 
insufficient co stimulatory molecules; or they may lack the required MHC class II 
molecules to present antigen to effector CD4 cells.
Charlton (Charlton et al., 1997) studied the ability of splenic antigen presenting cells, 
from nine independent mouse major histocompatibilty complex (MHC) haplotypes, to 
present recombinant streptoccocal exotoxin A (rSPEA) to heterogeneous T cells and 
mouse T cell clones using using proliferation assays.
The authors reported a marked variation between in proliferative capacity between 
MHC haplotypes, which were ranked as follows:
H2' >H2*= H 2'=H 2 '’=H 2 =H 2 H2 “ >H 2 '’=H 2 "
(H2^, C57BL6 strain)
The conclusion from these studies was that there was significant inter strain variation 
in the ability of different alleles of both E and A molecules (these are the homologous 
murine equivalent to class II molecules in man) to bind and present rSPEA.
5.5 R ole o f  H aplotype in FIX  Presentation
From the work described above, it was shown that haplotype influences antigen 
presentation, and the likely occurrence of immune responses (Charlton et a l, 1997). 
In the following series of experiments the role of haplotype was examined to 
determine whether the haplotype of the C57BL6 strain was playing a role in the 
observed responses to intravenous administration (Fields et al., 2001a) of Adeno viral 
vectors. C57BL/6 is an inbred strain of mice (haplotype H-2‘') that is deficient in the 
MHC class II allele IE, but can present peptides by MHC class II molecules encoded 
by the lA allele.
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In particular, the question asked was whether the absence of IE in C57BL6 was 
affecting the response to circulating factor IX after AdhFIX IV administration. Since 
C57BL6 mice are deficient in the class II allele IE, it could be hypothesised that this 
allele is important in antigen presentation of human factor IX as shown below:
Figure 37 Role o f  H-2 Alleles in antigen presentation
H- 2 Alleles in C57BL6 : Ag presentation
FIX Ag ------------ m  ■   ► C57BL/6
Absence IElA
APC
As can be seen from the above diagram, if the presence of the IE allele is 
required for antigen presentation, no factor IX antigen may be presented to 
reactive effector T cells, resulting in failure of induction of an immune response 
(via T cell ignorance) and resulting factor IX expression.
Aim
This hypothesis was tested by conducting a similar experiment in another strain 
of mouse also deficient in the class IE allele. If the absence of IE is truly 
implicated, elevated levels of factor IX should circulate in this haploidentical 
strain (IE deficient)
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Some commonly listed mouse haplotypes are listed in the figure below: 
Table 6 Murine Haplotypes
H2 H A PLO T Y PE S O F  C O M M O N  M O U SE ST R A IN S
Strains H aplotypes H-2 gene com plex
K A E S D
C 57B L 6 C57BL10, FVB b b b - b b
B A L B /c , D BA/2 d d d d d d
A K R ,C BA ,C 3H  k k k k k k
SW R q q q q q q
A mouse strain with a similar haplotype to the C57BL6 mouse is the FVB strain i.e. 
IE deficient. Therefore, a similar experiment was performed in this strain, whereby 
intravenous AdhFIX was administered to a cohort of 4 FVB mice.
Method
A cohort of four FVB mice (n=4 obtained from Charles River Laboratories USA) 
were injected intravenously at day 0 with AdhFIX vector at a dose of 4x10 vg per 
animal.
Vector
The vector selected was an Adeno viral vector encoding the human factor transgene 
under the control of a CMV promoter. The dose of vector administered was 4x10^° 
vector genomes per animal.
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Results
Figure 38 Antigen and Antibody levels in FVB following AdhFIX injection
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The right hand panel in the above graph also illustrates that the falling levels of factor 
IX antigen coincided with the appearance of circulating antibodies to the factor IX 
antigen, indicating that the situation seen in these animals was not that echoed in the 
haploidentical C57BL6 strain. Therefore the lack, of the IE allele does not appear to 
be directly responsible for the C57BL6 unique response to AdhFIX intravenous 
injection. This result appears to be in keeping with another group's attempts to 
explain the long term gene expression observed with the C57BL6 strain using the 
alpha antitrypsin transgene (Barr et a l, 1995).
5.6 The Role of Interleukin 10
An alternative explanation for tolerance induction in the C57BL/6 may be the unique 
pattern of cytokine expression following systemic delivery of the viral vector via the 
intravenous route. Interleukin 10 (IE-10) has been documented to be involved in 
antigen-specific tolerance by its ability to down-regulate immune responses, including
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down-regulation of MHC class II expression and inhibition of production of 
inflammatory cytokines (Tan et al., 1995). lL-10 is implicated in the negative 
regulation of T cells and induction of tolerance in CD4^ T cells (Knolle et al., 1995; 
Knolle et al., 1998a; Knolle et al., 1998b). Expression of IL-10 in Kupffer cells, 
professional APCs (dendritic cells) in the liver, may serve as an autoregulatory 
mechanism for antigen presentation by liver antigen presenting cells (Knolle et al., 
1998b). It has been shown that Kupffer cells secrete IL-10 in response to endotoxin 
challenge and regulate local immune and inflammatory reactions in the liver sinusoid 
(Knolle e ta l ,  1995).
Aim
In the intravenous route of administration the majority of antigen presentation takes 
place in the liver. In order to examine whether regulation of IL-10 expression in the 
liver, the main target of gene transfer following IV injection of adenoviral vector, 
plays a role in tolerance or immunity against FIX antigen, two sets of experiments 
were carried out, both in wild type C57BL6 and Balb/ C and also simultaneously in 
the same strains deficient for IL-10. The aim of this experiment was to test out 
whether IL-10 was playing a role in the observed tolerance to the circulating factor IX 
antigen in the C57BL6 animals. The central hypothesis being tested is outlined 
schematically below:
Figure 39 Role o f  IL-10
Role of IL-10: Immune response
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Down regulation o f immune 
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Induction o f T cell anergy
Failure o f local immune response
Higher levels o f circulating FIX Ag ? ?
143
Methods
2 cohorts of IL-10 deficient mice (C57BL6 IL-10 KO, Balb/C IL-10 KG) were 
challenged with IV (via tail vein) injections of the adenoviral vector encoding hFIX. 
The IL-10 knockout (KO) mice were provided by Professor J Farrell at the University 
of Pennsylvania Veterinary School.
Vectors
The vector used for these experiments was an E1/E3-deleted adenoviral vector, ad- 
hFIX expressing of human FIX from the CMV enhancer/promoter was constructed as 
described (Walter et a l, 1996). The vector was replicated in HEK-293 cells and 
purified from cell lysate by two rounds of CsCl density gradient centrifugation using 
standard protocols. The vector has a total particle: pfii ratio of 25:1 as determined by 
plaque assay (Walter et al., 1996).
FIX Antigen and Antibody estimation
Human FEX antigen in murine plasma samples was measured by Elisa as described. 
(Chapter 3, page 65). This assay does not detect murine FIX. Antibodies against 
human FEX were detected in plasma samples (1:32 dilution) by subclass specific Elisa 
as described (Chapter 3, page 66).
Results
The graph below shows the antigen levels achieved in the IL-10 knockout animals. 
BALB/c mice (haplotype H-2^) have been shown by others to produce anti-hFEX 
following EV injection of adenoviral vector (Michou et al., 1997). As shown in the 
graphs below, IL-10 deficient C57BL/6 mice produce high systemic levels of hFEX 
without detectable antibody formation.
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Figure 40 FIX Ag IL-10 KO mice
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The IL-10 knockout Balb/C mice failed to produce high level and long-lived antigen
expression. This would be expected if IL-10 was truly acting as an immunosuppressor 
in liver derived antigen presentation of human factor IX.ln contrast to C57BL6 mice, 
normal and IL-10 deficient BALB/c mice synthesised IgGl, IgG2a, and lgG2b anti­
hFIX by day 14 post vector administration, thereby blocking systemic expression 
efficiently. This is illustrated in the figures below:
Figure 41 Anti FIX Ah Balh/C mice
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[t therefore appears, from the data described above, that there is no evidence of 
involvement of IL-10 expression in the tolerance observed to hFIX to explain the high 
levels of factor IX expression observed in the C57BL6 strain via the intravenous 
route.
Summaiy
The previous two sets of experiments (role of haplotype and role of IL-10) attempted 
to address the possible mechanisms of the paradoxical results displayed by the 
C57BL6 strain of mice. Neither hypothesis could explain the results observed. The 
results displayed by the C57BL6 strain point out the importance of strain variability 
and their responses to gene transfer (Fields et al., 2001a). This point should be borne 
in mind when devising pre-clinical gene therapy protocols. Therefore, because of their 
inherent permissive state, interpretation of gene expression in this strain may not be 
relevant when extrapolating to other strains of mice and different species of animals.
Discussion
When considering the immune responses to gene transfer there are many factors to 
take into account, both internal and external to the process, which may influence the 
outcome. The early part of this chapter showed that vector selection plays a 
significant role in the outcome and leads to the generation of differing immune 
responses according to which vector is selected. (Adenoviral, Plasmid > Adeno 
associated). Therefore, the choice of vector is crucial to the overall efficiency of the 
procedure and this point clearly needs to be borne in mind when designing gene 
therapy protocols in animal models and humans. In this respect, it appears that AAV 
viral vectors appear to induce a T helper cell response that results in a dominant IgGl 
subtype antibody to human factor IX.
Based on the observations from immunoglobulin profile data, it may be predicted that 
AAV muscle based transduction induces a more dominant Th2 response, which is 
associated with a less cellular cytotoxic T cell response as compared to the plasmid 
and adeno viral responses. The only definitive way to confirm these observations is to 
develop a Cytotoxic T cell assay (CTL) to the transgene product, human factor IX. 
This is the subject of the work discussed in the following chapter.
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Similarly, the choice of transgene influences outcome. Early experiments in gene- 
based strategies were hampered by the lack of appropriate homologous transgenes 
available for study in the relevant animal models. This has not allowed 
straightforward interpretation of the immune responses generated. Now, with the 
availability of the relevant homologous transgenes and the wider availability of vector 
choice, a more critical evaluation of immune responses may be carried out in animal 
model preclinical studies. Finally another important consideration to take into account 
is the effect of strain on the results obtained. Many early studies in gene therapy used 
the C57BL6 strain as the recipient animals of gene transfer. Bearing in mind their 
relative permissive state to high immunogenic challenge, the results obtained for this 
strain should be bom in mind with relative caution.
The results also point out that, in the wider context of gene therapy, for each different 
gene therapy strategy planned (i.e. a particular combination of vector, transgene and 
target tissue), the immune response needs to be critically evaluated for each 
individually designed component of the protocol. Finally, other factors, such as route 
of administration of gene delivery clearly influence outcome and also need to be taken 
into account when devising gene therapy protocols.
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CHAPTER 6
CELLULAR BASED IMMUNE
RESPONSES IN NORMAL AND
HAEMOPHILIC MICE
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6.1 Introduction
Compared to conventional treatment of haemophilia by the infusion of plasma derived 
or recombinant clotting factor concentrates, a gene-based approach involves both the 
intracellular and extracellular production of clotting factor protein. This approach 
therefore, will involve different mechanisms of antigen presentation. Generally, 
immune responses in a gene therapy setting may differ from those encountered during 
infusion of protein because the endogenously synthesised FIX is presented in context 
of MHC class I as well in addition to MHC class II determinants. A transgene product 
expressed by cells following gene transfer, presented by MHC class I molecules on 
the cell surface, will create a potential target for destruction by MHC class I-restricted 
cytotoxic T lymphocytes (CTLs, CD8^ T cells). The differences in the pathways are 
shown below and illustrate the possibility of entering an MHC I pathway in addition 
to the generation of an MHC II pathway. Therefore in a gene-based approach 
consideration needs to be given to the possibility of an MHC class I response 
occurring leading to the generation of a cytotoxic T cell response.
Antigen processing : Presentation in a gene based approach
INTRACELLULAR 
(cell surface peptide^
MHC I
VECrOR/TRANSGENE
F T X A g
Cellular cytotoxic T cell 
responses
Destruction o f target tissue
EXTRACELLULAR 
(secreted into the circulation )
MHCn
Antibody T helper cell dqjendent 
responses
Antibody formation to vector / transgene antigens
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the non-species-specific transgene product hFIX which are predominantly composed 
of an IgGl subtype (chapter 5, page 120).
This observation suggests that a cellular cytotoxic T cell response may not be 
occurring in the context of AAV muscle directed gene transfer. In order to prove 
whether this is true, the only definitive way is to set up an assay which is capable of 
showing whether a cytotoxic T cell response (CTL) is induced to human factor EX. At 
the time of starting this work no published study had addressed this question.
Aim
The aim of the studies in this chapter was to see whether AAV vectors encoding the 
human factor IX transgene could elicit a cytotoxic T cell response to factor EX antigen 
in a muscle directed gene transfer approach.
6,2 Development o f Cytotoxic T Cell Assays (CTL)
The development of a cytotoxic T cell assay requires many stages and reagents. The 
development of the assay was first tested by using the reporter gene Beta 
Galactosidase and using the protocol as previously published (Fisher et al., 1997). 
Once efficacy was demonstrated with the reporter gene, the assay was refined to test 
out the CTL response against the secretable protein human factor EX.
6.2,1 CTL responses to fi galactosidase protein
Before embarking on assays to test the CTL response to a secretable protein i.e. factor 
EX, a CTL assay was set up to reproduce the previously published data about the CTL 
response to the beta galactosidase protein encoded by an Adeno associated vector and 
an adenoviral vector. The previously suggested data reported there was a strong CTL 
response to the Beta galactosidase protein encoded by an adenoviral vector (Fisher et 
al., 1997) but not by an Adeno associated vector. It should be borne in mind that Beta 
galactosidase protein is a highly immunogenic non-secretable bacterial protein and the 
results yielded by this protein may differ from the human secretable transgene product 
human factor EX.
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Two processing pathways
The diagram above illustrates that there are two possible antigen-presenting pathways. 
Intracellular (endogenous) and extracellular (exogenous) antigens present different 
challenges to the effector immune system. Extracellular antigens such as infused 
clotting factor concentrates are eliminated by secreted antibody, whereas intracellular 
antigens i.e. those produced endogenously are most effectively eliminated by 
cytotoxic T lymphocytes. To mediate these responses the immune system uses two 
different antigen-presenting pathways; Endogenous antigens are processed in the 
cytosolic pathway and are presented on the membrane with MHC class I molecules. 
Exogenous antigens such as infused soluble protein antigens are presented on the 
membrane with class II MHC molecules.
Gene transfer to professional antigen presenting cells (APCs) such as dendritic cells 
may result in MHC I presentation and, subsequently, activation of antigen-specific 
CTLs (Yang et al., 1995a; Yang & Wilson, 1995; Yang et ah, 1995c; Jooss et ah, 
1996; Jooss et al., 1998a; Jooss et al., 1998b; Jooss et al., 1998c). Uptake of 
exogenous protein by APCs will result in presentation of peptides by MHC class II 
molecules, thereby potentially activating T helper cells (CD4^ cells). In mice, cells of 
the T helper cell subset are known to differentiate into Thl or Th2 cells depending on 
factors such as the local cytokine milieu. Proliferating Th2 cells characteristically 
secrete IL-4 and IL-10 cytokines and are capable of activating B cells resulting in 
mice in production of antibody dominated by the IgGl isotype. Thl cells, 
characterised by secretion of IL-2 and IFN-y, stimulate proliferation of CTLs, and 
activate B cells secreting IgG2a (Yang et al., 1995a; Yang & Wilson, 1995).
While Th2/IgGl responses are typical for the immune response against an infused 
soluble protein, Thl/IgG2a responses are more typical for protein expression in the 
context of viral infections (Yang et al., 1994b; Yang et al., 1995b; Yang et al., 1995c; 
Yang et al., 1996a). However, depending on the nature of the protein, dose, route of 
administration, and presence of adjuvant, an infused protein may also cause Thl 
responses (Lagrange, 1977). As shown in chapter 5 in response to AAV based 
transduction, expression of human FIX in immunocompetent mice persists in AAV 
vector-transduced muscle fibres despite the presence of neutralising antibodies against
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Method
The experiment was performed by injecting two cohorts of four mice intramuscularly 
(C57BL6 littermates) either with an adenoviral or adeno associated vector encoding p 
galactosidase at a dose of 4 xlO^ ® vector genomes per Kg. At day 10 a CTL was 
performed to assess the cytotoxicity of the recipient lymphocytes against a target cell 
expressing the p galactosidase protein.
Generation of Target cells
Briefly target cells (MHC-1 compatible, C57SV cells: a gift from Dr Yvonne 
Patterson, University of Pennsylvania) were mock infected, infected with Adlac Z, or 
stably transduced with a lac Z  retrovirus.
Generation of Effector cells
At day 10 the spleen and draining lymph node cells of the injected animals were 
removed and cell suspensions prepared to act as effector cells. These cells were 
restimulated in vitro for 5 days with p galactosidase protein (10 pg/well. Sigma), 
AAV lac z, or AD lacz (5x10^ /well, UV inactivated), or mock medium in 24 well 
plates. At the end of the stimulation period conventional chromium release assay was 
performed as previously described (Yang et ah, 1996a).
Results
a) In vitro Cytolysis of B galactosidase
The results for the degree of cell lysis are shown in tabular form below: As can be 
seen maximal cell lysis occurs for those target cells labelled vdth Adpgal. Lysis also 
occurs to the RVpgal labelled cells. The higher degree of lysis seen in the former 
represents a CTL to both the Adenovirus and the p gal protein components of the 
Adpgal vector.
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% LYSIS
TC Rat io Ad B qal RV B qal AAV B qal
50 30 12 <1
25 17.4 10 <1
12.5 7 10 <1
6.25 6.4 10 <1
3.12 5.4 9 <1
1.5 3.2 10 <1
0.75 1.8 6 <1
h) A A V V5. Ad: Cytolysis fo r  fi  galactosidase
The graph {figure 42) below shows that the Adenoviral-immunised animals exhibit a 
strong cytotoxic response against the target cells B galactosidase (30-40% lysis target 
cells). In contrast the animals immunised with an adeno-associated vector failed to 
demonstrate a significant CTL response.
Figure 42 % Target cell lysis Beta Galactosidase
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Summary
From the above experiment it appears that the AAV vector did fail to induce a CTL 
response when encoding the non-secretable transgene B galactosidase. The data from 
these experiments were further supported by analysis of the mouse immunoglobulin 
subtypes to B galactosidase in the immunised animals. It was shown that the dominant 
subclass induced in the adenoviral-immunised animals was of a IgG2 subclass,
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whereas in the adeno-associated immunised animals the dominant subclass induced 
was an IgGl subclass. These profiles would reflect Thl driven cellular CD4 response 
for the adenoviral immunised animals and a more dominant Th2 response in the adeno 
associated immunised animals. The next stage of the experiments was to design a 
study to determine whether there were cytotoxic T cell responses to the secretable 
transgene product human factor EX.
6.3 A Study of The CTL Responses to the Transgene Product Human Factor IX 
in the Context of Adeno-Associated or Adenoviral Mediated Gene Transfer
In order to address the question of whether a cytotoxic T lymphocytes (CTL) response 
was occurring against the secretable transgene product human factor EX, an in vitro 
CTL assay was set up.
Experimental design
These experiments were set up to determine if normal mice (C57BL6) immunised 
with an Adeno associated viral vector encoding human factor IX could generate a 
cytotoxic T cell response to human factor EX. The experiments were also performed in 
haemophilic mice on a C57BL6 strain background. As a positive control, separate 
cohorts of mice were also immunised with an adenoviral vector encoding human 
factor EX. The methods for the CTL assay were developed along the same lines as 
those previously described (Yang et al., 1996b; Fisher et al., 1997; Jooss et al., 
1998a).
Generation of antigen stimulated T cells (Effector cells)
C57BL/6 mice were immunised by IM injection with adenoviral or AAV vectors 
expressing hFEX at a dose of 4 xlO^^ vector genomes per Kg (n=3 per vector). The 
identical experiment was also carried out with two cohorts of haemophilia B mice 
(C57BL/6 background) immunised with ad or AAV (n=2 per vector).
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Splenocytes and lymphocytes isolated Ifrom the draining lymph nodes of the injected 
limbs were combined for in vitro expansion of effector cells derived from each cohort 
of mice. Lymphocytes were plated out in a 24-well plate at a density of 5x10^ 
cells/well and cultured in 10% CO2 at 37°C for 5 days. The cells were stimulated with 
hFIX secreted from C57SV (fibroblast) feeder cells infected with a retroviral vector 
expressing hFIX (MFG-hFEX). C57SV cells were seeded at a ratio of 1:50 with the 
lymphocytes. (Initially it was decided to use a feeder cell transfected with a plasmid- 
encoding factor EX, but this procedure failed to work despite repeated attempts. 
Therefore, a retrovirally-infected feeder cell was used instead). Prior to seeding, 
feeder cells were irradiated at 2000 Gy for 20 minutes to stop their proliferation in 
vitro during the culture period. Effector cells were harvested after 5 days, and a CTL 
assay was set up against H-2 compatible target cells (H-2b) infected with a retroviral 
vector expressing hFEX.
Generation of Target Cells
The target cell line TC-1 was transduced with a retroviral vector for expression of 
hFEX. Lung epithelial-derived TC-1 cells are derived from C57BL/6 mice and can 
serve as histocompatible target cells for CD8^ effector T cells from this mouse strain 
(Lin et al., 1996). Prior to seeding with the effector cells, target cells were checked for 
expression of FEX. Target cells (C57BL/6-derived lung epithelial cell line TC-1 (Lin 
et al., 1996) were labelled with ^^Cr and subsequently incubated with effector cells at 
ratios of 100:1 to 0.75:1 (effector: target) for 5 hrs at 37°C in 10% CO2. Specific 
target cell lysis was calculated as follows:
experimental release c p m  -  spontaneous release c p m  
maximum release c p m  -  spontaneous release c p m
XlOO
(CPM = counts per minute)
All experimental values given represented the average of three wells; maximum (i.e. 
target cells incubated with 10% SDS) and spontaneous (i.e. target cells incubated with 
medium alone) were also averaged from three wells. Spontaneous release was
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consistently less than 30% of the maximum release. Standard deviation for triplicate 
measurements of ^ *Cr release ranged from 1-16% of mean values.
Mock transduced target cells (i.e. target cells that are not expressing FIX) were used 
as a negative control for lysis by effector cells to account for non-antigen-specific 
lysis. Lysis of target cells by effector cells from uninjected mice was consistently 
<3%.
An outline of the experimental schema is shown below:
Fig 43 In vitro CTL
Invitro CTL
A
Day 10
Injection 
vector AdhFIX/ AAVhFIX
In vitro Stimulation
5 days 37”
• =  Effector cell
® “  Feeder cell 
° =  Target cell ( ^ t r )
Lysis step 
37” C. 6hrs
Isolation Spleen, 
draining lymph node
"olÿ w  V '
Measure Chromium release
The invitro CTL is shown above. Briefly 2 cohorts o f mive were injected with either an 
AAV or Ad vector encoding human factor IX. At day 10, the spleen and draining 
lymph node were removed and cell suspensions prepared to be used effector cells in 
an in vitro CTL assay.
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Results 
In vitro CTL
As judged by chromium release assay, adenovirus-injected normal and haemophilic 
mice developed hFIX-speciflc cytolytic activity causing lysis of up to 30-55% of 
target cells at the highest effector: target cell ratio (Figure 44a, b). Lysis of hFIX 
expressing target cells incubated with lymphocytes from AAV-injected normal or 
haemophiliac mice was similar to mock-transduced target cells indicating absence of 
FIX-specific CTL activity. Lysis of mock transduced cells is likely caused by NK 
cells, and is often found increased when effector cells from adenovirus immunised 
mice are used (HCJ Ertl, unpublished observations). These in vitro data correlated 
with infiltrates of CD8^ T cells in adenovirus-injected muscle and absence of CD8^ 
infiltrates in AAV-transduced muscle at the site of transgene expression (please see 
chapter 5,page 120).
Fig 44 In vitro CTL results 
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B)
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The graphs above show the percentage specific lysis o f  target cells as a function o f  
effector cell: target cell ratio. Ay B. Lysis o f  hFIX-expressing TC-1 target cells (hFIX 
expression from a retroviral vector) after incubation with lymphocytes from AA V- 
(AA V-hFIX /  FIX) or adenovirus -injected mice (Ad-hFIX /  hFIX). Mice were normal 
C57BL/6 in graph A and hemophilia B mice on C57BL/6 genetic background in graph 
B. Mock controls represent lysis o f  untransduced TC-I target cells (i.e. cells not 
expressing FIX) by lymphocytes from AA V- (AA V-hFIX /  mock) or adenovirus - 
injected mice (Ad-hFIX/  mock).
Summary
As can be seen from the above graphs both wild type and haemophilia B animals 
immunised with the Adenoviral vector elicited strong CTL responses to the human 
factor IX transgene product. The AAV immunised animals however failed to elicit 
any comparable CTL response above negative control values. The data lend support to 
a relative absenee of a CTL response via AAV mediated gene transfer. These results 
confirm histologically with a relative absence of inflammatory infiltrates seen in the 
AAV animals (Chapter 5, page 121).
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6,3,1 Cytokine analysis o f injected animals
As well as directly looking for a CTL response to the transgene product human factor 
IX, another way of dissecting out the immune response at a cellular level is to try and 
establish the cytokines expressed during the immune response by effector cell 
populations involved in the immune response. If a true CTL response was occurring 
CD4 T helper cells would secrete the Thl cytokine IFNy and IL-2, both known to 
correlate with CTL responses.
Method
Splenocytes and lymphocytes from the draining lymph nodes of injected muscle were 
cultured in DMEM (supplemented with 2% heat inactivated foetal calf serum and 10'  ^
M-2 mercaptoethanol) and restimulated in vitro with antigen. The antigens used were 
either Mononine (c2.5pg/ml) or heat inactivated AdhFIX vector (250 particles/cell). 
Cell free supernatants were harvested at 96 hours and analysed for the presence of IL- 
2, IFNy, IL-4 and IL-10 by ELISA. Antibodies against murine cytokines and cytokine 
standards were provided by Pharmingen. Mock-stimulated cells were used as negative 
controls (for method seeChapter3, page 67-69).
Results
The results are shown in tabulated form below:
Table 7 Cytokine release assay 
Stimulating Antigen : FIX Ad-FIX
Injected VectorVector IL-2 IFNy IL-10 IL-2 IFN-g IL-10
mice (pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/ml)
Wild Ad 24 440 45 124 3200 65
type AAV 0 0 12 0 0 0
HB Ad 22 260 17 39 996 163
mice AAV 0 0 20 0 0 0
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As can be seen from the above table, the AdhFEX injected mice displayed high levels 
o f the cytokines IL-2 and IFNy in keeping with a Thl (CTL) profile. In contrast the 
AAV injected animals did not elicit this type o f profile and instead elicited a small 
amount of IL-10 expression more in keeping with Th2 response. These data support 
the CTL responses and histological findings (Chapter 5) observed for the Adenoviral 
injected animals.
6.4 In  Vivo CTL
A possible confounding factor in the above results was that the above experiment 
represents an in vitro assay and may not be fully representative o f the in vivo 
situation. Because o f this, an in vivo CTL was set up to analyse whether the in vitro 
results could be confirmed.
The experiment performed was an adoptive transfer experiment, whereby 
lymphocytes from immunised animals were adoptively transferred into double 
knockout animals (Haemophilia/ Rag-1 double knockout) expressing high levels of 
factor IX to see if  the recipient animal’s factor IX levels could decreased by the 
adoptive transfer o f the immunised animals lymphocytes. Haemophilia B/Rag-1 mice 
were generated by cross breeding o f haemophilia B (HB) mice with immunodeficient 
Rag-1 mice. These mice lack mature B and T cells and have no circulating 
immunoglobulins (Mombaerts et al., 1992). HB/Rag-1 mice were intravenously 
injected with the adenoviral vector resulting in high systemic expression o f circulating 
hFIX antigen.
Pooled lymphocytes from AAV and adenovirus injected C57BL/6 mice (isolated on 
day 10 after IM vector administration, a time point when the mice do not have 
detectable anti-hFfX, n=3 for each set of mice) were adoptively transferred to the 
HB/Rag-1 double knockout mice (n=2 for each pool o f lymphocytes) on day 1 o f the 
experiment. Prior to transfer, splenocytes/lymphocytes were depleted for B cells using 
a CD45R antibody column. B cell depletion was confirmed by flow cytometric 
analysis The reason for B cell depleting the adoptivley transferred cells was to ensure 
that any oberved fall in circulating factor EX in the recipient animals was due to a
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cellular response, and not a humoral response. To interpret the results o f these 
experiments, if  a true CTL had occurred in the immunised animals then the factor EX 
level would fall in the recipient double knockout animals. The experiment is described 
in more detail below.
Adoptive transfer of T cells
Haemophilia B/Rag-1 mice received intravenous injection o f 1x10^' particles o f ad- 
hFIX vector resulting in systemic expression o f hFEX as confirmed by ELISA for 
hFIX in plasma samples. C57BL/6 mice received EM injections o f AAV or adenovirus 
vector as described above (n=3 per vector) and were sacrificed at day 10 for adoptive 
transfer o f B cell-depleted splenocytes/lymphocytes to hFIX expressing HB/Rag-1 
mice. Draining lymph nodes (inguinal and popliteal nodes) o f injected muscle were 
carefully dissected. Lymph nodes and spleen were isolated, crushed, and washed 
twice in lymphocyte separation medium (Amersham Pharmacia Biotech, Arlington 
Heights, IL). Isolated cells were pooled for each o f the two cohorts o f mice and run 
over a Ficoll gradient (Histopaque, Sigma, St. Louis, MO) to separate out red blood 
cells. The gradient was spun at 2000 rpm for 20 min, and the mononuclear cell layer 
was carefully aspirated off and washed twice. The isolated mononuclear fraction was 
incubated with micro beads coated with CD45R monoclonal antibody (clone B220, 
Miltenyl Biotech, Germany) at room temperature in order to remove B cells. B cell 
depletion was confirmed by flow cytometiy using conjugated anti-CD3 and CD45R 
antibodies. Residual B cells were 2.9±1.1% o f the final cell population.
Finally, a cell count was performed, and a total o f 1x10^ cells were adoptively 
transferred into HB/Rag-1 via tail vein injection (100 pi cell suspension/mouse, n=2 
for lymphocytes from each cohort o f immunised C57BL/6 mice). Mice were 
subsequently bled from the tail vein one and four days after the procedure. A 
schematic diagram of the experimental procedure is shown below;
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Fig 45 In vivo CTL
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The diagram shows that the injected cohorts (wtC57BL6) spleen and draining lymph 
node cells were removed, and B cell depleted over a column. These T cells were 
subsequently adoptively transferred back into HB/Rag-1 double knockout animals, 
which were expressing high levels o f  circulating hFIX. Subsequently these FIX levels 
were measured in these animals to look to see i f  the FIX levels were decreased by the 
introduction o f the adoptivley transferred lymphocytes i.e. whether a CTL was 
induced.
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Results
Fig 46 In vivo CTL
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The results o f  the adoptive transfer shown above illustrate that in the right hand panel 
the adenoviral immunised animals dropped the factor IX levels in the recipient 
animals by 100% and 50% respectively. Conversely in the left hand panel it can be 
seen that the AA V immunised animals failed to decrease the factor IX levels in the 
double knockout animals.
These results from the adoptive transfer experiment confirm that there appears to be 
no in vivo CTL response with the AAV viral vectors.
6.5 Discussion
These results presented in this chapter show the antigen (FIX) specific T cells 
adoptively transferred from the Adenoviral immunised animals elicited an in vivo 
CTL response in the double knockout animals, whilst the AAV immunised animals 
failed to elicit such a response. These results subsequently confirmed the earlier 
described in vitro findings. In summary therefore it appears that Adenoviral based 
muscle transduction induced a cellular Cytotoxic T cell response to the human factor
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IX antigen whilst AAV based muscle transduction did not. The proposed mechanisms 
of both AAV and Adenoviral based muscle transduction are shown below:
Fig 47 Adenoviral Transduced Muscle
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In the above diagram it can be seen that adenoviral based transduction is able to elicit 
both an MHC class 1 response resulting in the destruction of transduced muscle and 
also a class 11 response. In the above response two profiles of an antibody are 
produced (IgGl and lgG2) in keeping with both a Thl and Th2 response, as well as 
CTLs through MHC class 1 and 11 presentation of FIX expressed in APCs or secreted 
from transduced muscle cells. Immune responses against the transgene product are 
also likely critical for the elimination of transduced muscle fibres (Tripathy et al., 
1996). The CTL response is directed both to the viral proteins as well factor IX. Why 
a CTL response is induced here to the factor IX maybe because the Adenoviral based 
response may be sufficient to trigger a CTL response to the factor IX transgene by 
creating a sufficient cytokine milieu to induce this response.
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Fig 48 Adeno-associated based Transduced muscle
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In the above immune response it can be seen that a CTL response is not induced in 
response to AAV based transduction. The response induced is predominantly a TH2 
driven cellular immune response as evidence by the humoral profiles demonstrated 
(IgGl). This appears to be the major difference from adenoviral based transduction. 
The mechanism as why this maybe the case is currently under study although a 
previous report documented that AAV vectors were relatively inefficient at 
transducing antigen presenting cells and so enter into an MHC class 1 pathway.
In the context of AAV vectors, only MHC class II presentation is part of the immune 
response, resulting primarily in activation of Th2 cells through uptake of muscle cell- 
derived FIX.
This model would predict that antibody production against a secreted protein is 
independent of protein synthesis in APCs and can therefore not be prevented by use of
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a tissue-specific promoter (i.e. a promoter that is not active in APCs) as has been 
proposed for some gene therapy protocols (Pastore et al., 1999). Additionally other 
factors such as immunogenicity of capsid proteins (Dai et al., 1995), infection of cell 
types other than muscle fibres such as dendritic cells, and adjuvant effect from 
compounds present in the vector preparation may all play a role in immune responses 
to viral vectors.
Explanation for lack o f cellular immunity to AA V based transduction
The lack of immune responses to the transgene product in AAV based muscle 
transduction is different to that observed in Adenoviral based transduction where 
transduction of APCs is required for T cell activation to the transgene
The mechanism of why AAV vectors at least in murine species fail to elicit activation 
of an MHC class I pathway is unclear, but it s been suggested that AAV fail to 
transduce APC cells efficiently (due to post entry block) and thus do not enter into a 
cytotoxic pathway.
One could therefore hypothesise that efficient transduction of APCs is defective in the 
context of AAV. This hypothesis was tested by Jooss et al (Jooss et al., 1998c) in the 
following experiment. Naive APCs purified from spleen were exposed to high titre 
AAV prior to adoptive transfer into C57BL6 mice previously injected intramuscularly 
with AAV lac z. Direct analysis of the APCs failed to reveal evidence of B 
galactosidase expression. Furthermore these animals failed to activate T cells to B 
galactosidase and expression of the transgene was stable.
Mechanism o f defective antigen presentation o f APCs
There are several mechanisms by which antigen presentation may be avoided in the 
context of AAV based gene transfer.
1) Insufficient activation of the APC for presentation of antigen
2) Suppression of antigen presentation
3) Inability of AAV to transduce APC.
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The most likely reason for the observed difference in antigen presentation between Ad 
and AAV transduction is selective transduction of APCs by the different vectors. 
Transduction of fractionated populations of APCs with Adlacz demonstrated lac Z 
expression in dendritic cells and some macrophages, which effectively activated T 
cells to B galactosidase following adoptive transfer. Lac Z expression was not 
detectable in APCs following exposure to AAVlacZ, nor were these cells capable of 
activating T cells in vivo.
These findings were essentially consistent vsdth the notion that AAV efficiently enters 
a number of cell types, most of which are not permissive for transduction due to post 
entry blocks. The post entry bock was studied in vitro, which showed on FISH 
analysis that the vector genome localises in a perinuclear distribution. In order to be 
transcriptionally active the genome needs to enter the nucleus. Coinfection with an El 
and E4 expressing adeonovirus mobilised the AAV genome into intranuclear 
replication centres, which were transcriptionally active. The data produced from these 
experiments indicated AAV enters APCs in a non-productive transduction (Jooss et 
al., 1998c).
The significance of the findings in this chapter point out the critical importance of 
vector selection and the influence this has on the cellular responses observed to gene 
transfer (Fields et al., 2000). In particular and crucially for AAV vectors, there 
appears to be no CTL response elicited when these vectors are employed, so 
facilitating the long term gene expression observed with these vectors. These findings 
have wide implications for future human clinical trials.
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CHAPTER 7
INHIBITOR FORMATION
FOLLOWING GENE TRANSFER:
CHARACTERISATION AND
IMMUNOMODULATORY
STRATEGIES
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7.1 Background
The most devastating effect of replacement therapy in haemophilia is the occurrence 
of inhibitors, which occurs in up to 25% of patients with haemophilia A, and 3-4 % of 
haemophilia B. The presence of inhibitory antibodies to either factor VIII or FIX 
dramatically complicates therapy for these patients, with a consequent decrease in 
quality of life and life expectancy. The range of treatments available to treat inhibitor 
formation include the use of bypass therapy with activated and non activated 
prothrombin complex concentrates, high dose factor VIE, porcine factor VIE, and 
recombinant factor YE (Chapter 1, pages 28-32)
Several strategies have been used (so called “immune tolerance regimens”) that aim to 
induce tolerance to exogenous clotting factor VIE or IX, and have included the use of 
very high doses of clotting factor concentrates alone, or in conjunction vsdth immuno 
modulating agents. These treatment modalities are extremely expensive, require daily 
or twice daily administration and are not infrequently unsuccessful, especially when 
the inhibitor is well established and present in high titre.
Any novel treatment plan for haemophilia always raises concerns about potential 
inhibitor development, and therefore, at the outset of therapy the ability to predict 
which patients are at risk of inhibitor formation, and identify factors that predispose to 
inhibitor development would allow for the development of therapies which could 
either prevent or overcome this complication. The treatment of haemophilia by a 
gene-based therapy represents a new treatment strategy in which the risk of inhibitor 
formation is currently unknown. The work presented in this chapter is divided into 4 
subsections.
• Present understanding of the development of inhibitors in conventional 
replacement therapy particularly in relation to haemophilia B
• The immunological pathways involved in inhibitor formation
• Possible strategies to immunomodulate inhibitor formation
• Experimental data
a) Inhibitor formation in Haemophilia B mice without immunomodulation
b) Inhibitor formation in Haemophilia B mice with immunomodulation
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7.2 Aetiology of Inhibitor Formation
The aetiology of inhibitor formation is a complex issue. However several studies have 
tried to address the risk factors involved, which may be broadly divided into genetic 
and non-genetic causes.
7.2.1 Non Genetic factors
Several non-genetic factors have been studied, but none to date have shown clear 
associations with the incidence of inhibitor development. In general it is accepted that 
the type and purity of coagulation factor concentrates, age at the time of initial 
treatment, initial doses of concentrate, and frequency of dosing prior to inhibitor 
development have not been shown to be associated with risk (Hoyer, 1995).
Exceptions however, include cases whereby processing in manufacture lead to neo 
antigenicity of the clotting factor concentrate and subsequent inhibitor development. 
Two small clusters of patients, who had been previously tolerant to factor VIII 
infusion have developed inhibitors following infusion with new pasteurised factor 
VIII concentrates, which appeared to cause changes in the molecular structure leading 
to increased immunogenicity (Peerlinck et al., 1993).
Other factors, which alter the immune characteristics of a susceptible individual, may 
lead to the generation of sufficient inflammatory signals and trigger off an immune 
response resulting in an inhibitor formation. Although the HTV epidemic in the early 
1980's did not affect the propensity to develop inhibitors it was later subsequently 
shown that the chronic HIV infections were associated with spontaneous 
disappearance of inhibitors in both high and low responder populations. The 
subsequent loss of CD4 positive T helper cells lends support to the notion that T cells 
are integral in the pathogenesis of inhibitor development {vide infra)
7.2.2 Genetic causes
In general the more severe the genetic defect, the greater the loss of coding 
information and the more likely the development of an inhibitor. Therefore it is
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predictable that the risk of inhibitor formation is related to the underlying mutation 
.The incidence of inhibitor formation is much higher in haemophilia A (20%) (de 
Biasi et aL, 1994) than haemophilia B (4%) (Briet et al., 1984) and this is, in the main 
is accounted for by the mutation type leading to the disease. The following table 
shows the prevalence of inhibitor formation in Haemophilia A and B and the 
frequency of genetic defects leading to severe disease.
Figure 49 Mutation incidence in Haemophilia A and Haemophilia B
Haemophilia A Haemophilia B
Prevalence of inhibitor formation 20-30% 3-4%
Frequency of large gene deletion/ 
inversion in severe disease
40-50% 4-7%
Inhibitors in patients with 
•Large gene deletion:36% 
•inversion :35%
•Stop mutation:38% 
(missense mutation:4%)
50-60% of inhibitor 
patients with 
hemophilia B 
have a large gene 
deletion
Nature of the underlying mutations in Haemophilia B
Based in the UK, the haemophilia B database published annually since 1990 
(Giannelli et al., 1994; Giannelli et al., 1996; Giannelli et al., 1997; Giannelli et al., 
1998), is now the largest database of disease-associated mutations, with 1713 patient 
entries representing 652 unique molecular events (Giannelli et al., 1997). In a study 
performed by Sommer (Sommer 1992), 260 consecutive haemophilia B cases were 
sequenced (in terms of the predicted protein). 63% of the patients had mis-sense 
proteins, 30% garbled proteins (truncated, frame shift, or partial or full deletions), 7% 
abnormal splicing, and 0.6% decreased expression.
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Mutation and Inhibitor risk in Haemophilia B
In terms of mutations associated with inhibitor formation, it was recognised early on 
that the presence of a large gene deletion constituted a risk; in the study of Green et al, 
17/25 patients (68%) with a deletion involving at least one exon developed an 
inhibitor (compare to overall risk of 2-3%, vide supra) (Green et al., 1991). Overall, 
deletions account for 5% of all mutations resulting in haemophilia B, but 50% of 
mutations in patients with inhibitors (Sommer and Ketterling 1996). In addition to 
large deletions, mutations associated with loss of coding information (frame shift and 
termination mutations) also carry an increased risk of inhibitor formation.
In a Swedish study (Green et al., 1991), the a priori risk of inhibitor formation in a 
patient with an unknown mutation was 3% but near zero for a patient with a mis-sense 
mutation and -20%  for those with mutations resulting in loss of coding information. 
Similar results were observed in a study of 18 children who exhibited anaphylactic 
reactions to FIX on developing an inhibitor (Warrier, 1998; Warner & Lusher, 1998). 
10/18 of the children carried a large gene deletion.
Although 50% of inhibitors in haemophilia B are accounted for by large gene 
deletions the rest are largely due to point mutations. These are listed in the 
haemophilia B database (Giannelli et al., 1997) and some are described in table 8. It 
should be noted the database specifically excludes large gene deletions. It can be seen 
that inhibitor formation is largely confined to cases where there is an absence of 
detectable antigen. The single exception to this occurs in a mutation that alters the 
active site serine, an invariantly conserved residue in all the serine proteases.
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Table 8 Point mutations in the human FIX gene associated with inhibitors
Patient Act Ag
Nucleotide 
Position & 
Mutation
Amino
Acid
Change
Comments
UK 12 <1 6,392, A 1 6 Frame shift
Madrid 3 <1 <1 6,401-10,A10 9 Frame shift
Bonn 2 <1 <1 6,402-6, A5 9 Frame shift de novo in 
mother
Chongqin <1 <1 6,460,C -►T 29,R-^Stop 16 cases including 2 
inhibitors
HB7,
Japan
<1 <1 6,680-1, A 2 39 Frame shift terminates 
at aa46
>100 Bethesda units
HB5,
Japan
<1 <1 20,551, C -> T 191,Q-^S >100 Bethesda units
unnamed <1 <1 20,551, C-►A 191,Q-^K
Malmo 5 <1 <0.1 20,561, G -M . 194,Stop
HB6,
Japan
<1 <1 30,821, G -►A Destroys 
AG splice 
site
>100 Bethesda units
UK 140 <1 <1 30,863, C “ ►t 248,R,Stop 15 cases including 1 
inhibitor
Malmo 1 <1 <0.1 30,950-7,A8 277 Frame shift
Varel 1 <1 86 31,213-14,
TA->CG
365,S -^G Active site, silent 
mutation at aa364;
Mutation incidences in Haemophilia A
Schwaab (Brackmaim et al., 1993) and colleagues have reported that intra 
chromosomal mutations were associated with inhibitor formation in 42.4% of 
patients, whilst stop mutations and large gene deletions with 35% and 23.1% 
incidence respectively, whereas mis-sense mutations and small gene deletions were 
associated with only 6.7% and 9.1% incidence of inhibitors respectively. The 
currently accepted hypothesis is that large gene deletions, gene inversions and stop 
mutations lead to no circulating factor VIII protein and therefore substituted FVin  
factor represents a foreign protein evoking a host immune response.
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In contrast mis-sense mutations possibly result in circulating non-functional factor 
Vni protein creating immune tolerance in most of these patients. Despite the clear 
association with underlying mutation status, it still remains unclear why only 42% of 
patient and not 100% of patients with a large gene inversion develop inhibitors.
7.3 Other Inherited Characteristics
7,3,1 HLA Association
Several investigators have examined the possible role of the MHC locus in inhibitor 
formation; particularly MHC class 11 molecules since they are involved exogenous 
antigen processing. However no correlation of DR types in inhibitor versus non­
inhibitor patients has been found. However, the earlier studies were not able to take 
into account the mutation type. It is possible therefore diverse molecular defects may 
have interfered with the ability to closely examine the influence of immune response 
genes in inhibitor formation.
To address this problem, the influence of HLA genotype(01denburg et al., 1997) was 
investigated exclusively in patients with an intron 22 inversion as a uniform mutation 
type. Seventy-one patients were studied, 42 without and 29 with inhibitors (13 high, 9 
low, and 7 transient responders) and were genotyped for MHC Class 1 HLA -A , B, C 
and class 11 HLA -DQA, DQB, and DRB loci. No strong correlation of any HLA 
allele to inhibitor or non-inhibitor status was demonstrated. However alleles of the 
haplotype HLA-A3, HLA-B7, HLA-C7, HLA -DQA0102, HLA-DQB0602, HLA- 
DRl 5 were more often found in inhibitor patients. These alleles are more common in 
those of Northern European descent suggesting a racial predisposition.
In a further study, demonstrating the importance of race, a Japanese group (Ohta et al) 
serologically (HLA, A, B, Cw, DR and DQ) tested and genotyped (HLA -DQAl, 
DQBl, DRB VI and DPBl) 46 patients. 20 of these patients developed an inhibitor to 
FVlll, but unlike Oldenburg's study the genotype was not constant and 9/20 patients 
had a gene deletion, 6/20 a gene inversion, and no deletion or inversion in 4 patients 
and unknown status in one patient.
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In this study, it appeared that absence of the HLA-A24 allele was a principle risk 
factor for inhibitor development (p=. 0003). Other haplotypes HLA-DR4.1, DQ4, and 
DQAl*0301=2 were positively associated with patients developing inhibitors when 
compared to normal subjects. The authors concluded that the association between 
HLA antigens and the formation of inhibitor was dependent on racial background.
7.4 Pathways Involved in the Immune Response
In the conventional approach to treating haemophilia, the immune response represents 
the response observed to a soluble protein i.e. infused clotting factor. In this response 
there several different stages of the process involved in immune recognition and an 
immune response. There are likely to several different cell populations involved 
before the generation of an antibody response. Clotting factor protein antigens are 
taken up by an antigen-presenting cell and then presented in the context of MHC class 
11 molecules to effector CD 4+ cells. The simplified process is shown schematically 
below:
Figure 50 CD4 T cell help pathway
Soluble protein: T cell help pathway in a mouse
Circulating factor IX
BCell IL-4, IL-10
Ig G l
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As can be seen from the above diagram, there are three cell types central to the above 
process a) APCs, b) CD4+ cells, and c) B cells and subsequent antibody production. 
Characterisation of these cellular interactions will provide clues to the aetiology of 
inhibitor formation, and offer ways of developing therapies to overcome the response. 
Each of these components will now be considered in more detail.
7.4,1 Antigen processing pathways
Before the effector immune system actually meets antigen, several things occur to the 
antigen before it is ready to be presented to this system. Antigen processing is highly 
complex and ordered process. T lymphocytes recognise peptide fragments that are 
bound to cell surface proteins encoded by genes of the major histocompatibility 
complex (MHC). MHC molecules serve to display peptides to T cells. Peptides 
derived from cytosolic proteins are bound to MHC class I molecules and are 
recognised by CD8+ T cells, which are usually cytolytic T cells (CTLs). CTL' s 
provide the major host defence system against intracellular microbes which produce 
proteins in the host cell cytoplasm. Therefore proteins made by the intracellular 
introduction of transfected genes via a gene transfer process, may enter the pathways 
described above, and generate a cellular cytotoxic T cell response (CTLs).
In contrast, peptides derived from extracellular proteins such as infused clotting factor 
proteins are endocytosed by specialised cell types and bound to class H molecules and 
are recognised by CD4 +T cells, which are usually helper T lymphocytes. Helper T 
cells are most effective in eliminating extracellular and phagocytosed antigens.
Antigen Presenting cells
The generation of complexes of MHC molecules and peptide antigen on the surface of 
APC's involves intricate multistep pathways within the APC. In general, both MHC I 
and MHC II pathways have features in common:
1) Peptide antigens are generated by proteolysis of intact proteins within subcellular 
organelles of APCs
2) Peptide binding to MHC molecules occurs prior to cell surface expression.
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3) Both class I and class II MHC pathways of antigen processing and presentation 
utilise subcellular organelles and enzymes that have generalised protein degradation 
and recycling functions that are not exclusively used for antigen display to the 
immune system.
4) Both class I and class II antigen processing and presentation pathways do not 
distinguish self proteins from foreign antigens but rather display peptides from a 
sampling of all endocytosed and cytoplasmic proteins for T cell surveillance.
Types of APC
The two requisite properties that allow a cell to function as an APC for class II MHC 
restricted helper T lymphocytes are the ability to process endocytosed antigens and 
the expression of class II MHC gene products. The best-defined APCs for helper T 
lymphocytes include three cell types classified as Professional antigen presenting 
cells: Dendritic cells, macrophages, and B-lymphocytes.
The distinguishing feature of these cells is their ability to express class II MHC 
molecules and their ability to deliver a co stimulatory signal {vide infra). These cells 
differ in their mechanisms of antigen uptake, in whether they constitutively express 
class II MHC molecules, and in their co stimulatory activity: Dendritic cells are the 
most effective antigen presenting cells, and because they constitutively express high 
levels of class II and co stimulatory activity, they can activate naïve Th cells. 
Macrophages must be activated by phagocytosing microorganisms before then 
expressing class II MHC molecules or the co stimulatory B7 membrane molecule. B 
cells constitutively express class II MHC molecules but must be activated before they 
express the co stimulatory B7 molecule. Several other cell types, classified as non­
professional antigen cells, can be induced to express class II MHC molecules or a 
costimulatory signal.
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Antigen presenting cells 
Professional antigen presenting cells Non professional antigen cells
Dendritic cells Fibroblasts
Macrophages Glial cells
B dells Pancreatic beta cells
Thymic epithelial cells 
Thyroid epithelial cells 
Vascular endothelial cells
Therefore in the consideration of an inhibitory immune response, it is important to 
consider where the possible response is taking place, and what kind of antigen 
presenting cells are accessible i.e. whether they are professional or non professional. 
In a gene-based approach the target tissue selected for gene expression will differ in 
its cellular APC populations, and the capacity to mount an effective immune response 
may not or may be present.
7.4,2 CD4 T+ helper cell activation
Antibody responses to protein antigens are considered T cell dependent since they 
require the participation of antigen specific T helper cells (van den Eertwegh et al., 
1992; Romagnani, 1996; Romagnani, 1997). These T cells provide signals essential 
for B cell activation and subsequent differentiation towards antibody secretion. Once 
engaged with an APC, CD4+ T helper cells are activated to produce cytokines and to 
proliferate in response to recognition of specific antigen, in the form of processed 
peptides bound to class II MHC proteins on antigen presenting cells (B cells, dendritic 
cells and macrophages).
Individual murine CD4 + cells can be broadly grouped into two major classes based 
on the production of certain representative cytokines in a mutually exclusive fashion. 
Thl cells which produce IL-2 and IFN gamma and Th2 cells which produce IL-10 
and IL-4(Romagnani, 1996; Romagnani, 1997; Romagnani et al., 1997). ThO have the 
ability to produce both sets of cytokines.
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An individual T cell has the ability to acquire either a Thl or Th2 phenotype. If T cell 
activation occurs in an environment rich in IL-12 and IFN y, development of the Thl 
phenotype is favoured whereas in the presence of IL-4 the Th2 phenotype is favoured.
7.43 Role of Antibody Subtype and the immune response
As stated above, the immune response to soluble protein antigens is a T cell 
dependent antibody driven cellular humoral immune response. The nature of the 
underlying antibody subclass induced can suggest which type of T cellular subsets 
humoral response are involved in antibody generation. In man there are four antibody 
subclasses IgM, IgD, IgGl, Ig02, lg03, Ig04, IgE, IgAl and IgA2;
With rare exceptions the inhibitory antibodies in man are found to be of the IgG 
subtype and are predominantly of the IgG4 subclass. This finding suggests that that 
induction of the humoral response is T cell dependent and characteristic of a Th2 
cellular immune response, i.e. it requires the presence of IL-4, IL-10 to provide help 
for B cell differentiation, maturation and subsequent isotype switching. Additionally 
the fact that certain patients with inhibitors can be made tolerant to infused clotting 
factor concentrates also suggests that T cells play a role in the development of 
antibody production.
Mice have antibodies of the classes IgM, IgD, IgGl, IgG2b, IgG2a, IgE, IgA and IgA; 
In the mouse, T cell dependent humoral responses are dominated by IgGl, IgG2a, 
IgA, and IgE (Severinson et al., 1982; Tesch et al., 1984). By characterisation of the 
antibody subclass induced in an immune response, it is possible therefore to 
extrapolate and determine which CD4 T cell helper subsets involved in the 
pathogenesis of an inhibitory antibody response. The diagram below summarises the 
CD4 T cellular responses in mice and their correlation with antibody profiles. This 
information is useful to the later work presented in this chapter, since the information 
yielded by the antibody subtypes induced by different vector selection was used 
initially as clue to which type of immune response was occurring prior to the 
development of cellular assays (CTL) which could answer definitively whether a 
cellular response was occurring (Chapter 6, page 152-160).
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Fig 51 Humoral profiles in mice
H u m o ra l  a n t ib o d y  p ro f i les  in m ice
HP
CD4 
T h2 cell
IL-4, IL-10
B C e l lB C e l l
CTL
^  CD4 
Tni cell
lgG2 lgG l
As can be seen from the above diagram the presence of an IgGl response correlates 
with a Th2 cellular humoral response whilst an IgGl response correlates with a Thl 
driven cellular response. Therefore in a humoral (antibody response) occurring in 
mice, the antibody profile generated in this type of response would be an IgGl profile. 
Conversely, a cell-mediated response (CTL) would correlate with an IgG2 (IgG2a/ 
IgG2b) profile.
7.4.4 The requirement for Costimulation in T Cell Activation
A general property of lymphocytes including both B and T cells is the need for two 
distinct extracelluar signals, in order to induce proliferation and differentiation into 
effector cells (Bretscher, 1992; Lafferty & Gill, 1993). The first signal is provided by 
antigen binding to the antigen receptor .In the case of T cells, peptide-MHC complex 
binding to the TCR (and CD4 and CD8 co receptors) provides signal 1. The second 
signal 2 for T cell activation is provided by co stimulatory molecules, which are 
surface molecules on APCs, which bind to specific receptors on the T lymphocyte. A 
simplified diagram of this process is shown below:
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Figure 52 Costimulatory Pathways
Signal 2
Signal 1
CD28
B7.2
(CD86)
TCR
MHC: Ag 
com plex
T cell activation requires two signals. Signal 1 is the presentation o f a 
peptide fragment from the foreign protein, displayed in the context o f an 
MHC molecule, to the T cell receptor (TCR). Signal 2 is a co stimulatory 
signal from an antigen-presenting cell (APC)
The importance of co stimulatory signals is evidences by what happens to T cells in 
their absence. By this approach two important roles for costimulation have been 
established:
1) Co stimulatory signals are required, concurrent with antigen induced signals in 
order for T cells to achieve full activation responses. When T cells recognise 
foreign antigen in the absence of costimulation i.e. they receive signal 1 without 
signal 2, they do not become fully activated to perform effector functions. This 
can be shown experimentally by treating pure populations of CD4 + cells with 
TCR agonist ligands such as polyvalent anti CD3 in the absence of any accessory 
cells. Under these conditions, the T cells produce very few cytokines and do not 
proliferate. If a source of co stimulatory signals, such as monocytes is added the T 
cells will respond vigorously to the anti CD3.
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2) A lack of costimulation at the time of antigen presentation may eliminate a T cell 
from the pool of antigen responsive lymphocytes either by promoting its death or 
by inducing a state of unresponsiveness (anergy)
The expression of co stimulators is restricted to certain cell types and is highly 
regulated, Although there are various molecules which have been shown to have co 
stimulatory properties, the most potent co stimulators are expressed at high levels only 
on professional APCs such as mononuclear phagocytes, activated B cells and 
dendritic cells. Costimulator expression is often on resting APCs and is upregulated 
by stimuli such as cytokines, which accompany inflammation. These properties 
therefore profoundly regulate T cell mediated responses in the following ways:
a) The regulated expression of co stimulators ensures that T lymphocytes are 
activated at the correct time and place. An example being that a time of infection 
both microbial products and cytokines elaborated by inflammatory cells will 
upregulate costimulator expression on local APCs and thereby promote 
appropriate T cell activation to microbial antigens.
b) The coexpression of costimulators amplifies interactions between T cells and B 
cells and between T cells and macrophages. As well as serving as professional 
APC's, both B cells and macrophages are recipients of T cell help i.e. they 
respond to products of activated T cells by themselves becoming activated and 
performing their functions. Therefore co stimulator expression on these APCs 
promotes activation of both the T cells and the APC's.
c) The absence of co stimulators on unactivated or resting APCs in normal, 
uninflamed tissues contributes to the maintenance of tolerance to self-antigens.
Costimulatory signals for T cell activation are mediated by the molecular interactions 
between receptors on T dells and ligands on APCs. A key costimulatory signal results 
from the binding of CD 28 and cytotoxic T lymphocyte antigen (CTLA) -4  (CD 152) 
receptors on T cells to CD80 and CD86 molecules are often referred to using trivial 
names, B7.1 and B7.2 respectively. One of the best characterised and most important
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CO stimulatory pathway in T cell activation involves the T cell surface molecule CD28 
which binds the co stimulatory molecules B7.1 (CD80) and B7.2 (CD86) expressed 
on APCs. CD28 delivers signals that enhance T cell responses to antigen. During the 
process of an immune response either CD80 or CD86 molecules on APCs can provide 
costimulatory signals for T cell activation (Linsley, 1995a; Linsley & Goldstein, 
1996). These are surface molecules on APCs, which bind to specific receptors on the 
T lymphocytes. CD80 and CD86 are members of the immunoglobulin superfamily 
that share limited sequence homology in the extracellular domains. These molecules 
are expressed on the surface of activated B cells, dendritic cells and macrophages, but 
exhibit distinctive patterns of expression and regulation. CD86 is reported to be 
constitutively expressed in some APCs such as dendritic cells and monocytes and 
rapidly upregulated upon activation. The kinetics of upregulation of CD80 is slower 
than of CD86.
In addition, another T cell surface molecule, CTLA- 4 also binds B7.1 and B7.2 but in 
contrast to CD28 it transmits signals that inhibits T cell activation. In addition to the 
effects of cytokines, the initial activation of CD4 + Th cell and subsequent responses 
by Thl cells are markedly enhanced and in some cases dependent on concomitant 
engagement of CD28 on T cells by B7.1 or B7.2 molecules on antigen presenting 
cells. B7.2 engagement may favour the development of Th2 cells whereas later and 
more persistent B7.1 engagement may favour the development of Thl response.
On mature dendritic cells the surface expression of CD86 is 10 times greater than that 
of CD80 and contributes to about 90% of CD28/CTLA -4  binding. Activated B cells 
macrophages and mature dendritic cells have relatively high surface CD80 and CD86 
and are therefore strong activators of T cells. These cells are often referred to as 
professional antigen presenting cells. In contrast resting B cells and immature 
dendritic cells express MHC molecules but have low levels of CD80/CD86 on their 
cell surfaces. These cells present antigens poorly and probably induce T cell 
tolerance. These APCs are referred to as non-professional APCs. Costimulatory 
signals from antigen presenting cells have a central role in regulation of T cell 
tolerance in the periphery (Lenschow & Bluestone, 1993; Lenschow et al., 1994). 
Thus, it can be seen that interference with these pathways may induce tolerance, {yide 
infra, pl87).
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7.4.5 Mechanism of tolerance and inhibitor development
One of the cardinal features of the immune system is its ability to recognise and 
respond to foreign antigens but not to self-antigens. This is called self- non self­
discrimination. The unresponsiveness of the immune system to antigenic stimulation 
is called immunological tolerance. The phenomenon of self-discrimination is evident 
for a protein such as factor DC where this protein in normal individuals is non- 
immunogenic. However, in a FIX haemophiliac challenged with replacement therapy 
with factor DC, this may evoke an inhibitory antibody response. The challenge for any 
haemophilia therapy is to allow tolerance to the novel factor DC therapy, whether it is 
derived from a protein or gene based approach.
Immunological tolerance is the phenomena of antigen induced functional inactivation 
or death of specific lymphocytes resulting in the in ability of an organism to respond 
to that antigen. Lymphocyte activation and tolerance are two possible results of 
specific recognition of antigens by lymphocytes. Antigens that induce tolerance are 
called tolorogens, to be distinguished from immunogens, which generate immune 
responses. Tolerance to self-antigens is a fundamental property of the immune system, 
its failure resulting in autoimmune disease. Normally all self-antigens act as 
tolorogens. Many foreign antigens can be immunogens or tolorogens depending on 
their physiochemical characteristics, form, dose and route of administration.
The general properties of immunological tolerance are outlined as follows:
1) Tolerance is immunologically antigen specific and therefore must be due to the 
deletion or inactivation of antigen specific T and / or B-lymphocytes. Both 
lymphocyte activation and tolerance are induced by interaction of antigens with 
the same types of clonally distributed receptors on antigen specific cells i.e. 
membrane immunoglobulin on B cells, or the T cell receptor on MHC restricted T 
cells
2) Immature developing lymphocytes are more susceptible to tolerance induction 
than are mature or fully competent cells. During their normal maturation in the 
generative lymphoid organs, all lymphocytes go through a stage at which antigen
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recognition lead to their death or inactivation. At this stage potentially self 
reactive lymphocyte clones encounter self- antigens and become tolerant to these 
antigens. This type of tolerance, which is induced by immature lymphocytes 
within the generative lymphoid organs, has been called central tolerance. Central 
tolerance is important for maintaining unresponsiveness to self-antigens that are 
present at high concentrations in the generative lymphoid organs, but it does not 
play a role in tolerance to foreign antigens administered in the periphery.
3) Tolerance to foreign antigens is induced even in mature lymphocytes when these 
cells are exposed to antigens under particular conditions. Tolerance induced in 
mature lymphocytes that encounter antigens in peripheral tissues is called 
peripheral tolerance.
Tolerance and inhibitor formation
From the standpoint of the immune response, inhibitor formation in haemophilia can 
be viewed as an appropriate response to a foreign protein, particularly in the case of 
patients with mutations that result in the loss of coding information. Tolerance to a 
protein is a complex phenomenon that is closely linked to antigen presentation 
(Matzinger, 1994; Matzinger, 1998) (Rammensee, 1996). For T cells, antigen 
presentation is dependent on the major histocompatibility proteins, which bind and 
display peptide fragments. Class I proteins, found on nearly all cells, bind peptides 
derived from proteins synthesised in the cell that displays them, while class II proteins 
display peptides from proteins taken up from the environment. Class H expression is 
normally confined to monocytes, dendritic cells, and B cells. Peptide bound to class I 
protein is recognised primarily by CD8+ T cells, while peptide bound to class II 
protein is recognised by CD4+ cells.
Tolerance, or unresponsiveness, can be due to one of several mechanisms. During 
foetal development, presentation of self-antigens in the primary lymphoid organs (the 
thymus for T cells, bone marrow for B cells) results in cell death {clonal deletion) or 
inactivation {clonal anergy) of those clones 'with high affinity for self. Other 
lymphocytes with lower affinity for self-antigens may persist, because the interaction 
falls below a threshold needed to trigger either deletion or anergy. This phenomenon, 
where cells have the potential for recognition of self, but fail to respond, has been
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termed clonal “ignorance” (Nossal, 1993) under certain circumstances, e. g. a marked 
increase in antigen concentration, these lymphocytes may no longer “ignore” the 
stimulus. Finally tolerance may result from suppression, or immunoregulation, in 
which T cells actively suppress the immune response to antigen by a mechanism that 
is not well understood. Sustained production of antibodies on exposure to antigen 
requires promotion of B cell activation by helper T cells.
Recognition of an immunodominant epitope by T helper cells would result in T helper 
cell activation. For mutations that allow expression of even low levels of an 
immunodominant epitope, deletion of responsive T cell subsets can occur during 
foetal development. However, for mutations associated with complete absence of 
expression of these epitopes, one would predict a higher likelihood of inhibitor 
formation.
With respect to haemophilia, normally self-reactive T cells (i.e. such as those against 
clotting factors) are deleted or anergised during T cell development. However, 
individuals with haemophilia however because of their inherent genetic defects may 
not express the sequences i.e. the epitopes that are recognised by T cells specific to 
the wild type protein. Thus, these T cells mature in haemophiliac patients and on 
subsequent encounter with the antigen i.e. with replacement therapy promote 
induction of a neutralising antibody response.
Breaking of Tolerance
In order to avert inhibitor formation, it is necessary to induce tolerance to newly 
introduced clotting factor proteins whether derived from protein replacement therapy 
derived fi*om a gene-based approach. There are numerous experimental systems for 
inducing tolerance to protein antigens. These include the administration of large doses 
of antigens without adjuvants, oral antigen administration, repeated exposure to the 
antigen and administration of mutated forms of the antigen. In all these situations 
tolorogens induce unresponsiveness by inhibiting the proliferation and differentiation 
of CD4 + T cells or by stimulating regulatory cells.
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From the point of view of haemophilia, tolerance to infused protein antigens will 
require that T cells do not become activated and go onto developing an immune 
response. There are several points at which the failure of activation could take place. 
Simply blocking the signal one or signal two i.e. blocking the co stimulatory signal. 
These costimulatory signals are required for T cell activation. The diagram below 
illustrates the pathways of T-B cell interaction and the possible modes of interference 
in these pathways, which may lead to failure or of either T or B cell activation, and 
subsequent tolerance induction.
Figure 53 Costimulatory pathway blocking
CD86 CD28
celAFC
CD80 CTLA-4 CD40L CD40
It can be seen therefore, that in order to induce tolerance to clotting factor proteins, 
interference with co stimulatory pathways and the blocking of signal 2 (shown by 
dashed green lines in the figure above) may result in T cell anergy and the failure of B 
cell activation and subsequent antibody production.
As well interfering with T cell activation from CD80/CD86 pathways, as can be seen 
from the above diagram interference with CD40L pathway may lead to failure of B 
cell activation (Armitage et al., 1992; Noelle et al., 1992a; Durie et al., 1994a; Durie 
et al., 1994b). Cognate interaction of B cells with CD4 Th helper cells requires that 
the T cells express a protein ligand, CD40 ligand that engages CD40 on the surface of 
the B cell. Ligation of CD40 and interaction of antigen with surface immunoglobilin 
are sufficient to induce robust B cell proliferation to enhance the amount and affinity 
of antibody produced and to allow for B cell to switch production of antibodies from 
IgM to IgG, IgA or IgE production. Therefore, these bi-directional signals between T
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and B cells (and other antigen presenting cells) are central to the efficient 
development of de novo cellular and humoral immunity to protein antigens.
7.5 Characterisation of Inhibitory Responses in A Gene Based Approach
In order to study the occurrence of inhibitor formation in a gene based approach, a 
series of experiments were carried out to characterise firstly the occurrence of 
inhibitor formation in both normal and haemophilia B mice models. The central 
hypothesis tested was to determine the incidence of antibody formation in a gene- 
based approach, and factors that affected it. In particular, the protein based approach 
has demonstrated that underlying mutation status correlates with likely inhibitor 
outcome with those mutations carrying a greater loss of coding material resulting in a 
more likely occurrence of inhibitor development.
7.5.7 Haemophilia B mice studies
From the normal mice studies, follow up studies were performed in Haemophilia B 
mice bred on a C57BL6 background. Haemophilia B mice were generated by gene 
targeting techniques in the laboratory of Dr Darrel Stafford (Lin et aL, 1997). These 
animals carry a large gene deletion effecting exons 1-3 of the factor DC gene which 
results in no FIX mRNA transcripts being made with the result that these animals 
produce no circulating factor DC antigen. They display a severe Haemophilia B 
phenotype, which mirrors the human condition. One would predict therefore that 
expression of circulating factor DC antigen via a gene-based approach in these animals 
would elicit antibody formation.
The experimental design of these experiments was to inject Haemophilia B mice with 
an AAV construct encoding murine factor DC and follow the animals out post 
injection to observe and characterise the occurrence of inhibitor formation in 
Haemophilia B mice carrying a large gene deletion for murine factor DC
Method
9 male Haemophilia B mice aged 8 weeks were injected intramuscularly at day 0 with 
an AAV vector encoding murine factor DC at a dose of 4x10^^ vg/kg. The animals
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were first anaesthetised with inhalational mefofane before injection. The genotype 
was determined by two sets of PCR reactions (one specific for the FIX wild-type 
allele, one specific for the knock out allele) on genomic DNA isolated from blood 
samples. Amplification primers and PCR conditions were as reported previously 
(Mombaerts et aL, 1992)
Vectors
A plasmid encoding AAV vector AAV-CMV-mFIX contains the murine FIX cDNA 
(2.7-Kb BamRl fi-agment) under transcriptional control of the cytomegalovirus IE 
enhancer/promoter, and includes a chimeric CMV/p-globin mini-intron (5’ to the mF 
IX cDNA), and the human growth hormone polyadenylation signal. The expression 
cassette is flanked by AAV serotype-2 inverted terminal repeats (ITRs). AAV-CMV- 
mFIX was produced by triple transfection of HEK-293 cells in a helper virus-fi'ee 
system (Matsuhita 1998, 1999), and purified by repeated CsCl gradient centrifugation 
(described in Chapter 4, Page 95-107). Vector titres were quantitated by slot blot 
hybridisation. Purified vector was stored at -80°C in PBS containing an osmotic 
stabiliser, and further diluted with sterile PBS prior to injection of mice.
Antibody determinations
The presence of antibody was detected by western blot and subclass specific Elisa. 
The Elisa was performed to gain a more detailed analysis of the antibody responses 
and a subclass specific Elisa was set up to delineate which murine immunoglobulin 
subclasses IgGl, IgG2a, IgG2b, and IgG3 were induced (Chapter 3, page 67-68)
APTT and Bethesda titre determination
The method described for APTT estimation is as described in chapter 3, page 64. For 
inhibitor titre estimation. Test plasma was serially diluted in imidazole buffer. 50 pi 
of test plasma (or diluted plasma) was incubated with normal mouse plasma for 2 
hours at 37°C. Following the incubation 50pl of the mixture was added to 50pl FIX
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deficient plasma and incubated with 50pl APTT reagent. The APTT was recorded and 
the residual FIX was calculated by using a standard curve, which was generated from 
normal mouse plasma. The Bethesda titre was then calculated and adjusted according 
to the dilution of the test plasma.
Results
Haemophilia B mouse A A VmFIX injections
a) Western blot analyses shows the temporal pattern of antibody production following 
the injection of an AAV vector encoding murine factor FIX. Figure 53 shows the 
serum samples measured at 2, 4, 8 weeks post injection. The blots show no antibody 
detectable in the pre, 2 weeks samples. However by 4 weeks signal was detectable 2 
out of the 4 mice and 8 weeks signal was clearly detectable in all 4 mice. (For method, 
see Chapter 3, page 76).
Fig 54 Western Blot, Temporal pattern antibody formation
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b) In order to characterise the further the nature of the antibodies induced, the 
subclass specificity of these antibodies was determined by setting a subclass specific 
elisa as described in materials and methods (Chapter 3, page 67). The figure below 
shows the titres induced of IgG 1, Ig02a, or Ig02b post injection
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Figure 55 Subclass Antibody induction following A A VmFIX injection
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The figure above shows the antibody subclasses after injection with an AAV vector 
encoding murine factor IX. The antibodies produced were almost exclusively of an 
IgGl class in the injected animals, suggesting a Th2 driven humoral response was 
occurring.
Further CD4 Th cell subtype characterisation in antibody response
As discussed above in the introduction (p i80) the presence of an IgGl response in 
mice is associated with a CD4+T helper subset, which secretes the cytokines IL-4, IL- 
10 that activate B cells to produce IgGl.
A further experiment was designed to inject Knockout mice, deficient in CD4^ cells or 
lL-4 and follow whether these animals made antibodies. Since the production of 
antibodies is a T cell dependent process, knockout mice deficient for CD4 would not 
be expected too produce antibodies. Similarly the production of antibodies in mice 
deficient in IL-4 may be expected to produce less or no antibodies (see figure 
51,pi 80)
191
Aim
The aim of the experiments were to define if antibodies could be made in these strains 
(IL-4 KO, CD4 KO). If no antibodies were produced this would support the 
importance of CD4+, IL-4 participation in antibody production.
Methods
Both strains of mice bred (n=4) on a C57BL6 background were obtained from 
Jackson Laboratory (USA). These animals received IM injections at day 0 with the 
AAV vector as described above.
Results
a) CD4 + Deficient mice
Following administration of AAV vector, none of the CD4+ deficient mice (n=4) 
made any anti human FIX ab when assayed at 4 and 8 weeks post injection (data not 
shown). The result was identical for IgGl, IgG2a, IgG2b and IgG3 subclass 
confirming the T cell dependent nature of the anti hFIX after vector injection.
b) IL-4 deficient mice
IL-4 deficient mice failed to develop IgGl anti hFIX following injection (n=4, 
assayed at 4 and 8 weeks post injection). They did show IgG2a/b responses (data not 
shown). Since Th2 proliferation is IL-4 dependent, these mice cannot develop Th2 
help. These results demonstrate that that a part of anti hFIX production after AAV 
vector administration is due to activation of Thl helper cells, although Thl responses 
are low compared with adeno virus injected mice as demonstrated by cytokine release 
(Table 7,pl59)
Assessment o f FIX inhibitory activity o f antibodies
After the AAV injections, mouse serum was drawn at 2 weekly intervals for 
estimation of clotting times by APTT assay, as described in Chapter 3, page 64. 
Normal values were 60-80 seconds for a haemophilic mouse, and 26-36 seconds for a
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normal mouse. In order to determine whether these antibodies were inhibitory or not, 
a Bethesda assay was carried out to quantitate the antibody titre (Chapter 3, page 64)
a) APTT values.
The graph below shows the values for APTT values after injection. 
Fig 56 APTT values o f  Haemophilia B injected animals
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The figure shows that none of the injected mice corrected their APTT value after 
vector injection. The area between the two blue lines represents the normal APTT 
values for a mouse.
b) Bethesda Titre
Due to the failure of correction in APTT, the presence of inhibitory antibodies was 
tested by Bethesda assay. The results are shown in the graph below:
Figure 57 Bethesda titres o f  Haemophilia B mice post injection
18 
16 
S  14
I:
■S 8
I  6
I 4
2
Bethesda control values (n=9)
/
1 2
M on th s
193
As can be seen the Bethesda titre became maximal at about 2 months post injection. 
None of the injected mice showed correction in their APTT (range 60-80s) indicating 
factor IX inhibitory antibody activity. Although there was individual variation in the 
titre and temporal appearance of the antibodies by 1 month all animals had developed 
a positive Bethesda titre. The Bethesda titres ranged between 4-16 BU at 1 month and 
declined slightly over time but remained sustained at 6 moths post injection.
Summary
The data presented above show that none of the injected animals corrected their 
APTTs. All of the injected animals developed antibodies to murine factor IX as 
shown by both subclass specific Elisa and western blot. The antibodies were of 
predominantly of IgGl subclass and inhibitory in nature as shown by Bethesda titre. 
These experiments demonstrated that these gene-deleted animals make antibodies to 
FIX as would be predicted by a protein-based approach. In this regard it appears that 
the result by the gene-based approach is no different from the protein-based approach.
7,5.2 Cellular Immune responses
All the above experiments described were designed to look for the occurrence of a 
humoral immune response. However it is possible (Chapter 1, pages 57-59) to elicit a 
cellular immune response using a gene based approach due to the intracellular 
production of proteins entering an MHC class I pathway.
Although a CTL assay for human factor IX was eventually devised (as described in 
Chapter 6), because of the unavailability of reagents at the outset of these studies it 
was not possible to study whether there was a CTL response in a murine model of 
haemophilia B. Therefore an experiment was designed to see whether there was 
evidence of expression of murine FIX in the injected muscle. This would at least 
provide indirect evidence of whether a CTL response was occurring in the transduced 
muscle. If a CTL response was occurring then should not be possible to detect FIX 
mRNA sequences since this would be destroyed by a CTL response. However, if no 
CTL response was present FDCmRNA should be detectable.
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Experimental Design
The experiment was designed by injecting murine muscle as described above and 
looking for expression of factor IX expression by an RT PCR assay to look for the 
presence of factor IX mRNA. The aim of these experiments was to demonstrate 
whether evidence of Factor IX expression in muscle could be detected at 2 months 
post injection.
Method
2 haemophilia B animals were injected at day 0 with AAVmFIX at a dose of 4x10*^ 
particles per animal. At 2 months post injection, the mice were sacrificed and the 
injected muscle was excised. Total RNA was isolated from muscle using Trizol 
reagent (Gibco/ BRL). RNA (Ipg) was reverse transcribed using a kit from Gibco/ 
BRL. PCR primers specific for the mFIXcDNA (forward primer 5’- 
G ATTGTA ACTGCTGCCC ACTGTCT-3 ' and reverse primer 5’-
AATCTTTGCCTCCTTCCGGTAGC-3’) were used to amplify 434-bp of the mFIX 
transcript using 1/5 of the cDNA product as the template (annealing temperature of 
54°C, 35 amplification cycles). No amplification product was obtained from 
un injected muscle or from RNA that was not reverse transcribed.
Vector
The vector used for these experiments is described in the previous section (page 181) 
Results
Once the extracted mRNA was reversed transcribed, the DNA was run out on agarose 
gel as shown below:
Fig 58 FIX DNA expression in injected muscle
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The figure shows a strong positive signal for the factor DC cDNA (size 1.4 Kb) 
illustrating that expression was still present in muscle at 2 months post injection. This 
study provided indirect evidence that there could not have been a CTL response 
directed against the injected muscle, since if there was, no expression of murine factor 
DC would have been demonstrated by RT-PCR.
Summary
The experiments performed shows that AAVmFDC intramuscular injection in 
haemophiliac animals does not appear to manifest a CTL immune response. This is an 
important result, since this property supports the use of these vectors in gene transfer 
protocols .The results also support the data described in chapter 6, where it was shown 
that AAVhFDC based transduction in muscle dose not elicit a CTL response.
7.6 Haemophilia B Treated with Immunomoduiation
The results observed in the previous section show that all the injected animals 
produced an inhibitory antibody response by 2 months post vector injection. This 
situation presented here is different from the conventional protein-based approach for 
several reasons. Firstly, in the protein-based approach in Haemophilia B, there is a 
mixture of mutations leading to inhibitor formation, which includes both large gene 
deletions and point mutations. Most of the mutations result in point mutations i.e. mis- 
sense resulting in a circulating protein which although present in normal amounts is 
qualitatively abnormal. However in the animals treated in this gene based approach, 
the animals carry a large gene deletion in the first three coding exons affecting the 
promoter of the factor IX gene where no circulating factor IX antigen is produced. 
This represents the worst case scenario for provoking the development of inhibitors 
since there are no circulating epitopes, which may tolerise the animal to any future 
neo antigenic challenge.
An experimental strategy was designed to try and avert formation of inhibitors in a 
gene-based approach. The approach taken was to inject the gene-deleted animals with 
the vector and give them at or around the time of injection an injection schedule with
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an immunomodulatory agent designed to suppress any antibody formation should it 
occur.
Use of Immunomoduiation in a gene based approach
Although there have not been many studies addressing the blocking of an inhibitory 
response to the transgene product several studies have looked at immunomodulatory 
strategies in the context of viral vector readministration. Kay et al (1995) successfully 
used the agents CTLA-4 Ig and CD40L Ab combined to block both cellular and 
humoral responses to Adenoviral vectors to allow vector readministration.
In order to block the immune response to the transgene product factor IX, it is 
necessary to disable the effector arm of the response. Since the development of 
inhibitor formation is a T cell dependent response, it will be necessary to eliminate or 
render the T cell component functionless. Immunologically, this means either clonally 
deleting the antigen specific T cell clones, or anergising them. This may be achieved 
by a host of different agents, which interfere or block the co stimulatory pathways 
involved in cognate T and B cell activation pathways.
The proposed agents for use in these studies is as follows
Cyclophosphamide 
FK506 
CTLA4-Ig 
Cyclosporin A 
CD40 L Ab
The mechanisms of action of the various immunomodulatory agents tried in the 
following experiments are shown below and it can be seen that each agent has 
different mode of action.
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Fig 59 Immunomodulatory agents in T- B cognate cell interactions
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The overall aim of these strategies was to effectively disable the immune system at 
the time of antigen presentation. This would allow tolerance to occur to the neo 
antigens being introduced -  in this case human factor IX. Several of these agents have 
been tried in other gene based protocols are described in detail below:
Cyclophosphamide
Cyclophosphamide belongs to the nitrogen mustard subclass of akylating agents. It 
has a wide application in the treatment of neplastic and autoimmune disorders. The 
drug is also used to suppress antibody formation in the setting of acquired FVIII 
inhibitors, or those arising in the setting of haemophilia (as part of the Malmo 
tolerance induction regimen). It works by inserting into the DNA helix and becoming 
cross-linked leading to disruption of the DNA chain. It is especially effective against 
rapidly dividing cells and is therefore sometimes given at the time of grafting to block 
T cell proliferation. Cyclophosphamide in these studies will inhibit the both B and T 
cell pathways in antigen presentation of factor IX.
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Use in gene therapy
Liver and Lung
In a gene-based approach cyclophosphamide has been used to prolong transgene 
expression following administration with an Adenoviral vector in both mouse liver 
and lung. (Jooss et aL, 1996), it appeared to do this by blocking activation and 
mobilisation of CD4+ and CD8+ cells. As a result transgene expression was 
prolonged with reduction of inflammation and using higher doses of 
cyclophosphamide formation of neutralising antibodies was prevented allowing 
further readministration of the vector. Slightly different results were obtained in the 
lung where it was found that only at the highest dose was it possible to prolong 
transgene expression whereas at all doses low to high it was possible to prevent the 
formation of neutralising antibodies. These experiments pointed out the importance of 
target tissue variability in the outcome of prolonged gene expression.
Muscle
Other investigators have looked at the use of cylophosphamide in blocking the 
response to human factor DC secretion from an adenoviral vector. The experiments 
were carried via a muscle directed approach in Adult Swiss Webster mice. The 
investigators attempted to tolerise the host to adenoviral and FIX protein, using 
Cyclosporin A (CyA) and cyclophosphamide (CyP) (Dai et aL, 1995) in the hope that 
CyA would block cell mediated immunity, while cyclophosphamide would act by 
killing rapidly dividing cells involved in immune activation.
Using this approach it was found that CyA alone had no effect while CyP alone and in 
conjunction with CyA prolonged expression. The regimen of cylophosphamide 
administered was 50mg/kg every 2 weeks for 8 weeks. In the animals treated with 
cyclophosphamide, all animals showed elevation in plasma factor IX levels and one 
animal was completely tolerised. Although only one animal was completely tolerised 
to it did point out that this strategy was possible to achieve tolerance, but more 
numbers will be required to reproduce these results.
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FK506
Lochmuller et al (Lochmulier et al., 1996), demonstrated that following Adenoviral 
(Ad) vector encoding a dystrophin transgene, use of the immunosupressive agent 
FK506 over 5,10,30 and 60 days after Ad mediated gene transfer resulted in 
maintenance of the initial transgene expression for at least 2 months even when 
FK506 was discontinued after 1 month. This was in keeping with a marked reduction 
in the inflammatory infiltrates observed at the injection sites in muscle. Additionally it 
was found that FK506 efficiently suppressed the humoral immune response against 
both the vector proteins and the transgene product dystrophin. They concluded that 
the initial sensitisation of the immune system by the antigenic load triggered a 
humoral and cellular immune response which could be significantly subverted by 
relatively short term immune suppressive treatment.
Cylosporin A
Cylosporin A (CyA), FK506 are ftmgal metabolites with potent immunosuppressive 
properties. Although chemically unrelated both drugs have similar mechanisms of 
action. They block the activation of resting T cells by inhibiting the transcription of 
genes encoding IL-2 and the high affinity IL-2 receptor, which are essential for T cell 
activation. The drugs exert their actions by binding to cytoplasmic proteins called 
immunophilins forming a complex that block phosphatase activity of calcineurin. This 
prevents the formation and nuclear translocation of the cytoplasmic subunit NF-ATc 
and its subsequent assembly into HF-AT a DNA binding protein necessary for 
transcription of the genes encoding IL-2 and IL-2R. The drugs therefore inhibit Th 
cell proliferation, Th cytokine expression, and reduce subsequent activation of various 
effector populations involved in graft rejection.
CD40-CD40L interactions
The activated CD4+ T cell expresses a protein on its surface CD40 ligand that 
engages CD40 on the surface of the B cell. Ligation of CD40 and the interaction of 
antigen with surface immunoglobulin are sufficient to induce robust B proliferation 
and to enhance the amount and affinity of antibody produced and to allow the B cell
2 0 0
to switch from IgM to IgA, IgG, or IgE production. (Clark & Ledbetter, 1994; Foy et 
aL, 1994a; Foy et aL, 1994b). The importance of the pivotal role of CD40-CD40L in 
B cell activation and isotype switching comes from the studies of X linked hyper 
immune syndrome, which is characterised by elevated IgM levels and the absence of 
other isotypes. The defect results from mutations in the CD40L gene.
The importance of the CD40-CD40L interaction has led to the development of a 
hamster monoclonal antibody (MRl) directed against murine CD40 L, which in vitro 
blocks T and B cell proliferation (Noelle & Snow, 1992; Noelle et aL, 1992a; Noelle 
et aL, 1992b). When used in vivo it is also able to inhibit primary and secondary 
antibody responses to TD (Thymus dependent) antigens SRBC and TNP -KLH. (Foy 
et aL, 1994b). The basis of these actions of this antibody forms the rationale for its use 
in blocking antibody formation in the experiments described later in this chapter.
7,6,2 Experimental protocol to study immunomodulatory approach in a gene based 
situation
Aim
The aim of these experiments was to try and block inhibitor formation in a gene based 
approach. The experimental design taken was to follow the protocol as described 
above and inject haemophilia B mice with an AAV encoding murine factor IX, but in 
addition to combine this the use of an immunomodulatory agent given at or around 
the time of vector injection.
Method
8-week-old haemophilia B mice were injected at day 0 with AAVmFIX at a dose of 4 
xlO^^ vector genomes per Kg. Around the time of injection, immunomoduiation 
therapy was administered to the mice according to the schedules outlined in the 
following table. The injected mice were then bled at 2 weekly, and then at monthly 
intervals to monitor for the development of inhibitors by plasma based assays (Elisa, 
Western Blot) and functional based clotting assays (APTT, Bethesda assay). The 
scheduling and dosing of the various immunomodulatory agents used in the following 
experiments is shown in below:
2 0 1
• CD40 L Antibody
0.1 mg I/P at d -3 , dO, d+3, d+6, d+9
• Cyclosporin A
100 mg/kg I/P 3 times weekly
• Cyclophosphamide
50mg/kg I/P at dO, week 2, week 4, week 6
• FK506
I25pg S/C Alternate days from d 0
• CTLA- 4 Ig
O.Img I/P at d-3, dO, d+3, d+6, d+9
7.6.3 Results
a) Cyclophosphamide Ab treated groups
The drug was given at a dose of 20 or 50 mg/kg on a biweekly schedule starting from 
the day of vector administration (IxIO'* vg/mouse) up to 6 weeks after gene transfer. 
As shown in the figure below, the combination of vector administration and repeat- 
injections of cyclophosphamide gave a partial to complete correction of the APTT in 
4/6 mice. Two mice, which had received cyclophosphamide at only 20 mg/kg, formed 
inhibitory antibodies with a Bethesda titre of 3-7 BU, while the other animals treated 
did not form inhibitors. Expression of mFIX in those mice (n=2) that showed 
complete correction of the APTT which was sustained for the duration of the 
experiment (>6 months) indicating that transient immune suppression was sufficient 
to obtain long-term expression without induction of an immune response
Figure 60 Cyclophosphamide treated mice
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As can be seen from the above figure the administration of cyclophosphamide 
suppresses antibody formation in two of the injected animals, and did show some 
partial correction in the other injected animals.
b) CD40L Ab treated
Administration of anti-CD40L starting three days before injection of vector up to day 
9 after gene transfer resulted in partial correction of the aPTT in 3/5 mice during the 
first two months of the experiment. By the third month, aPTT values had returned to 
pre-treatment values, and inhibitory antibodies were measured in 4/5 mice by 
Bethesda assay (<10 Bethesda units). These data indicate a marginal impact of anti- 
CD40L administration on the anti-mFIX immune response.
Figure 61 anti CD40L Ab treated mice
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c) FK506 treated
Treatment with FK506 invariably resulted in partial correction of the aPTT (5/5 mice) 
at one month after IM injection of AAV vector. However, systemic mFIX expression 
was subsequently lost, and low titer inhibitory antibodies <3 BU were measured at 3-4 
months. FK506 was effective in blocking the antibody formation against mFIX as 
long as the drug was administered (up to day 30 on every alternate day). This effect
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did not persist once administration of the drug was discontinued, thus resulting in a 
delayed and weakened immune response, which was, however, sufficient to prevent 
efficacy of treatment by gene transfer. Additionally, several animals developed 
infections as a result of the prolonged immune suppression.
Figure 62 FK506 treated mice
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c) Cyclosporin A
9 mice were injected with concomitant cylosporin A. These animals showed 
substantial renal toxicity and often died within the first month of treatment. Those 
animals (n=3) that survived showed no signs of correction of their coagulation times 
despite reduced or undetectable inihibitor titres (data not shown).
e) CTLA-4 Ig treated
Mice were treated with CTLA4-Ig on an identical schedule and showed partial 
correction of their APTT (3/4 mice) during the first two months, but APTT levels 
returned to baseline by the third month in 3/4 mice. Two mice developed a low titer 
inhibitory anti-mFIX (3-5 Bethesda units at a 5 month time point), while one animal 
continued to express mFIX for at least 5 months with no detectable Bethesda titer 
(data not shown). These data show that transient immune suppression combined with
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gene transfer can result in sustained mFIX expression and partial correction of the 
haemophilic phenotype.
Figure 63 anti CTLA-lg treated mice
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7.7 Discussion
Data from the haemophilia B database suggest that increased loss of coding 
information, as occurs with an early stop codon or a deletion in the FIX gene, may 
increase the risk of inhibitor formation in protein-based replacement therapy.
It may be predicted therefore, that in the setting of gene transfer, similar results may 
be obtained. Use of a human transgene in a gene-based setting prevents a 
straightforward interpretation of data because of the occurrence of a humoral response 
to the non-species specific transgene product. A relative advantage of haemophilia B 
as a paradigm disease for the treatment of this genetic disorder by gene therapy is the 
availability of small and large animal models of the disease. The cloning of murine 
factor IX and its incorporation into a construct encoding this transgene facilitates a 
more accurate analysis of immune responses in the homologous murine haemophilia 
B animal model. The mice selected for these studies carry a large gene deletion 
without detectable mFIX transcript or antigen, and they represent perhaps the most 
stringent test in terms of lack of tolerance to the protein product of the donated gene.
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The experiments described in this chapter were designed to characterise the formation 
of inhibitory antibodies in a gene-based approach for haemophilia B using an AAV 
vector. All of the injected mice formed inhibitory antibodies by 2 months. The results 
echo the situation for a protein-based approach where possession of a large gene 
deletion correlates with an increased likelihood of inhibitor development.
The antibodies produced in these experiments were of an IgGl subclass in keeping 
with a Th2 driven T helper cell response and were inhibitory in nature as evidenced 
by the raised Bethesda inhibitor titres. In order to carry out these studies further to 
define risk, it will be necessary to test out these injections in animals carrying 
different mutations i.e. point mutation s to see if this results in a lower incidence of 
inhibitor formation. Some of these questions will be addressed in chapter 8.
Although the injections in these gene deleted mice generated the production of 
inhibitory antibodies no evidence of cellular destruction (CTL response) of the 
injected muscle was demonstrated as evidenced by the long-term persistence of factor 
DC mRNA.
These studies demonstrated that inhibitory antibodies are made to the transgene 
product human factor DC and in keeping with the protein based situation. Therefore it 
is important to look at strategies, which can overcome this response.
It is known from replacement therapies, that immune tolerance regimens have been 
used to treat already established inhibitor responses. In these treatments, clotting 
factors are given on a prolonged daily basis in high dosage (+/- immune suppression) 
to achieve tolerance although the out come in these cases is not always predictable. It 
may be argued therefore, that a process where clotting factors are continually 
produced such as a gene-based appraoch, may itself be tolerogenic and used a therapy 
for the treatment of inhibitor development (Evans & Morgan, 1998).
A number of immunomodulatory strategies were devised to test whether 
immunomoduiation given at or around the time of vector administration could avert 
inhibitor development. It should be emphasised that is a different challenge to the 
protein-based approach, where clinicians usually try to avert inhibitor formation once
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it has occurred. In the approach described in these experiments the aim was to try and 
block inhibitor formation before it occurred.
Transient immune suppression has been evaluated in a number of studies as a tool to 
prevent formation of neutralising antibodies against viral vector particles or to reduce 
cellular immune responses and inflammation typically seen with early generation 
adenoviral vectors. However, little is known about the effect of such immune 
modulation on a humoral immune response against a secreted transgene product such 
as FIX. Activation of T helper cells and B cells following antigen presentation by 
APCs is not only dependent on presentation of peptides (T cell epitopes) by MHC 
class n  molecules and binding to T cell receptors, but also requires the presence of co­
stimulatory signals to achieve full activation. These co stimulatoiy signals include the 
interaction of CD40 and CD40 ligand (CD40L), an important signalling pathway 
required for B and T cell activation (Kay et aL, 1997; Wilson et aL, 1998), and the 
B7-CD28 co-stimulatory pathway. The former pathway can be specifically blocked by 
anti-CD40L antibody, the second by soluble CTLA4-Ig fusion protein or anti-B7.1/2 
antibodies (Linsley, 1995a; Linsley, 1995b; Linsley et aL, 1995; Linsley & Golstein, 
1996).
Both strategies have been investigated as a tool for prevention of humoral and cellular 
immune responses against viral gene transfer vectors (Kay et aL, 1997). It is known 
that efficient antigen presentation in the absence of the necessary co-stimulatory 
signals will result in antigen-specific T cell anergy, i.e. subsequent inability of these T 
cell clones to initiate an immune response against the antigen that they recognise.
In the experiments presented in this chapter the aim was try and prevent the formation 
of inhibitory antibodies by interfering with activation of effector CD4 cells and 
subsequent proliferation of antibody producing B cells. Several agents were tested 
including both antibodies (anti CD40, CTLA-4 Ig) and drugs (Cyclophosphamide, 
FK506, Cyclosporin). These agents have been previously been studied in the context 
of gene therapy as shown in the following table:
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Table 9 Immunomodulatory agents
Agent Target Tissue Reference
Cyclophosphamide Lung Jooss et al
Cyclophosphamide Liver, Lung (Jooss et aL, 1996)
Cyclophosphamide Muscle (Dai et aL, 1995)
FK506 Muscle
(Lochmuller et aL, 1995; 
Lochmuller et aL, 1996)
CTLA-4 Liver, Lung
(Kay et aL, 1995),(Jooss et 
aL, 1998b)
CD40L Ab Liver and Lung (Yang gr a/., 1996c)
CD40L Ab/ CTLA-4 Liver (Kay et aL, 1997)
Cyclosporin A Muscle (Dai et aL, 1995)
The formation of inhibitory anti-mFIX was somewhat weakened and delayed in mice 
treated with anti-CD40L, yet overall the effect was marginal, and mice still developed 
inhibitors. Better results were obtained with CTLA4-Ig. Only 2/4 mice developed 
(low titre) inhibitors, and 1/4 animals showed sustained correction of the APTT 
coagulation time. CTLA4-Ig has been successfully used to prevent rejection of 
transplants in experimental models (Linsley, 1995a; Linsley et aL, 1995; Linsley et 
aL, 1996; Linsley & Golstein, 1996) and has also been tested for prevention of 
inhibitors against human FVlll protein infused intravenously into haemophilia A 
mice. In this study, antibody formation could only be prevented if CTLA4-lg was 
given at the same time as the FVHl antigen.
In the work described here, reduced inhibitor titres were seen in all mice treated with 
CTLA4-lg that resulted in transient partial correction of the haemophilia B phenotype 
as a result of prolonged transgene expression. Moreover, one animal showed sustained 
correction (for several months after vector injection) without inhibitor formation. This 
result suggested that it was possible to achieve long-term expression by transient 
blockage of a co-stimulatory pathway.
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Optimisation of the dosing and schedule with administration of CTLA4-Ig may result 
in a greater success rate with this approach. A disappointing result was obtained with 
the combined use of CD40 ligand antibody and CTLA- 4Ig and it is unclear why this 
was so. Previous experience with these two agents in a gene-based approach has 
yielded considerable success in vector readministration experiments (Kay et aL, 
1995), (Halbert et aL, 1998), (Kay et aL, 1997). It may be that simple adjustments to 
the amount and timing of dosing of this approach may yield better results. This type 
of dosing experiments will need to be done in the future to test this hypothesis
In addition to blocking costimulatory pathways, tolerance may be induced by the use 
of specific drugs with immunemodulatory properties. Dai (Dai et aL, 1995) and 
colleagues have previously shown that tolerisation could be affected by the use of the 
immune suppressive drug cyclophosphamide in the context adenoviral gene transfer 
encoding the canine transgene for factor DC in a murine model. There is a wide range 
of immunomodulatory drugs available for use in the clinical setting, and several of 
these drugs were tried out to avert inhibitor formation in a gene based approach. 
These agents work either by blocking differentiation and/or proliferation of B and T 
lymphocytes (Cyclosporin and FK506) or by clonal deletion of antigen specific T 
cells.
The agent FK506 (Tacrolimus) blocks intracellular signalling pathways, and prevents 
T cell activation. The drug has been shown to reduce cellular and humoral immune 
responses and is successfully used to prevent rejection of organ transplants in the 
clinical setting (prevention of allograft rejection, graft versus host disease and others). 
Equally FK506 has been used successfully in gene transfer experiments to block 
cellular and humoral responses to Adenoviral gene transfer encoding the mini 
dystrophin gene in the mdx mouse model of Duchenne muscular dystrophy 
(Lochmuller et aL, 1995; Lochmuller et aL, 1996). When tested in these experiments, 
consistent administration of FK506 resulted in marked reduction of APTTs without 
measurable anti-mFIX responses in all of the treated mice. However, correction of the 
haemophilic phenotype was lost after discontinuation of the drug, and low-titre 
inhibitors emerged at later time points indicating that induction of tolerance to mFIX 
with this treatment was unsuccessful. When the drug was given continuously
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correction of the haemophilic phenotype was achievable. Therefore, if  long-term 
administration were attainable in a non-toxic fashion, this regimen holds considerable 
promise.
Cyclosporin a widely used immune suppressant in the field of clinical renal and bone 
marrow transplantation induced strong toxicity when administered to the mice at the 
initial dose of lOOmg/kg. Subsequent lowering of the dose to non-toxic levels did not 
give evidence of systemic mFIX expression following gene transfer and therefore the 
studies with this agent were abandoned. The results with this agent were a little 
disappointing, and perhaps in future studies consideration could be given to use of this 
agent as an adjunct to treatment with other agents.
In contrast, cyclophosphamide, a drug that is cytotoxic to proliferating cells such as 
activated B or T cells, was effective at a dose of 50 mg/kg (3/3 mice had correction of 
coagulation times) and partially effective at 20 mg/kg (1/3 mice) in blocking an 
immune response that could prevent sustained systemic expression of mFIX. In two 
haemophilia B mice, the combination of muscle-directed gene transfer and transient 
immune suppression with cyclophosphamide achieved sustained complete correction 
of the APTT. The mode of action of cyclophosphamide in the setting of bone marrow 
transplants is thought to be a combination of clonal deletion of antigen-specific 
lymphocytes and induction of T cell anergy.
In this gene based approach cyclophosphamide probably works via a similar action. 
The success of cyclophosphamide in these studies confirms results seen in other gene 
based therapies where this agent successfully suppressed immune responses either in 
the setting vector readministration or primary immune response to the vector or 
transgene.
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Summary
From these studies, it appears that FK506 and Cyclophosphamide are promising 
agents in suppressing inhibitor formation (Fields et al., 2001b). More importantly, it 
seems that the overriding principle of transient immune suppression given around the 
time of vector administration may be useful in suppressing inhibitor formation in a 
gene based approach(Fields et al., 2001b). However, the use of agents such as 
cyclophosphamide in humans is a contentious issue, since the use of this agent brings 
with it concerns over infertility induction and the long-term risk of insertional 
mutagenesis and oncogenicity. Further studies will be required to try and optimise 
these strategies, and also to test out new agents as they become available as more 
knowledge accrues about the mechanism(s) involved in the induction of T cell 
tolerance and co stimulatory pathways.
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CHAPTER 8
GENE TRANSFER IN A LARGE
ANIMAL MODEL OF
HAEMOPHILIA B
2 1 2
8.1 Introduction
One of the major requirements of any gene therapy strategy is the successful 
application of a proof of principle strategy in a large animal model before proceeding 
to human subjects. In haemophilia, there are large animal models for both 
haemophilia A and haemophilia B and this affords the opportunity for pre clinical 
studies. The existence of large animal models has proved invaluable in permitting pre 
clinical studies to test the feasibility of scaling up to determine if the promising results 
gained from the mouse studies could be reproduced in dogs. This is not a trivial 
exercise and represents a scale up of 400 {Figure 63). One of the main problems 
encountered is the extra vector amount that is required to produce the equivalent dose 
in a dog.
Figure 64 Scale up in animal models
x800
25g 20kg 70kg
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8.2 Canine Models of Haemophilia
Three canine models of haemophilia B have been described and are outlined in the 
following table.
Canine Model Mutation Reference
Chapel Hill( USA) Mis-sense [G— ^  A ntl477] Evans et al(1989)
Aubem (USA) Small deletion Exons Mauser et al ( 1996)
Cornell (USA) Complete deletion Brooks et al(1997)
The one selected for the studies in this chapter is the colony kept at Chapel Hill, North 
Carolina United States. The genetic defect in the dog colony is a mis-sense mutation 
at a highly conserved glycine residue in the part of the gene encoding the catalytic 
domain (Evans et a i, 1989).
Fig 65 Canine mutation 
Haemophilic Canine FIX
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Leu 377
This defect results in a FIX transcript being produced, but with FIX activity and 
antigen levels of less than 1%. Molecular modelling suggests that the mutant protein 
is unstable because it cannot fold properly (Evans et ah, 1989). The absence of the 
protein in the circulation suggests that the mutant protein is destroyed intracellularly, 
but importantly the levels achieved may be enough to induce T cell tolerance to the
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protein (Evans et al., 1989). It is important to note that the dogs used in the study 
carry a different mutation to the mice (Chapter 7) that carry a large gene deletion 
resulting in no mRNA transcripts and no protein production intracellularly. Generally, 
these dogs do not develop inhibitors in response to treatment with canine plasma. Two 
other mutations have been described, the first by Mauser et al(Mauser et al., 1996) in 
which dogs maintained at the university of Auburn carry a small deletion in the 
portion of the gene encoding the activation peptide. FIX transcripts are barely 
detectable on northern blot. A third colony with haemophilia B has been also been 
described with a complete deletion of the factor IX gene (Brooks et al., 1997).
8.3 Gene Therapy In Canine Models of Haemophilia B
Despite a lot of preclinical work in mouse models, only one reported study has been 
able to report sustained expression of factor DC in a canine model of haemophilia B 
where a retroviral vector was used in a liver directed route (Kay et al., 1994). In the 
studies conducted, the plasma levels achieved were low at 2-4 ng/ml (sub therapeutic) 
and also required several invasive procedures such as portal vein cannulation and 
partial hepatectomy. This approach would not be practical and unappealing in 
humans.
Intramuscular Gene Transfer in Haemophilia B
The studies described in dogs were designed to question whether the early promising 
pre clinical data on mice could be translated into a large animal model. The 
experimental design of the experiment was an ongoing dose escalation study in which 
the canines received AAVcFDC at day 0.
Aim
The aims of the studies were to look at immune responses using an intramuscular 
approach in a large animal model of Haemophilia B. The remainder of chapter is 
divided up into first an analysis of the humoral responses and then of the cellular 
responses.
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Humoral responses
Humoral responses were analysed to the transgene product canine factor IX (cFEX). In 
order to study humoral responses knowledge of canine immunoglobulin subclasses is 
required.
8,3.1 Canine Immunoglobulin subclasses
Subclasses of IgG have been well described in man and other species with particular 
functional characteristics have being ascribed to them. These variants are well 
described in man and four subclasses IgGl IgG 2 IgG3 IgG 4 are defined on the basis 
of their concentrations in the serum of normal individuals and their biochemical 
properties, such as electrophoretic mobility (Schur, 1987). The subclasses are 
functionally different. For example IgGl and IgG3 bind most effectively to the FcyR 
receptor of mononuclear cells and IgG3 is the most efficient at complement fixation 
via the classical pathway. The expression of specific subclasses in different immune 
responses is probably related to factors such as the nature of the stimulating antigen 
and the local presence of specific cytokines, which regulate isotype switching of the 
immunoglobulin subclasses. For example human IgGl and IgG3 subclasses 
predominate in the immune response to protein antigens and may be induced by 
interleukin 10, whereas chronic stimulation with a protein antigen results in a 
predominance of IgG4 which maybe induced by interleukin 4 and interleukin 13 
(Briere et al., 1994). Carbohydrate antigens preferentially induce IgG2 antibodies 
(Barrett & Ayoub, 1986) and the expression of this subclass may be up regulated by 
interferon y. (Kawano et al 1994)
In the canine species, four subclasses of canine IgG have also been isolated and a 
panel of monoclonal antibodies have been defined which can specifically identify 
each subclass in serological or immunohistochemical assays (Mazza et al., 1993; 
Mazza et al., 1994a; Mazza et al., 1994b). This panel of monoclonal antibodies have 
been used to identify the canine subclasses involved in the pathogenesis of 
autoimmune disease in dogs; in particular autoimmune haemolytic anaemia where the 
predominant antibody was shown to be of the IgGl subclass. In a further study carried 
out in animals with hypothyroidism the dominant subclasses of antibody found were
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IgGl, Ig03, and Ig04 (Day & Mazza, 1995). With respect to the development of an 
inhibitory response to infused clotting factor protein in dogs, there is very little 
documentation of these responses in the literature. In a large animal species such as 
dogs, one might speculate that a humoral driven response occurs, resulting in a Th2 
driven response since the antibody characteristically seen in humans is an Ig04 
subclass.
In the series of studies performed in haemophiliac dogs, plasma samples were 
analysed for the presence of antibodies and their subclass determined by using anti 
dog IgGl or IgG2 polyclonal antibodies. These antibodies were used to study 
antibody subclasses in dogs infected with leishmania. Both IgGl and IgG2 were 
detected in sera from infected dogs but the IgG2 subclass was the dominant type 
involved.
Cellular responses
A T cell proliferation assay was set-up to look at the recall responses of circulating T 
cells to canine factor DC. Additional experiments were then set up to look at the 
cytokine profiles expressed by the proliferating lymphocytes in the injected dogs. This 
was performed by setting up an RT-PCR assay to look at intracellular cytokine 
expression of the proliferating cells.
8.4 Canine Experimental Protocol
Method
For the gene transfer experiments, an AAV vector encoding canine factor DC was 
injected intramuscularly into the haemophilia B canine model described above. A 
total of 7 dogs over a period of two years were injected with the AAV construct over a 
range of 8-60 intramuscular sites. Carbon particles were added to some aliquots of 
vector to facilitate identification of injection sites for later histological evaluation.
In performing this study, the following parameters were analysed, the production of 
canine factor DC antigen, clotting functional based assays the APTT and WBCT
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(Whole blood clotting time). The presence of antibodies was examined by both Elisa 
and Western blot. To assess whether these antibodies were inhibitory or not, a 
Bethesda assay was performed.
The WBCT for a normal dog is 6-8 minutes and for a haemophilic dog is >60 
minutes. In these studies a critical evaluation was made to look for the development of 
inhibitory antibodies during the course of the study. Additional further 
characterisation of the humoral antibody profiles was performed by using a subtype 
specific elisa was run with a polyclonal antibody to both IgGl and Ig02 canine 
subtypes (Bethyl, US)(see chapter 3, page 73).
Vector
The construct used for the injections was prepared in a triple transfection method 
(Adenoviral free, see chapter 4,page 96) as described by (Matsushita et al., 1998).
The recombinant AAV vector is shown as follows
1-kb
ITR ITR
^ P ( C M V ) ~ J | j  cF.IX cDNA |  ! : ! : !
pglob hGH
The vector contains AAV inverted terminal repeats ITRs flanking an expression 
cassette containing the following. A) A cytomegalovirus immediate early enhancer / 
promotor, CMV splice donor/ p -  globin gene splice acceptor (p globin) , canine 
factor DC cDNA (cFDC) up to the EcoRl site at nucleotide position 2565 (Evans et al., 
1989), and human growth hormone polyadenylation signal (hGH). The vector 
produced for these injections was made in an adenoviral free system (Nakai et al., 
1999). Briefly, 293 cells were co transfected three plasmids, pAAV-CMV-cFDC, a 
second plasmid (pHLP19) providing the AAV replication and capsid functions, and a 
third plasmid (pLadeno5) providing the adenovirus helper functions, E2a, E4, and 
VA. Cells were detached from the culture flasks with an EDTA solution 72 h post­
transfection pelleted by centrifugation and lysed by repeated freeze/thaw. 
Recombinant AAV was purified by repeated CsCl density gradient centrifugation
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(Fisher et al., 1996b). The vector was titered by slot blot hybridisation on DNA 
extracts from viral particles.
Transient transfection of 293 cells in the presence of vitamin K (6 pg/ml medium) 
was used to show that the cFIX vector directs expression and secretion of functional 
canine FIX. Conditioned medium from AAV-cFIX transduced cells corrects the 
APTT of human FIX deficient plasma whereas conditioned medium from AAV-lacZ- 
transduced cells did not {data not shown). The total doses and dose per kilogram for 
each animal is shown in the table below.
Table 10 Vector Dosage schedule
Dog
Vector 
Dose/ Site VectorDose/Kg
Total
Vector
Dose
1(B45) 4.4x10'“ 1.4x10" 8x10''
2(B46) 1.25x10'^ 1.1x10'" 1x10'"
3(B48) 1.1x10'-' 3.4x10'" 6.7x10'"
4(B93) 1.4x10'-= 2.9x10'" 3.9x10^"
5(B85) 2.1x10'-= 8.5x10'" 5x10'"
6(D31) 2x10'^ 8.4x10'" 3.2x 10'"
7(B14) 1.2x10'" 1.1x10'" 2.3x10'"
Results
The results for all the injected dogs is summarised in the table below. The individual 
dogs are then discussed in detail.
Table 11 Results
Dog
Vector 
Dose/ Site VectorDose/Kg
Total
Vector
Dose
Anti 
canine 
Factor IX
Inhibitory
Antibody
titre
(*BU)
Duration 
of Inhibitor
1(B45) 4.4x10'“ 1.4x10" 8x10" None None -
2(B46) 1.25x10'" 1.1x10'" 1x10'" None None -
3(B48) 1.1x10'" 3.4x10'" 6.7x10'" IgG2 None -
4(B93) 1.4x10'" 2.9x10'" 3.9x10'" None None -
5(B85) 2.1x10'-^ 8.5x10'" 5x10'" IgGl, IgG2 < 6.8 BU 8 Weeks
6(D31) 2x10'" 8.4x10'" 3.2x 10'" IgG2 None -
7(B14) 1.2x10'" 1.1x10'" 2.3x10'" IgGl, IgG2 < 24.5 BU 2 Years
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Dogs 1 and 2
The first dog injected was at a dose of 1.4 x 10 particles/kg. Predicted from the 
early mice studies this should result in a level of expression of approximately 
2.5ng/ml. The canine factor IX level measured by Elisa was in the range 2-3 ng 
/ml.(Fig 1). This dog displayed no evidence of antibody or inhibitor formation as 
determined by Western blot, Elisa and inhibitor screen. A second dog was then 
injected with a higher dose of vector (10-fold increase, 1.1 x lO'^ vector particles/ kg. 
Again partial correction of the WBCT was seen and plasma levels of 10- 15ng/ml 
canine factor IX were reached. This was not enough to cause a correction in the 
APTT.
(Low levels of antigen cause WBCT correction before correction of the APTT, which 
requires higher antigen levels to achieve correction). No inhibitor was demonstrated 
by Bethesda screening and no anti cFIX antibodies were detectable by Western 
immunoblot.
Figure 66 Canine FIX Antigen levels Dogs I&2
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As can be seen at the doses injected both of the dogs failed to reach sufficiently high 
enough levels to attain the correction to take a haemophiliac from a severe phenotype 
to a mild category i.e. greater than 1%. The next stage of the study was therefore to 
proceed to a higher dose.
2 2 0
Dogs 3 and 4
A third dog was then injected at a dose of 3.4 xlO'^ vector genomes per kilogram. 
Again early on, (< 2 weeks), the whole blood clotting time was partially corrected 
(15-20 minutes), and was maintained. The graph below illustrates the canine factor IX 
antigen levels against time
F igure 67 Canine FIX Antigen Dog 3
cFIX A ntigen v e rsu s  WBCT Dog 3
20
10 I t
0  20
1  10 
0
10 20 
T im e  (W ee k s)
-WBCT ■
30
CFIX Ag
A non-inhibitory antibody was detectable by day 14 as determined by western blot 
and elisa. The subtype of antibody was classed as an IgG2 subtype ifig 68). This was 
performed using a polyclonal sheep anti canine IgG that does not cross-react with 
other immunoglobulins. The exact mechanism of this type of antibody formation has 
yet to be elucidated but it may reflect a weak B cell response without T cell help.
Figure 68 Antibody titre dog 3
1.5
O P  fo r IgG l a n d  lgG2: B48
1U)
™ 0.5
0
0 20 40 60
T im e D ays
IgGl igG2
80
221
The production of this antibody was self-limiting, but the antigen levels in this animal 
was too low to reach therapeutic benefit. A fourth dog was injected at a similar dose 
but again the antigen level attained was too low to be of therapeutic benefit.
Dog 5 Inhibitory antibody
The fifth dog received an injection at a dose of 8.5x lO’^  vector genomes /kg AAV- 
CMV- cFIX. The WBCT on day 4 and 7 were corrected, however this increased by 
day 14 and remained at pre-treatment levels until day 77. An inhibitor screen revealed 
prolongation of the APTT of normal plasma at days 14, which then markedly 
prolonged at between days 28-42. Further analysis of this dog, showed that this dog 
made an inhibitory antibody as determined by Bethesda assay. The appearance of the 
circulating inhibitor coincided with a fall in the circulating canine factor antigen {fig 
69) .The graphs below illustrate the fall in antigen level and the appearance of the 
inhibitor.
Figure 69 Canine antigen dog 5
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When analysed further the antibody was inhibitory in nature as seen by the Bethesda 
titre and the increase in APPT level to baseline. Subclass analysis showed that this 
dog produced a further subclass of antibody to factor IX i.e. both IgGl and lg02. This 
is illustrated below:
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Figure 70 Antibody data Dog 5
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This graph shows the appearance o f both 
an IgGl and IgG2 subclass antibody to 
the canine factor antigen.
The inhibitory antibody response was self-limiting as evidenced by the subsequent 
reduction in Bethesda titre over time. This occurred with no further therapy to 
eliminate the antibody i.e. no high dose concentrate infusion. The dog was later 
subsequently challenged with normal canine plasma (D110-D112) and failed to 
demonstrate any signs of an amnestic response.
Dog 6 (D31)
A sixth dog was injected with a similar dose of vector at 8.4 x 10 ‘^ /kg. This dog also 
made an antibody, which was transient and non-inhibitory. The WBCT was prolonged 
D14 -42 and from D49 began to shorten again with a rising factor IX level. In this 
dog cf. Dog 5, which made an inhibitory response, there was no inhibitory antibody 
made. The results from dog 5 and 6 suggest that there may be a threshold dose above 
which antibody formation is induced. It appears though there is no discrimination at 
this dose as to the nature of the antibody induced i.e. whether inhibitory or not. In 
order to look at this further, the next dog was injected with an even higher dose of 
vector.
Dog 7 B I4
This dog was injected with a dose of 1.1 x 10 vg/kg, and again early correction of 
the WBCT was noted to 15 minutes at 2 weeks post injection. However at 4 weeks 
post injection the WBCT increased and subsequently the dog produced an antibody to
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canine factor IX detectable by western blot and Elisa. Additionally as observed in 
Dog 5, this antibody was inhibitory as evidenced by Bethesda assay {fig 71).
Figure 71 Dog 7 WBCT time and Bethesda titre
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A more detailed analysis of the subtype induction in these cases once again revealed 
the presence of two subclasses being induced IgG land Ig02.
Figure 72 Antibody subclasses dog 7
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The presence of a further subclass of antibody induced may reflect further induction 
of additional CD4 T helper cell subsets. Because of the previous observations in the 
fifth, dog (i.e. the occurrence of a transient inhibitory antibody) and in this dog, it was
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anticipated that an inhibitor response may be observed. In order to study this in more 
detail, further characterisation of the observed immune responses was made by 
looking at the cytokine profiles in the CD4 Th helper cells in this animal. This 
information would be helpful in determining what type of T helper response cell was 
occurring. Therefore in this animal, a study of prospective T cell proliferation indices 
was undertaken at 2 weeks, 8 weeks and 12 weeks post injection and the results of this 
are outlined later in this chapter.
Conclusions
All of the injected dogs displayed early correction in their WBCT which was 
sustained at the time of writing for greater than 1 year, indicating persistent 
expression and biological activity of muscle derived factor DC. However the levels of 
factor IX expression were low until a certain threshold in dose was reached.
From the results appeared that the presence of an inhibitory antibody was induced 
once above a threshold of >8.5 xlO^^ vector genomes per kilogram. In these animals, 
it appears that the inhibitory antibodies were associated with both IgGl and lg02 
subclasses. However, in the transient non-inhibitory antibody cases only an lg02 
subclass was observed. These results suggest the possibility of further CD4 helper 
subsets induction in the inhibitor dogs. These results show that inhibitor formation 
may be related to the increasing dose of vector used. i.e. when a threshold dose of 
8.5x 10/*  ^vector genomes/kg is reached.
8,4,1 Cellular Immune responses seen
As described earlier in a gene therapy approach, there is the potential for the protein 
to be produced intracellularly and be presented to the immune system in an MHC 
class 1 pathway. The results obtained from the small animal model showed that there 
is no damaging CTL response to the transduced muscle in murine haemophilia B. 
However because of a paucity of the correct homologous reagents in the canine model 
it was not possible to develop a CTL assay to directly look at this in canine 
hemophilia B. However histological analysis was performed to look for the presence
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of inflammatory infiltrates by haematoxylin and eosin staining, and for the presence 
of CDS infiltration by immunofluorescence.
1) Histological analysis 
H&E Staining
In a preliminary experiment 2.8 x 10*' AAV cFIX vector particles was injected into 
the tibialis anterior muscle of a phenotypically normal dog. Biopsies of the injected 
tissue were taken from where the carbon particles were localised. Serial sections of 
the injected muscle revealed no evidence of any inflammatory infiltrated as 
determined by H&E staining and immunohistochemistry for CDS analysis
Figure 73 Histology canine muscle
The section here shows a normal 
architecture o f the injected muscle. The 
black particles seen are carbon particles, 
which are mixed prior to injection with the 
vector suspension. This aids localisation o f  
the injected muscle when the muscle is 
excised.
Canine factor IX antigen
T.-
In order to look for FIX antigen 
expression sections were stained 
serially by immnunohistochemistry 
to look for the presence o f canine 
factor IX  antigen.
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Immunohistochemical CD8 staining
This was performed on the injected muscles to look for evidence of CDS infiltration. 
In the AAV injected dogs there was no evidence any CDS infiltration indicating a 
relative absence of any inflammatory cellular infiltrates.
2) Cellular responses
The observed antibody responses in dogs 5and 7 suggested a T cell helper response 
was occurring which induced antibody formation. Therefore, a cellular proliferation 
assay was set up to look for evidence of cellular proliferation to canine factor IX in 
the peripheral mononuclear fractions of the injected dogs. I wish to acknowledge the 
helpful comments by Professor Felsburg at the Veterinary School in the university of 
Pennsylvania (USA) and Dr Michael Day at the Bristol University (UK) Veterinary 
School in setting up this assay (Day, 1999).
Results o f the Stimulation Indexes
In the fifth dog injected, administration of 1.1 x 10 vg/per site resulted in a 
maximum inhibitor titre of 24.5 BU followed by a slow decline to roughly 1 BU. 
Proliferation of T cells derived from PBMCs and stimulated in vitro with cFIX protein 
was high during the first three months after inhibitor formation (stimulation index < 
15). Low or absent T cell proliferation was observed at later time points without 
inhibitor formation {data not shown).
Figure 74 Stimulation indices
Dog 5 : Stimulation Indexes
Time Weeks
Series 1
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The T cell proliferations observed in this animal indicate that a T cell dependent 
immune response was occurring during this inhibitory antibody response.
8,4.2 Canine Cytokine Analysis
Intracellular cytokine estimation of proliferating cells
An additional step was incorporated in the protocol to determine the cytokine patterns 
produced by the proliferating cells. Using a RT PCR technique, first extracting the 
lymphocyte mRNA, and then performing a RT PCR reaction to look for the presence 
of intracellular cytokines IL-2, IL-10, IL-4, and Interferon gamma in the proliferating 
lymphocytes performed this. This modification was primarily performed because of a 
lack of available canine reagents to measure cytokine levels by Elisa in the 
proliferating wells by conventional cytokine release assay.
RT PCR Analysis of Intracellular Cytokines
In order to look at the cytokine profiles generated in Dog 7, mononuclear cell cultures 
were obtained by the method as described above, and plating out the cells at 10  ^per 
plate, and setting up a proliferation culture to canine factor IX antigen. The cells were 
assayed at 48 and 72 hours to look for expression of intracellular cytokines by an RT- 
PCR method. (The method is described in materials and methods in chapter 3, page 
81). The proliferating cells were harvested at 96 hours and cellular RNA was then 
extracted and then an RT PCR assay was performed to generate cDNA for analysis of 
the four cytokines IL-4, IL-2, IL-10, and Interferon gamma. A mock uninjected dog 
was used a control, and the internal control amplified gene was p actin. The results are 
described in the following diagram:
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Fig 75 RT-PCR for intracellular cytokine expression in canine T cells
Haemophilia B dog: Dog 7 Dog 7 Dog 7 Uninjected Dog
Invitro Stimulant: Con A cFIX Mock cFIX
IL-2
IL-10
IFNy
p Actin
The results of the RT PCR reaction are shown above. In the reaction, Concanavalin A 
was used as a positive control to stimulate the lymphocyte cells and the internal 
control used was B actin (a constitutive gene), which shows that RNA was being 
amplified up in the PCR reaction.
For the test samples with cFlX used as the stimulant, IL-10 was produced from the 
proliferating cells along with IL-2, however no interferon y detectable.
The profile described here for canines would indicate both in mice and humans, a Th2 
profile in keeping with a humoral driven response. Although the cytokine profiles for 
the canine species are not completely described, if one extrapolates the results from 
both murine and human species, the results also appear to be in keeping with Th2 
cellular driven response.
229
8.5 Immunodulation Strategies to Overcome Inhibitory Responses
As as result of the observed responses in dogs 5 and 7 (i.e. the development of 
inhibitory antibodies), strategies were devised to tiy and avert inhibitor formation. 
Based on the experiments using haemophilia B mice that are at high risk for inhibitor 
formation because of a large factor IX (FIX) gene deletion, a protocol was developed 
that was aimed at avoiding inhibitor formation following intramuscular (IM) 
administration of an adeno-associated virus AAV vector expressing FIX.
Aim
The aim of the experiment was to try and avert inhibitor formation by the use of the 
immunmodulator drug, cyclophosphamide. A total of four doses of cyclophosphamide 
was given around the time of vector administration starting from day 0 and then 
biweekly thereafter upto week 6. This treatment efficiently prevented antibody 
formation against murine FIX in the mouse studies.
Method
The dogs used in this study (Dogs 6 and 8) were littermates and went onto receive 
similar doses of vector but the second dog (dog 8) additionally received 
cyclophosphamide to try and avert inhibitor formation. Dog 6 received AAVcFDC 
vector at a dose of 8.5x10^^ vector genomes in 16 sites via intramuscular injection. 
This dog did not receive any further immunosuppressive treatment .Dog 8 received a 
similar dose of vector (8.5x10^^) but additionally received a total of six intravenous 
infusions of cyclophosphamide {200 ng/m^) at the day of vector administration and 
during weeks 2, 3, 4, 5, and 6.The dosing schedule is outlined in the table below:
Table 12 Dosing Schedule immunomodulation in dog 6&8
Variable Dog 6 Dog 8
Cyclophosphamide No Yes
Vector dose per IM 
site
10^ "^  vector genomes 10^ "^  vector genomes
Number of IM sites 16 13
Vector dose per kg 8.5x10^^ vector 
genomes
5.6x10*"  ^vector 
genomes
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Results
The figure below shows the cFIX Ag expression attained in both dogs. 
Figure 76 Canine FIX Antigen Dogs 6 & 8
Dogs 6 and 8 Canine FIX Ag
c FIX
ig/ml 40
30
Dog 6 
Dog 8
T i m e  W e e k s
The antigen results show that initially Dog 6 did not show expression of antigen. 
There was the appearance of an antibody in the plasma of initially IgM antibody 
followed by IgG2 antibody. In the dog treated with cyclophosphamide (Dog8) there 
were minimal levels of antibody detectable both by Elisa and western blot as shown 
below.
Figure 77 Elisa Antibody titre Dogs 6 & 8
1) Elisa o f Dogs 6 and 8 looking for IgM, IgGl, IgG2
D6
1.2 -450
o. '
D .
0 . 6 -
IgG2
I g M0 .4 -
0 .2 - IgGl
0 5 10 15
D8
450
0.4
0 .2 -
0 2 4 10
weeks weeks
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As can be seen from the above diagram Dog 6 continued to make detectable amounts 
of the IgG2 subclass. However in comparison the IgG2 made by Dog 8 was 
suppressed.
2) Western Blot 
Method
Western blot analysis for detection of anti-cFIX in canine serum samples is shown 
below. Briefly, Canine FIX (1 pg/lane) was transferred onto a nitrocellulose 
membrane and incubated with canine serum samples (1:200 dilution). Antibody-cFIX 
complexes were detected with anti-canine IgG coupled to horseradish peroxidase and 
visualised by ECL (Amersham) detection. Samples were drawn at weeks 0, 2, 4, 7, 9, 
11, and 13 for D6 and at weeks 0, 4, 6, 8, and 9 after vector administration for D8.
Figure 78 Western hlot
D6 D8
0 2 4 7 9 11 13 0 2 4 6 8 9
The western blot shows that in dog 8, there was no evidence of antibody detectable at 
all the time points measured, however in dog 6 antibody was detectable at weeks 7 to 
13.Both sets of the above data (western blot and Elisa) indicate that in the Dog 8 it 
was possible to block the production of antibodies by the administration of 
Cyclophosphamide. This result suggests that it may be possible to suppress antibody 
formation in the setting of a large animal model of haemophilia although to confirm 
this result more numbers will be required.
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8.6 Discussion
In these canine studies, the proof of principle concept of a gene therapy approach in a 
large animal model for haemophilia was shown; that is to say long term gene 
expression is possible, with long-term expression of factor DC. These studies represent 
a significant advance over those carried out by Kay et al (Kay et al., 1994) where 
sustained levels of factor DC were demonstrated (using a retrovirus), but at levels too 
low to be therapeutic. The studies presented here indicated that using a different 
vector and target tissue, up to 20 to 30 fold higher levels were achieved which in one 
case resulted in a therapeutic sustained level of greater than 50ng/ml being achieved.
The approach taken represents a new strategy for the treatment of haemophilia. This 
raises the question of inhibitor development against the transgene product canine 
factor DC. ELISA, western blot and Bethesda assay monitored all dogs for the 
presence of antibodies. The results described, indicate that these dogs may make an 
inhibitory response to factor DC when challenged with a vector dose above 8.5 xlO^^ 
vector genomes per kilogram. A more detailed analysis of the immune responses 
against canine factor DC suggests an increased likelihood of inhibitor development 
with an increase of vector dose per site. Animals injected with 1.4 x 10 / site had no
detectable anti cFDC (Dogs 1&2) or a highly transient (2 weeks) non-inhibitory 
antibody, or a transient low titre (2 BU) inhibitor at a later time point (1 Dog) after 
trauma and extensive infusion of normal plasma. However two dogs injected with 
2x10^^ vg/site had either a transient inhibitor (Dog 4) or a transient non-inhibitory 
antibody, and when this dose was increased further as in dog 7 an inhibitory antibody 
response was seen. More study of predictable risk factors in a gene-based approach is 
required, so that this response may be averted. It would be interesting to look at how 
cytokine profiles differ with escalation of dose.
The inhibitor formation observed, was shown to be T cell dependent as judged by the 
mononuclear proliferation assays and also appeared dose dependent. The antibody 
responses appeared to be transient and self-limiting and characterised by spontaneous 
remission. In the characterisation of immune responses studied, in this large animal 
model, it is important to bear in mind the mutation under study. In this model, the 
haemophilic phenotype was caused by a point mutation resulting in no circulating
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antigen being detectable, but the presence of mRNA transcripts are detectable. Thus it 
is possible that canine factor IX protein is produced intracellularly, but destroyed at 
this stage because of instability of the protein. It may still be possible therefore to 
present the relative dominant epitopes to the developing immune system so that later 
antigenic challenge may lead to tolerance. This may explain lower incidence of 
inhibitor formation seen in the canine model (2/7), as compared to murine of 
haemophilia (described in chapter 7) where the mutation is caused by a large deletion.
As shown in dog 7, T cell proliferation was observed to canine factor EX antigen 
indicating the T cell dependent nature of the response. To avert this, ways of blocking 
the inliibitor response were explored. It was shown that using cyclophosphamide in 
dog 8, that this agent may be useful in suppressing the inhibitory response. More 
numbers will be required to confirm this result. Other methods aimed at inducing 
tolerance to the transgene product should be explored such as blocking of co 
stimulatory responses with immunomodulatory agents such as CD40 ligand, and 
CTLA-4 Ig. The difficulty presented here is the requirement to have the relevant 
species-specific homologous reagents available for study in the canine model. Equally 
important, will be the testing out of further mutation types in large animal models, and 
their likely effect on the development of inhibitor formation. In any new 
developmental therapy for haemophilia, it is important to look prospectively for the 
development of inhibitors.
The studies presented here, show unequivocally that a gene therapy approach in large 
animal appears safe and efficacious and provides the rationale and pre clinical data to 
support translation of this approach into studies involving human subjects.
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CHAPTER 9
SUMMARY OF RESULTS
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The results produced in this thesis may be divided as they relate to the relative 
components of the immune response as described in the Figure 77, page59.
The results identified 6 major areas, which appear to characterise and influence the 
occurrence of an immune response to a gene transfer process. These are as follows:
• a) The role of the vector in a gene based approach
• b) The role of the transgene used in a gene based approach
• c) The role of the animal model
• d) The mechanism of antibody formation in a gene based approach
• e) The occurrence of whether a cellular CTL response was induced.
• f) The role of the underlying mutation in the recipient animals of gene transfer
The results are depicted in tabular form on the following page.
The initial experiments in chapter 4,5 look at the isotype profiles induced via different 
vector selection. The results demonstrated that the response was a T cell dependent 
process. The likelihood of an immune response was also correlated with the 
underlying mutation present (Chapter 7,8). The profiles generated were in keeping the 
results of the CTL experiments, which demonstrated that the presence of such a 
response correlated with a dominant IgG2 profile (Chapter 6).
Other exogenous factors such as the role of the animal model and route of gene 
delivery were also studied and clearly shown to influence the outcome of an immune 
response (Chapters 5,7,8). Finally because of the occurrence of an immune response, 
immunomodulatory strategies were sought to overcome the process, and this formed 
the final facet studied (Chapters 7,8).
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I  Table 13 Results summary
Facet Studied Specific Result(s) Evidence
a) Role of the Vector
The nature of vector selection 
Influences response to the 
transgene product
Differing antibody profile 
Adenovirus : IgG2 
Adeno associated virus : IgGl 
Plasmid: IgG2
b) Role of the transgene
Non Homologous transgenes 
generate immune responses
Injection of AAVhFIX 
to Ab production 
Injection of AAVmFIX 
fails to elicit Ab responses
R  c) Role of the Animal 
r  model
C57BL6 strain produce 
high circulating factor IX 
Different strains do not result 
in high circulating factor IX
Serum estimation 
Balb/c, C3H strains
d) Mechanism of 
Antibody formation
Is a r  cell dependentprocess Antibody isotype profiles 
in mice
Cellular Proliferation data in 
mice, dogs
e) Presence of a CTL 
response to a secretable 
transgene
AAV mediated -ve 
Adenovirus +ve
In vitro CTL, In vivo CTL 
Antibody profiles
f) Role of the 
mutation
Correlates with inhibitory 
outcome
Injection AAVmFIX 
to gene deleted mice 
results in Ab production 
in all animals 
Injection AAVcFIX 
to mis sense mutation 
results in Ab production 1/5 
animals
g) Immunomodulatory 
strategies in Antibody 
formation
It is possible to avert 
antibody formation in 
a gene based approach
Cyclophosphamide, FK506 
CD40L Ab
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CHAPTER 10
DISCUSSION
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Evolution of Therapies
The desire to cure a genetic disease by a gene therapy has been and is the dream of 
both scientists and haemophilia treaters alike. Haemophilia is an example of a disease 
that has undergone a dramatic revolution in treatment of the last 50 years. From being 
a disease with a high mortality, it is now a disease where now it can be expected that 
most patients can live relatively trouble free lives. These treatments have come about 
as the result of the recognition that the disease related complications could be 
prevented and ameliorated by the infusion of clotting factor concentrates and 
maintaining a clotting factor above 1%.
Despite these advances, haemophilia is an example of a disease where the new 
treatments did provide the necessary efficacy, but at a cost. The unknown 
contamination of plasma derived clotting factor concentrates resulted in devastating 
consequences for the haemophilia population with many patients becoming infected 
with hepatitis viruses and Human immunodeficiency virus. This led to a drive to 
produce purer clotting factor concentrates by recombinant technology circumventing 
the need for plasma-derived concentrates and their inherent associated risks. The 
result was the production of “state of the art” factor VIII and FIX recombinant 
concentrates for treating haemophilia A and Haemophilia B. Despite this, the high 
cost of these products makes their use prohibitive in several areas of the developing 
world and also in parts of the western world, including the United States where 
routine prophylaxis is not fi'eely available.
In the developing world there are virtually no countries using these products unless in 
special circumstances. This means that many patients in these countries still do not 
receive treatment for their diseases resulting in chronic morbidity and mortality. Many 
babies bom with haemophilia in African countries still die as a result of bleeding 
complications of circumcision, often, which go unreported {Personal communication 
to me by a father o f a little boy in Kenya with haemophilia). The use of a simple easy 
administered treatment in these countries would ameliorate the suffering of many 
untreated children.
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The next technological stage of progression from the use recombinant products would 
be the in vivo production of normal clotting factor in a human from a gene based 
approach Thus the need for a gene based approach is clear to see, and offers the only 
real hope for cure of this disease. This realisation would represent the natural 
progression of the advances made both in the understanding of the early descriptions 
of the disease in the Talmud right through to the molecular advances of the twentieth 
and twenty first centuries. It would represent a true evolution of therapies for this 
disease.
Figure 79 Evolution of therapy for Haemophilia
1960 s +1970 s >  1980 s 1990 s 2000 s
First use of plasma 
derived products
Cloning of the FVIIL 
and FIX genes
Expedites
Availability of recombinant 
concentrates
/
Phase I/I I in vivo 
gene therapy trials 
Haemophilia B
Availability of animal 
models for in vivo gene 
transfer strategies/
First cases of transfusion 
transmitted disease
Development of ex vivo 
gene transfer strategies
As can be seen from the diagram above, several of the new therapies have resulted in 
potentially damaging complications i.e. transfusion transmitted disease from plasma 
derived concentrates. The dawn of a gene-based approach for haemophilia also brings 
with it the possibility of complications as with any novel treatment for haemophilia. 
As described earlier a gene based approach brings with it hope, but also the potential 
for treatment related complications and at present limitations to the overall efficacy of 
the process. These limitations at present centre around vector design and the issues of
240
incorporating genes into them. This is exemplified by AAV where the maximal insert 
capacity is 4.9 Kb is sufficient for FIXcDNA, but not for FVIII.
Other inherent problems related to vectors include engineering ones with high 
transduction efficiency so optimal gene expression may be obtained. The results of the 
current ongoing muscle directed trial demonstrate that although gene expression is 
observed in the injected tissue, the circulating clotting factor levels obtained are too 
low to be therapeutic indicating insufficient gene expression of the target tissue. 
Finally, other issues such, as the amount of vector that can be produced safely under 
GMP facilities is a rate-limiting step for many current gene transfer protocols.
Immune Response Complications
The other major complication of a gene-based approach is the occurrence of an 
immune response. This complication, like any other conventional treatment for 
haemophilia is a distinct possibility, and one that requires a critical analysis before the 
treatment can be deemed safe enough to be offered as a routine treatment. The aim of 
my studies was to examine some of these issues surrounding a gene-based approach. 
At the outset of this thesis, gene therapy was still very much in its infancy and simple 
preconceptions about pre clinical gene transfer were often simplistic, misunderstood 
and misguided.
An example of this, were the numerous studies carried using non species-specific 
trasnsgenes, making results often difficult to interpret when extrapolated to human 
studies. This partly stemmed from the lack of availability of species-specific 
homologous transgenes for study. This also hampered the development (by gene 
targeting technology) of the relevant animal models for study. Fortunately, the 
development of the relevant animal transgenes has allowed for the acceleration of 
studies to be carried out appropriately so that immunological studies may be 
specifically designed to answer a particular question and allow predictability.
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Role of Vector in gene transfer
The studies in chapter five examined the role of the vector in gene transfer, and 
showed that this was particularly important in the immune responses generated. The 
results showed that both plasmid and adenoviral vector transduction resulted in more 
dominant IgG2 profile in mice which correlates with a Thl cellular antibody 
dependent response. Although this gave a clue to the type of immune response 
occurring i.e. by interpretation of the humoral profile, a more definitive approach to 
answer whether also a cellular cytotoxic response was occurring would be to set up a 
CTL assay to look at this. This complex assay took many months to develop. 
Importantly using this assay it has been possible to show that Adenoviral based 
transduction in muscle resulted in strong cytotoxic T cell responses to the transgene 
product human factor IX in both normal and haemophilia B mice (chapter 6). Similar 
experiments were performed using an Adeno associated virus, which failed to elicit 
CTL responses when encoding the human transgene factor DC in a muscle directed 
approach. This was a particularly important result, since most of the previously 
documented experiments using an AAV vector were performed a non-secretable 
transgene such as the 6 galactosidase reporter gene (Yang et a l, 1994b; Yang et al., 
1995c; Fisher et al., 1997; Xiao et al., 1997). The result confirmed earlier findings 
from the antibody isotype data, which predicted a lack of a CTL response i.e. an IgGl 
dominant profile. The results of the in vitro CTL experiments were later followed 
with an ambitious in vivo CTL experiment in which adoptively transferred alio 
reactive lymphocytes failed to induce an in vivo CTL response (Fields et al., 2000).
Role of the Transgene in gene transfer
A critical feature to any gene based protocol is the rationale design of the transgene 
which when translated intracellularly will lead to effective production of the desired 
protein product with the relative absence of an immune response to the transgene 
product. Early experiments performed in gene-based protocols often incorporated the 
use of reporter genes to demonstrate efficacy of the procedure. Sometimes these same 
reporter genes were also studied in vivo and not surprisingly lead to the development 
of humoral and sometimes cellular immune responses. The early experiments in 
chapter 5 showed that the use of a non-homologous human transgene in mice lead to
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the development a humoral response to human factor DC. When further similar 
experiments were performed with a murine transgene no immune responses were 
observed. This may seem on the surface a predictable result, but at the outset of these 
studies, many publications presented data with the use of non-homologous transgenes 
such as the reporter gene p galactosidase(Yang et al., 1994b; Yang & Wilson, 1995; 
Olthoff et ah, 1997). Clearly, these results can never be extrapolated to using 
appropriate homologous transgenes in an optimal system. The results in chapter 5 
demonstrated the crucial importance of incorporating the relevant homologous 
transgenes into vectors in order to accurately assess immune responses.
Strain variation
The results of chapter 5 also examined the role of other components influencing the 
immune response to gene transfer and particularly the route of administration in 
different strains of mice. The results of these experiments concluded that the 
haplotype of a mouse may be an important determinant of the immune responses 
observed. In particular the C57BL6 strain of mouse seemed to be permissive to high 
dose factor expression when transduced intravenously by Adenovirus expressing a 
human factor transgene. This would seem a highly unexpected result since firstly 
Adenoviruses are known to highly immunogenic, and secondly the transgene selected 
was non-homologous.
The mechanisms underlying results were explored and it was found the absence of the 
class II alleles IE was not responsible for this result. Similarly, it was also found that 
the immunosuppressive cytokine IL-10 was not responsible for these observed effects. 
These results point out that what happens in one strain of a species may not 
representative of other strains in the same species (Fields et al., 2001a). This is 
important, since many of the early pre clinical studies performed in mice were studied 
in the C57BL6 strain and may therefore give misleading results i.e. this particular 
strain of mice may be particularly permissive to gene transfer when challenged with 
known immunogens.
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Role of Mutation /  Genotype
It is known that the immune response may differ from species to species, and a 
response observed in one species may not be necessarily representative of what may 
occur in another species. Part of any pre clinical testing strategy for the efficacy of a 
gene transfer approach is to test out the protocol in a large animal model of the 
disease. Haemophilia is fortunate in that there are canine models of both haemophilia 
A and B. Chapter 8 examined the role of gene transfer and the immune responses 
observed in a canine model of haemophilia B.
The canine model studied was different to the murine model, in that the mutation 
giving rise to the severe phenotype was caused a w/5-sense mutation resulting in the 
production of FIX mRNA which is detectable by a PGR assay (Evans et al., 1989). 
No circulating FIX protein is found, since the protein-produced intracellulary is 
unstable, and destroyed before it is able to be secreted. The result is that some FIX 
peptides may be produced and allow thymic education and tolerance to some of the 
molecules immunodominant epitopes. This is a different scenario from the murine 
model, where the phenotype is cause by a large gene deletion resulting in no mRNA 
transcripts and protein being produced (Lin et al., 1997). The murine model therefore 
represents the worse case scenario for inhibitor generation as compared to the canine 
model.
The results observed from the canine experiments produced a transient inhibitory 
antibody in one animal, which was self-limiting and did not produce an amnestic 
response when challenged with infusion of plasma. The antibodies produced in the 
dogs were T cell dependent as evidenced by the results of the proliferation assays. 
These results are in keeping with current treatment of haemophilia by infusion of 
clotting factor concentrates. Not all the dogs produced inhibitory antibodies (4/5), and 
only the dog that received the highest dose made an inhibitory antibody. It will 
important to reproduce these results, and test out the influence of vector dose and 
vector dose per site to learn more about the pathogenesis of inhibitor formation in this 
setting. Contrarily, all of the haemophilia B mice that carry a large gene deletion 
produced inhibitory antibodies within 8 weeks of vector administration. The results of 
these experiments point out the significance of the role of the underlying mutation
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present, since it appears that the those animals with a more severe defect resulting in 
loss of coding material are at increased likelihood of inliibitor development. This 
echoes protein-based situation, where induction of inhibitor formation appears to 
correlate with severity of the mutation leading to a severe haemophilic phenotype. It 
will therefore be important in any gene-based protocol in humans to define the 
underlying mutation present prior to embarking with a gene-based protocol. The 
influence of underlying mutation is shown in the figure below:
Figure 80 Relationship between mutation and inhibitor development
Murine: Absent
Canine: Present
Dominant T cell epitope(s)
Immune Activation
Absent
Tolerance
Inhibitor Development
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Strategy of immunomodulation
Because of the observed responses occurred i.e. formation of inhibitory antibodies in 
both animal models of gene transfer, it is important to explore strategies to circumvent 
this. In the conventional protein based approach, suppression of inhibitor formation is 
very difficult to overcome once it has occurred. Immune tolerance regimens have 
been employed (sometimes vnth use of concurrent immuno suppression) to overcome 
the response. This is very costly and does not always succeed. The overriding feature 
of these approaches is to overcome the antibody responses to the circulating protein. 
The use of high dose concentrates +/- immunosuppression is designed to clonally 
delete or exhaust those alloreactive T cells involved in inhibitor formation.
Another way to eliminate these cells would be to effectively anergise them at the 
point of contact with immune inducing epitopes. This may be accomplished by 
interfering with co stimulatory pathways involved in T cell activation, i.e. blocking of 
signal 2 i.e. B7.1/7.2 with CD28 on potential cognate CD4 cells, interaction of 
CD40L/ CD40, interaction CTLA4 with CD28. In the murine animal model of 
haemophilia, co stimulatory blockade was attempted with the use of drugs and 
selective antibodies. Some limited success was achieved with use of CD40L antibody, 
although this was short lived. Similarly, administration of the agent FK506 produced 
a short-lived response. Use of the drug cyclophosphamide managed to block 
inhibitory antibody formation in three animals, and produced attenuated responses in 
others. This agent probably works by clonally deleting the alloreactive clones 
involved in inhibitor formation. The results obtained were not always predictable, and 
more sophisticated ways of blocking inhibitory responses are required. An important 
overriding principle of these results suggests that it is possible to block inhibitor 
formation given at or around the time of vector administration. To do this, more 
effectively further knowledge of the biological pathways involved in the immune 
pathogenesis of inhibitor responses will be required both in the protein based and 
gene-based approach.
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Implications of the work for gene therapy
Any gene transfer approach needs to be safe and efficacious. For a gene therapy 
approach to be successful, preclinical studies are required to show proof of principle. 
This needs to be shown first in vitro and then in both small and large animal models 
of the disease. Once these criteria are met, it would seem feasible to progress to 
clinical trials. The implications of the work presented in this thesis suggest that the 
immune response observed to a gene transfer approach can be influenced by many 
different factors. Crucially vector selection seems to strongly influence the response, 
and cause the formation of both humoral and cellular responses to the transgene 
product. The transgene itself should also be homologous to the animal it is being 
tested in to allow an accurate assessment of the immune responses occurring. Host 
cell factors need to be taken into account such as the nature of the underlying 
mutation; which should be known prior to any protocol being instituted. The results of 
the immunmodulation work suggest that this strategy may be successfully employed 
in overcoming the immune response, and this may be of further use in the future, 
when it may be needed to be combined with a gene based approach to make the whole 
process work.
Future work
The results produced from this work showed that a gene-based protocol in muscle 
using AAV directed gene transfer failed to elicit a CTL response. However, humoral 
responses were observed which appeared to be dose related in that a certain threshold 
dose triggered off inhibitory antibody formation. Suppression of these responses was 
possible with use of immunomodulation given around the time of vector injection. 
The results produced by the large animal canine model and the ongoing human 
clinical trial show that the muscle directed approach appears safe, although the levels 
of gene expression and clotting factors levels attained were low, and not sufficient as 
yet at this time to translate into therapeutic efficacy (Kay et al., 2000). In order to 
achieve therapeutic levels, gene expression needs to be higher and any inhibitory 
antibody response needs to be blocked should it occur. In order to achieve higher gene 
expression, injecting more sites with the vector could do this. However, this is not 
practical, since it may involve many more sites and at least 60-70 injection sites.
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which is not clinically feasible. Another way to produce more expression is try and 
gather information/knowledge as to what the biological factors governing AAV based 
transduction in muscle are. Ways of achieving higher expression have been explored 
and include using different serotypes of AAV vectors. The serotype selected for use in 
these experiments was AAV-2. Preliminary (unpublished) work in the laboratory 
suggests that serotype 1 vectors give x 20-40 increased gene expression when 
compared to serotype 2 (Arruda et al, 2001). This would increase gene expression but 
would bring an increased risk of inhibitor formation because of the expected increase 
in circulating clotting factor expression. Therefore, this strategy would require 
immunomodulation to suppress these responses.
Another potential way of ensuring higher doses is to increase targeting to muscle by a 
better delivery system than simple injection. Currently ways are being explored to 
achieve this, by selecting vascular arterial routes, which supply the target muscles 
involved. So-called “isolated limb perfusion studies” are under way to explore this 
approach. Preliminary results suggest that approach may yield much higher levels of 
clotting factor protein.
Finally, a third approach would be to select an alternative target tissue, which may 
yield higher gene expression levels .An obvious choice is the liver, since it is the 
known site clotting factor synthesis normally. Published data suggests that the levels 
attained by this approach yield higher levels of clotting factor, but there are fears 
using this route about the possible increased risk of inadvertent germ line 
transmission. Currently studies are ongoing to define these risks.
Other future work should centre around the biology of the immune response, and 
which specific cell types are involved .In particular the cell types in each target tissue 
involved in antigen presentation may give further clues to local and systemic immune 
response.
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Summary
It is now approximately 10 years since the first papers appeared showing that it was 
possible to transfect several different target tissues and produce biologically active 
clotting factor proteins. The concept of a gene-based approach is easy to realise but 
poses several difficulties in practice. These were hampered at the beginning of the 
previous decade by the lack of available tools to study the process preclinically before 
moving to clinical trials. The cloning of the relevant homologous transgenes and 
simultaneous development of their cognate animal models has facilitated rapid 
advances in demonstrating that the proof of principle works in an in vivo setting.
We have now moved from these preclinical studies into three ongoing human clinical 
trials. One of these studies using AAV in a muscle directed approach is nearing 
completion, and has proceeded uneventfiilly with no severe toxicity being 
demonstrated (Kay et al., 2000). However, the levels of gene expression remain too 
low to yield satisfactoiy therapeutic circulating human FIX, but if the process could 
be optimised with better levels of gene transfer, the prospect of success moves ever 
closer. The degree of investment being made from the scientific, academic, and 
corporate sector is enormous and serves to underpin the future success of the “dream” 
becoming a reality.
Although much still remains to worked out, one thing is certain, the progress made 
from a decade ago is vast, and it remains only a matter of time before haemophilia 
becomes one of the first human genetic diseases to be cured by this approach. The 
ability to arrive at this position would be a great feat for mankind and be the 
culmination of many decades of scientific and technological advances. Equally 
important it will bring hope to millions of sufferers afflicted with other human 
diseases, which may also, one-day benefit from these advances.
Postscript to the work
Since the completion of my work, the results of the preclinical data provided 
sufficient optimism to lead Professors High's group to proceed to a Phase 1 clinical 
trial using a muscle directed gene based approach in human subjects. The preliminary
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data from the trial published in Nature genetics shows has proceeded uneventfully 
with no severe toxicity being demonstrated (Kay et al., 2000). Importantly no 
deleterious immune responses have been observed, and are in keeping with that 
predicted from the pre clinical data. Other trials have also been initiated, including a 
liver directed approach and the results of these are eagerly awaited.
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